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Summary 
Traditional anticancer agents are mainly targetted on the DNA 
replication process in the nucleus. However, with the advancements in 
modern biology, a new class of anticancer drugs has emerged. These 
compounds target on enzymes involved in the earlier part of the cancer 
cell cycle. Protein kinase C (PKC) is one such enzyme which has been 
under intensive investigation because of its ability to cause tumour 
promotion. It belongs to a family of enzymes which catalyse the 
phosphorylation of serine and threonine residues using ATP. As well as 
being a natural direct PKC inhibitor, sphingosine (A) can also inhibit PKC 
indirectly by inhibiting phosphatidic acid phosphohydrolase (PAP). 
PAP catalyses the hydrolysis of diacylglycerol, the main PKC activator. 
Since N-methylsphingosine and N, N-dimethylsphingosine are better PKC 
inhibitors than sphingosine, it appears that the bulkiness around the 
amino group is important for inhibition. 
The first stage of the project was to establish reaction conditions 
for carrying out methylation, dimethylation and trimethylation of a 
primary amino group in compounds which are analogues of 
sphingosine. A selection of N-methylated, N, N-dimethylated and N, N, N- 
trimethylated analogues of sphingosine was synthesised from (R)-, and 
(S)-phenylalaninol and (1S, 2S)-2-amino-l-phenylpropane-1,3-diol. 
They were tested on two PAP enzymes under the supervision of Dr 
Pamela Scott at the Department of Medical Oncology, University of 
Glasgow. The results suggest that there is no clear correlation between 
the amount of inhibition and the bulkiness around the amino group. 
However increasing the bulkiness around the amino group in some 
cases did lead to an improvement in the inhibition. 
The tested compounds differ from sphingosine in the hydrophobic 
moiety. Since they had shown much less inhibitory effect on PAP than 
sphingosine, the length of the hydrophobic alkyl chain is likely to be a 
key structural feature for inhibition. A range of sphingosine analogues 
each containing a triple bond was synthesised diastereoselectively. 
Sphingosine was synthesised using the same route. However, only a 
small amount was synthesised, which was too small to be used for 
further reactions. 
A novel enantioselective synthesis ý of sphingosine analogues was 
proposed and its effectiveness was tested by applying it to the 
synthesis of (1R, 2S)-2-ethylamino-l-phenylpropane-1,3-diol and N- 
ethylsphingosine. 
A selection of sphingosine analogues was tested on a range of 
cancer cell lines under the supervision of Dr A. T. McGown at the 
Paterson Institute, Manchester. The sphingosine analogues containing a 
triple bond had IC50 values in the region of 1gM against these cell 
lines 
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CHAPTER ONE 
Cancer - An Overview 
1.1 History of Cancer 
Cancer is the second highest killing disease of our time, after 
heart disease. In the USA it is estimated that one in three people will 
develop cancer at some point in their life. 1 Even with the advanced 
technology in cancer therapy, cancer still has a profound effect on the 
population. Its statistics cast fear over people. The disease is not a new 
health problem because it has been present throughout the history of 
mankind. It started with the discovery of some Egyptian mummies 
diagnosed with bone cancers. During that period, the disease was 
believed to be a curse from God to punish sinners. Such misconception 
was held until the Middle Ages when questioning began. One of the 
first investigations into the cause of cancer was investigated by Sir 
Percival Pott around 1775. He discovered that young boys working as 
chimney sweeps had a high mortality rate due to scrotal cancer. The 
chimney soot was to blame but the development of cancer was found 
only to occur on chronic exposure. Such observation was important but 
the biological aspects of tumours were to remain a mystery until the 
discovery of the microscope in the 19th century. With this equipment, 
cancer was established as a cellular disease and most of the research 
was then focused into three areas: the cause, biological properties and 
treatment of cancer. 
1.2 Causes of Cancer 
Cancer is a disease at the cellular level as it causes abnormal cell 
proliferation. This is due to genetic alteration which results in a change 
in gene expression. But there is the question of what causes the genetic 
information to be altered. Epidemiological studies have shown that 
exposure to a variety of different external factors is responsible. These 
factors include viruses, a wide variety of chemicals, X-rays and ultra- 
violet radiation. Fuller knowledge of these factors coupled with their 
avoidance could prevent 90% of cancers. 2 
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1.2.1 Radiation 
The majority of skin cancers is caused by solar radiation. It is the 
ultra-violet light that damages cells at their genetic level, causing a high 
frequency of mutations, DNA damage and chromosome abnormalities. 
Chronic exposure may result in melanoma, a form of skin cancer which 
is considered to be the most lethal due to its behaviour. This form of 
tumour metastasises, that is, it invades neighbouring tissues and 
organs, and therefore cannot be easily removed through surgical means. 
It is this form of skin cancer that mainly accounts for cancer mortality. 
However, prolonged exposure to sunlight does not always lead to death. 
Non-melanoma is the less harmful form of melanoma and can be 
treated effectively by surgery. 
1.2.2 Medical X-Rays 
X-rays were, discovered by Roentgen in 1895. Initially, they were 
used to treat cancer. But after an X-ray technician, who was testing 
manufactured X-ray tubes, died from metastatic cancer, the use of X- 
rays was questioned. By 1908, animal experiments had showed that X- 
rays were carcinogenic. The risk was proportional to the degree of 
exposure. 3 Despite this discovery, X-rays are still used to treat non- 
malignant diseases. In Israel, X-rays are administrated to the head and 
upper body to treat ringworm of the scalp. Israel now has the third 
highest incidence of thyroid cancer in the world. 4 In contrast, 
Denmark, where X-rays have never been used to treat non-malignant 
diseases, has one of the lowest rates of thyroid cancer in the world. 5 
Nowadays, X-rays are used for the detection of skeletal deformities and 
for treatment of certain types of solid tumours. Since they are 
carcinogenic, they have to be used carefully and in small controlled 
doses. 
1.2.3 Chemicals 
In some work areas the handling of chemicals cannot be avoided. 
Employees in science and industry have new legislation (Control of 
Substances Hazardous to Health act) to help minimise the risk of 
working with chemicals. Even if we are not handling them we are still 
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at risk in society, mainly from the effects of tobacco. Cigarette smoke 
could be lethal because it contains 50 known carcinogens including 
arsenic, benzene, ' nitrosoamines and naphthylamine. This mixture is 
the main cause of lung cancer which accounts for one third of cancer 
mortality. There is a connection between the intake of smoke and life 
expectancy. A 30 year-old man smoking 40 cigarettes a day can expect 
to lose, on average, eight years from his life-span, as well as increasing 
his risk of cardiovascular and respiratory- disease. 6 Other cancers 
which have been linked to cigarette smoke are cancers of the oral 
cavity, pharynx, oesophagus, bladder, kidney and pancreas. The 
incidence of lung cancer is increasing as a result of changing lifestyles. 
This is due to the trend of more women smoking as well as more 
adolescents. 
1.2.4 Medicines that Cause Cancer 
Like medical X-rays, some medications have the ability to induce 
a second cancer as a result of their actions on normal cells. This is a 
side effect that a patient may have to face after treatment. These 
cancer-causing drugs have been removed from current practice but 
other potential carcinogens still remain in use. The benefits that these 
drugs bring generally outweigh the side effects. 
1.2.4a Anticancer Drugs 
Despite their ability to cause cancer, anticancer drugs are still 
used in chemotherapy. This will be discussed later in this chapter. 
Anticancer drugs are used to target all rapidly proliferating cells, that 
is, cancer cells, and any normal rapidly dividing cells. One example of a 
normal cell that is most affected by such drugs is the bone marrow 
forming cells. The effect of these drugs on normal cells might induce the 
development of a second cancer. Nevertheless, the benefits of these 
drugs outweigh the possibility that they will induce the development of 
a second cancer. 
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1.2.4b Hormones 
In the early 1970s, incidences of vaginal and cervical cancer 
among young women were becoming noticeable. The mothers of these 
women had been treated with the synthetic oestrogen, 
diethylstilbestrol (DES), during their pregnancy back in the 1940s and 
1950s. This practice no longer exists. However, oestrogen itself is used 
to treat menopause symptoms and osteoporosis (bone thinning). 
Postmenopausal hormone replacement therapy involves the use of high 
doses of oestrogen. Unfortunately this is a long-term treatment, and 
therefore carries the risk of developing endometrial cancer. This type 
of hormone replacement therapy is still practised because the risks can 
be reduced by the administration of another hormone, progesterone, as 
a co-drug. 
1.2.5 Oncogenic Viruses 
The common cold, herpes, polio, influenza and measles are all due 
to viral infections. Viruses invade cells to use the cells' biological 
machinery to reproduce. These oncogenic viruses incorporate their 
RNA into the DNA of a normal cell. This allows the virus to place its 
genetic make-up into the cells reproduction system to produce more 
RNA tumour viruses. The invaded cell then ruptures releasing virus 
progeny to infect . neighbouring normal cells. 
An example of this 
oncogenic virus is Hepatitis B. 
1.3 Cell Cycle and Growth 
The range of causes of cancer increases the difficulty of finding 
the appropriate treatment. In order to do this, understanding of how a 
cell survives and reproduces is needed. Cellular processes are 
presented as a cell cycle in which there are four kinds of cellular 
events. Overall, a parental cell duplicates its genetic material and 
passes one copy of each to its two newly formed daughter cells. 
When the parental cell is in the G1 phase, its metabolites become 
active and it is ready for DNA replication which happens in the S phase 
of the cycle (Diagram 1). By this time, the cell has two copies of its 
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genetic complement, and it is at its premitotic stage (G2 phase). In the 
remaining phase of the cycle (M phase), cell division occurs to form two 
daughter cells. Each cell contains one copy of the parental genetic 
material. 
The lengths of the M, S and G2 phases do not vary considerably 
from one cell type to another. The length of of GI phase varies 
depending on how soon newly formed cells are needed. Liver cells 
have a G1 phase of a few weeks since there is no urgent need for them 
to reproduce. In contrast, bone marrow cells have a Gi phase of a few 
hours in order to replace themselves efficiently. There are cells 
however which are permanently fixed at the GI phase. These include 
nerve cells and adult brain cells. Therefore the rate of proliferation of a 
cell depends on how long it spends in the Gi phase. There are some 
cells that stay in the Gi phase and have entered a phase outside the cell 
cycle (GO phase). They can leave the GO phase and return to G1, thus 
entering the cell cycle, if the cell is induced by an external signal. A 
wound on a piece of connective tissue would induce the synthesis of 
skin fibroblasts. 
After the M phase, normal daughter cells differentiate to undergo 
a programmed cell death since they are constantly being replaced by 
new cells. This keeps the cell population constant. With cancer cells, 
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they fail to die since they do not differentiate. Instead they go on to 
the S phase of the cell cycle having lost the ability to remain in the G1 
phase. They go on to reproduce further daughter cells which also fail to 
differentiate. Thus, cancer cells are continuously proliferating. 
1.4 Current Cancer Therapies 
There are three treatments used in practice today: surgery, 
radiotherapy and chemotherapy. The choice of treatment depends on 
the nature of the cancer. 
Surgery is effective against most localised tumours except brain 
tumours. It is useful in treatment of malignant melanoma which 
appears as lesions on the skin. Therefore, it can be easily seen and 
detected early. The success of surgery depends on the removal of all 
cancerous cells leaving none behind to continue the life cycle. This type 
of treatment is promising since there are no chemicals involved which 
may affect the body elsewhere. However it has its limitations. . Once 
cancer cells have metastasised, it is difficult to ensure that all of them 
have been removed. Also, most cancers are undetected until they have 
metastasised. Therefore, it is often too late for surgical treatment. At 
this stage radiotherapy or chemotherapy is required. 
Radiotherapy is sometimes used instead of surgery on localised 
tumours- because it can kill the cancer cells as well as the invaded 
adjacent cells. However, some cancer cells can only be removed by a 
combination of radiotherapy and surgery. The role of radiotherapy is 
to induce mutations by damaging DNA. DNA damage can be lethal to 
any cell especially to those that are rapidly proliferating since they use 
DNA much quicker. Thus radiation targets selectively on cells with a 
short cell cycle. However this provides a limitation to its use. Not only 
are the cancer cells destroyed but also normal rapidly proliferating 
cells. It is the S phase of the cell cycle that is most likely to be affected. 
In practice, radiotherapy is spread over a month to allow any resting 
cancer cells left to move into the S phase, as well as giving the patient a 
chance to recover from the side effects of the treatment. A number of 
side effects are due to the killing of normal proliferating cells such as 
cells of the bone marrow, skin cells and the cells that form hair. 
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Sometimes, tumours have already metastasised by the time of 
diagnosis. Surgery and radiotherapy are no longer effective towards 
these tumours. At this stage, chemotherapy will be required. The basis 
of chemotherapy is to administer a combination of drugs to interfere 
with the process of cell division. The main drawback of this treatment 
is that the drugs are largely non-selective and can induce a second 
cancer. It is common to administer a combination of drugs during 
chemotherapy in case cancer cells develop resistance to any one of the 
drugs. Chemotherapy may be used in combination with surgery and 
radiotherapy and is the only real hope for patients with metastatic 
cancer. 
1.5 Anticancer Drugs 
It is of paramount importance to organic chemists to understand 
the mode of action of anticancer drugs to provide them with a 
foundation for the design of better ones. The three main groups of 
anticancer drugs are alkylating agents, antimetabolites and natural 
products. 
1.5.1 Alkylating Agents 
The largest group of DNA damaging drugs are the alkylating 
agents which originate from the use of mustard war gases. The parent 
compound, nitrogen mustard, forms covalent bonds with nucleophilic 
centres in DNA and other biological molecules. These centres include 
amine, phosphate and hydroxy groups on nucleic acids, nucleotides and 
enzymes. A modified nucleic acid is formed when alkylation occurs 
once. However, -there- are some drugs- that have two alkylating sites. 
These agents crosslink two adjacent strands of DNA in its helical form, 
making it impossible for the double helix to unwind and replicate. The 
lone pair of nitrogen of the drug intramolecularly displaces the chloride 
to form an aziridinium ion (1) which reacts readily with an electron rich 




















Nitrogen mustard is too reactive to be of much clinical use. 
Instead a derivative, cyclophosphamide (2), is widely used for the 
treatment of carcinoma of the breast and of the bronchus. In contrast 
to its parent compound, it can be administered orally since it remains 
inactive until its target site has been reached. Its stability is aided by 
the delocalisation of the nitrogen lone pair with the P=O bond. 
ro C)) Oý IýNH 0,, IPNH 
Ný 
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After a combination of enzymatic and chemical activation, the 
drug is transformed into active phosphoramide mustard alkylating 
agent (Scheme 2). If a single alkylation step only occurs then it could 
lead to mispairing of bases or strand breakage. However, the remaining 
chloroethyl group could react with another molecule of guanine in the 
opposite strand of DNA to form a crosslink. Ifosfamide, melphalan and 































-G ----------- C- 
-C------------- G- 
Part of DNA 
Scheme 2: Formation of active phosphoramide. 8 
(CHO ro 
O,, P,, NH2 
I 
Crosslinked 
DNA /I 11 .O 
R= H2NP(O)O 
Nitrosoureas are another group of alkylating agents. The most 
frequently one used in cancer therapy is bischloroethylnitrosourea 
(BCNU, 3). 
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Nirosoureas are lipid soluble and therefore are able to cross the 
blood-brain barrier and so are frequently used to treat brain tumours. 
BCNU, like cyclophosphamide, is inactive until it undergoes metabolism 
to release a number of cytotoxic compounds. An isocyanate is one of 
these metabolites, which can react to form covalent bonds with 
proteins, causing some cytotoxicity. But it is the alkylation step that is 
ultimately responsible for most of the cytotoxicity. 
1.5.2 Antimetabolites 
Generally, anticancer agents act in several different ways to 
inhibit cell division. Antimetabolites often act by interfering with DNA 
synthesis. When a cell has entered the S phase of its cycle, it has a 
reserve of metabolites from the G1 phase. The bindings of natural 
metabolites onto enzymes are essential for the synthesis of DNA. If 
analogues of these metabolites are present, they too will bind onto the 
enzymes making the enzyme inactive. Antimetabolites are 
administered to mimic the natural metabolites present in the S phase 
and thus compete for enzymes. Therefore, cells that are rapidly 
dividing will have a higher mortality rate. These cells are producing 
their metabolites quicker, which in turn means their enzymes are 
inactivated sooner. 
Antimetabolites inhibit cellular enzymes involved in the synthesis 
of one or more of the nucleotides, the precursors of DNA. They also 
inhibit the synthesis of DNA itself. Methotrexate, 5-fluorouracil, 
cytosine arabinose, mercaptopurine and 6-thioguanine are all 
antimetabolites which inhibit DNA synthesis and are clinically used. 
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5-Fluorouracil (5-FU, 4) mimics the pyrimidine bases uracil (5) 
and thymine (6) of DNA. 5-FU is converted into its corresponding 5-FU 
nucleotide which inhibits thymidylate synthetase irreversibly once it 
has incorporated into the cell cycle (Diagram 2). This antimetabolite is 
used for the treatment of solid tumours and cancers of the breast and 
gastrointestinal tract. Bone marrow suppression and sickness are the 














Tetrahydrofolic acid (THA) is a co-factor for thymidylate 
synthetase (Diagram 2). Removal of THA will indirectly block the 
synthesis of DNA. Methotrexate (7), an analogue of folic acid (8), is 
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used for reducing the production of THA by competing for 
dihydrofolate reductase, an ý enzyme that catalyses the reduction of 
dihydrofolate to tetrahydrofolate. Methotrexate is used to treat acute 
leukaemia and choriocarcinoma. 
Other useful antimetabolites include cytosine arabinose, a 
nucleoside mimic used to treat myeloid leukaemia in adults; 6- 
mercaptopurine, a purine antagonist; and 6-thioguanine, which also 
inhibits purine synthesis. 
1.5.3 Natural Products 
Vincristine (9) and vinblastine (10) are two common alkaloids 
used in cancer therapy. , 
These compounds inhibit the process of mitosis 
by binding to the microtubules protein tubulin. Before mitosis can take 
place, chromosomes are held in a certain orientation by these 
microtubules, also known as spindles. By binding to tubulin, these 
alkaloids disrupt the mitotic spindles and block the cell division at the 
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M phase of the cell cycle. Vincristine is used to- treat leukäeinias and 
lymphomas, and vinblastine is used for Hodgkin's disease. 
Taxol (11), a taxane, is isolated from the bark of Taxus brevifolia. 
It is a potent anticancer drug and is mainly used for treating breast and 
ovarian cancers. Like vincristine and vinblastine, it affects the mitotic 
spindles. Taxol has been shown to stimulate the formation of 
microtubules and also to prevent their breakdown. 10 Any interference 
in the spindle formation will lead to an inbalance of microtubules. Such 
inbalance prevents normal cell division from taking place. Cancer cells 
are most affected because they are rapidly proliferating. Although 
taxol is an effective anticancer drug, its use is limited because of its 
poor water solubility and the difficulty in transporting the drug to the 
site of action. Instead, a phosphate derivative (12) is used because it is 
more stable and is water soluble. Unfortunately, only: small amounts of 
taxol can be isolated. Therefore taxol has to be synthesised. Due to its 
complexity, the total synthesis of taxol was not achieved until 1994 by 
the groups of Nicolaou l, l and Holton. 12 Analogues of taxol such as 
taxotere are proving to be very effective in treating cancers. 
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1.5.4 Miscellaneous Anticancer Agents 
Some chemotherapeutic drugs cannot be categorised under the 
three previous headings. The enzyme asparaginase is used to treat 
acute leukaemias. It breaks down the amino acid asparagine which is 
important for both protein and DNA syntheses. Asparagine is 
generated in normal cells whereas leukaemic cells rely on the blood 
supply for asparagine for growth. Therefore treatment with 
asparaginase reduces the supply of asparagine to leukaemic cells and so 
controls their growth. 
Cisplatin (13) is one of the few inorganic anticancer drugs. It is a 
square planar complex of platinium with two chlorides cis to one 
another. Its mode of action is very similar to that of alkylating agents. 
The chlorides can be replaced by nucleophilic sites on proteins or 
nucleic acids. Dialkylation can occur to produce DNA cross-linkage or 
monoalkylation can produce a modified protein or DNA molecule. 
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Although the mechanism- is ' not ' fully known, N-7 of guanine'-is 'probably 
the base that undergoes the SN2 displacement. Interestingly, the trans- 
isomer appears to be completely unable to induce DNA cross-linkages of 
the double helix. , 
Cisplatin is used for treatment of testicular cancer as 
well as being used in combination with other drugs in treating a variety 





Unlike alkylating agents which directly react with DNA molecules, 
there are some chemotherapeutic drugs which can cause DNA damage 
indirectly by interacting with the enzyme, topoisomerase II (Diagram 
3). Topoisomerase II, acts to break and rejoin DNA strands within the 
cell, and is required for a number of cell processes including DNA 
replication. - Etoposide and teniposide are chemotherapeutic drugs that 
are used to inhibit the rejoining process by forming a covalent complex 
with topoisomerase II and DNA. Thus any DNA already broken cannot 
be rejoined causing the DNA molecule to cleave permanently, leading 
eventually to cell death. Inhibition of topoisomerase II also occurs with 
the natural products daunomycin and doxorubicin. 
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1.6 Further Drug Development 
Patients are sometimes misled to believe that cancer therapy will 
cure them from the disease. The truth is that over the past fifty years 
of intense research, there has been no single drug found which will 
banish cancer cells completely. 
Whilst patients are undergoing therapy, they may also suffer the 
side effects of anticancer drugs. This is the price paid to extend the 
patient's life. Since the discovery of DNA, anticancer drugs have been 
designed to target on it. The nucleus of a cell was the main point of 
focus, that is, until more was known about how signals travel within the 
cell. Signal transduction pathways leading to cell division and 
sometimes tumour promotion were identified and so provided a fuller 
picture of the cell's behaviour. This expanded the range of drug design. 
If a certain biochemical pathway was found to lead to a faster rate of 
cell proliferation, a synthetic drug could be introduced to try to block 
this pathway. Thus a new field of targets was identified. The area of 
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focus shifted from the nucleus to other parts of the cell, in particular, 
the cytoplasmic enzymes involved in signal transduction pathways. 
Future drugs will be developed to target tumour promoting 
enzymes, instead of DNA. DNA is at the heart of the cell and damaging 
or modifying it will ultimately cause side effects. Thus new drugs will 
be developed to reduce these side effects. 
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CHAPTER TWO 
Cell Signalling and Cancer 
Cell growth and differentiation of' normal cells are carefully 
regulated by external signals. These external signal molecules are 
growth factors, neurotransmitters and hormones. Binding of' these 
signals onto specific cell surface receptors triggers a series of' reactions 
inside the cell (Diagram 4). This cascade of reactions serves to transmit 
a signal from the exterior surface of a cell to its nucleus. 't'his will alter 






A series of reactions 
Diagram 4 






Growth factors are a group of' small secreted proteins, typically 
IO amino residues long. They hind onto cell surface receptors (growth 
factor receptors) which serve as external sensors. Info-Illation in the 
form of a signal is transmitted Iron the extracelluIll- matrix to the 
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interior of the cell. Overall, information on the cell environment is sent 
to its nucleus resulting in a change in gene expression. This in turn 
produces cell growth and division. Many growth factor receptors are 
members of a family of proteins that function as protein tyrosine 
kinases (PTKs). 
Although the functions of many growth factors and their 
receptors have"' been established14, the exact sequence of ' events in 
signal transduction is still not fully understood. This area of research is 
still active. Nevertheless, some of the cellular reactions involved in PTK 
mediated growth have been identified. The understanding of these 
pathways opens up a new area for chemotherapeutic drug 
development. A synthetic drug can be used to target a known receptor 
in the signal transduction pathways so that it can intercept the signal 
from reaching the nucleus. This will arrest the growth of transformed 
cells which is the ultimate aim of cancer therapy. 
2.2 Role of Protein Kinase C in Cell Growth 
The PTK receptor consists of two domains: intracellular and 
extracellular because it is partially embedded in the cell membrane 
(Diagram 5). Binding of a growth factor onto the receptor activates four 
distinct target molecules in the cytoplasm. Phospholipase C is the most 
important target molecule activated. It catalyses the hydrolysis of 
phosphatidylinositol 4,5-bisphosphate, generating diacylglycerol (DAG) 
and inositol triphosphate. These two compounds appear to play an 
important role in regulating cell division. Inositol triphosphate opens 
up the calcium channel allowing the calcium concentration to increase 
in the cytoplasm. An increase of calcium will lead to the activation of 
several other calcium-stimulated protein-serine/threonine kinases. 
DAG activates the enzyme protein kinase C (PKC), a protein- 
serine/threonine kinase. 
PKC can stimulate cells to divide; thus it must be carefully 
regulated by the cell to prevent it from being overexpressed. Therefore 
the amounts of diacylglycerol present in the cell are crucial for cell 
division. The triol is only produced in small quantities by the 
hydrolysis of phosphatidyl 4,5-bisphosphate but most of it is derived 
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from the breakdown of phosphatidylcholine by the sequential action of 
phospholipase D and phosphatidic acid phosphohydrolyase. In 
conclusion, unregulated activity of PKC and the disruption of DAG 
production can contribute to tumour formation. Over the last few years 
some metabolites of sphingolipids have found to be regulators of both 















Outside the cell 
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2.3 Natural Inhibitors of Protein Kinase C 
Sphingolipids are located in the cell membrane and, like many 
other lipids, were thought only to have a structural function, that is, 
they allowed desired nutrients to travel across the membrane. Over 
the last decade, metabolites of membrane lipids have been shown to 
play an important role in cell functions and to act as mediators to the 
cells' environment. In particular sphingosine and related compounds 
which are metabolites of sphingolipids, have attracted a lot of attention 
as a result of their ability to inhibit PKC. In the past few years 
sphingoid bases have emerged as a new of class of bioregulatory 
substances. Current evidence suggests exogenous sphingosine is 
involved in the signal transduction pathways, and at present there is 
little evidence for effects of endogenous sphingosine. The mode of 
action of exogenous sphingosine on protein kinases and the possible 
role of endogenous sphingosine in modulating signal transduction 
pathways will be discussed later in this chapter. Understanding of the 
biosynthesis of sphingolipids has provided a better insight into how 
endogenous sphingosine could be generated and how it could then be 
used to inhibit PKC indirectly. 
2.4 Biochemistry of Sphingolipids and Sphingosine 
The backbone of all sphingolipids is sphingosine, a long 
unsaturated hydrocarbon chain containing an aminodiol. The structure 
of sphingosine and its reported syntheses are discussed in chapter 3. 
The amino group of each sphingolipid is linked to a fatty acid by an 
amide bond. The difference between each lipid is the head group 
attached to the primary hydroxyl group. In sphingomyelin the primary 
hydroxyl group is substituted by a phosphorylcholine unit whereas in 
glycosphingolipids, a sugar molecule is linked to the hydroxyl group by 
a glycoside bond. Sphingolipids and their metabolites are found not 
only in mammalian tissues but also in plants. Phytosphingosine is one 
example that is present in both mammalian tissues (such as kidneyl6 
and liver 17) and plants. 18 
The biosynthesis of sphingolipids and sphingosine has been 
established and is well documented. 19 Palmitoyl CoA and serine 
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condense to form 3-ketosphinganine ý which is then reduced to 
dihydrosphingosine (Scheme 3). Dihydrosphingosine can either be used 
directly in the biosynthesis of sphingolipids or after, its conversion into 
sphingosine. The amino group of sphingosine is acylated with a long- 
chain acyl CoA to form ceramide (N-acylsphingosine). This is the key 
intermediate from which all sphingolipids are synthesised by coupling 




































Galactose / Glucose Cerebrosides 
Sulfagalactose Sulfatide 
Oligosaccharide Glycosphingolipids 
Scheme 3: The biosynthesis of sphingosine and sphingolipids 
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Sphingomyelinases catalyse the hydrolysis of sphingolipids to 
their corresponding ceramides and polar head groups or, to their 
lysosphingolipids and fatty acids. These enzymes are found in 
lysosomes and in plasma membranes. The latter require magnesium 
ions for activation. The action of a plasma membrane ceramidase on 
ceramide produces sphingosine. The excess of sphingosine can be 
reacylated and then is fed back into sphingolipid biosynthesis. On the 
other hand, sphingosine can be removed by undergoing 
phosphorylation and by subsequent degradation into 
phosphorylethanolamine and palmitaldehyde. 20 
2.5 Role of Exogenous Sphingosine 
The inhibitory effect of exogenous sphingosine and other 
naturally occurring sphingoid bases on PKC was discovered by Hannun 
and co-workers. 21,22 Further studies show that lysosphingolipids are 
also potential inhibitors of' PKC. With these discoveries, sphingoid bases 
provided a better insight into signal transduction pathways. With the 
knowledge that sphingosine inhibits PKC and the fact that it is used in 
more and more studies, its role in cell growth begins to become 
apparent. Interestingly, sphingosine was found to stimulate other 
protein kinases, in particular, the epidermal growth factor receptor 
tyrosine kinase and human epidermoid carcinoma cells. 23-26 An 
important discovery into the effects of some sphingosine analogues on 
protein kinases was noted by Igarashi et al. 26 ' They reported that N, N- 
dimethyl-L-erythro-sphingosine is a specific stimulator of epidermal 
growth factor receptor tyrosine kinase but N, N-dimethyl-D-erythro- 
sphingosine, D-erythro-sphingosine, and several lyso-sphingolipids are 
all inactive. In addition, they also reported that N, N-dimethyl-D - 
erythro-sphingosine is a better inhibitor than the pure synthetic D- 
erythro-sphingosine. 27 However, N, N-dimethyl-D-erythro-sphingosine 
stimulated another protein tyrosine kinase, src kinase while D-erythro- 
sphingosine inhibited its activity. In short, exogenous sphingosine has 
multiple effects on several protein kinases. 
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2.6 Endogenous Sphingosine 
2.6.1 Production of Endogenous Sphingosine 
A model of the sphingolipid cycle has been postulated21 to 
illustrate how sphingosine may be generated inside the cell (Diagram 
6). Endogenous sphingosine may be obtained by hydrolysis of 
sphingolipids followed by deacylation of ceramide. The free 
sphingosine could then be used as a modulator of cell function. The 
action of sphingosine could be then terminated by either reacylation so 
that it could be reused ý in sphingolipid biosynthesise- or by 
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Diagram 6: The sphingolipid cycle 
The main drawback in earlier studies of endogenous sphingoid 
bases as cell regulators was that there was no way of knowing whether 
or not endogenous free sphingoids existed inside the cell. Recently, 
Kobayashi et al. 28 developed a sensitive HPLC method for quantitation 
of endogenous sphingoid bases. This technique, along with the use of a 
radioenzymatic method, developed by Van Veldhoven et al., 2 9 
confirmed that endogenous sphingoid bases are present in different 
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amounts depending on the cell type. Both methods also confirmed the 
biosynthetic pathways operating in the sphingolipid cycle. More 
studies were carried out on endogenous sphingoid base activation 
inside the cell. Of particular interest were the findings by Kolesnick et 
al. 30,31 They were the first group to demonstrate that DAG, and not 
phorbol ester, stimulated the activity of an endogenous 
sphingomyelinase, causing an increase in ceramide and sphingosine 
levels. The activation of PKC by DAG seems to stimulate the breakdown 
of sphingolipid yielding the PKC inhibitor sphingosine. 
2.6.2 Indirect Inhibition of Protein Kinase C by Endogenous 
hingosine 
Sphingosine can modulate the level of DAG by inhibiting its 
production and activating its breakdown. It is a potent inhibitor of 
phosphatidic acid phosphohydrolase (PAP), the enzyme which 
hydrolyses phosphatidic acid to form DAG. Brindley et al. 32 have 
shown that there are two distinct types of PAP activities in rat liver. 
Phosphatidic acid phosphohydrolase .1 (PAPI) is dependent on 
magnesium ions for its activity and is involved in the synthesis of 
triacylglycerols, phosphatidylcholine and phosphatidylethanolamine. 
PAPI is believed to be inactive in the cytosol and only becomes active 
when it is translocated to the endoplasmic reticulum. The other type of 
phosphatidic acid phosphohydrolase, PAP2, does not require 
magnesium ions for its activty and is located in the plasma membrane. 
It is believed that PAP2 is involved in signal 'transduction. 
The other enzyme which is affected by sphingosine, as recently 
shown by Sakane et al., 33 is diacylglycerol kinase isozyme. This 
isozyme converts DAG into phosphatidic acid and can be activated by 
sphingosine. Sphingosine may reduce most of the DAG levels by 
inhibiting PAP2 enzyme and by activating the DAG removal isozyme. 
Therefore it can inhibit PKC indirectly by decreasing the amount of DAG 
available for its activation. Kolesnick has proposed a model (Diagram 7) 
to help to explain how endogenous sphingosine terminates PKC 
activation. 31 According to this model, the levels of DAG and 
sphingosine are mutually dependent and are well balanced. For 
instance, the action of DAG may be terminated by activating a 
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membrane . sphingomyelinase to generate free sphingosine, thus 











Abbrevations: (Plus), stimulatory regulatory effects; (Minus), inhibitory regulatory 
effects; (1), phospholipase D; (2) phosphatidic acid phosphohydrolase; 
(3) diacylglycerol kinase; (4) sphingomyelinase; (5) ceramidase; 
PC, phosphatidylcholine; DAG, diacylglycerol; PA, phosphatidic acid; SM, 
sphingomyelinase; PKC, protein 
kinase C. 
Diagram 731: Dual action of sphingosine on diacylglycerol signal termination 
The various routes which have been used to synthesise 
sphingosine and related compounds are discussed in the next Chapter. 
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CHAPTER THREE 
Review of Sphingosine 
3.1 The Structure of Sphingosine 
Sphingosine (14) is termed as a regulatory compound2l, 22 and is 
the backbone of all sphingolipids. Such lipids are important in cell 
growth, cell adhesion and cell recognition. Since they constitute most of 
the cell membrane, they are compounds of increasing interest as they 
should provide a better insight into the role and function of cell 
surfaces. As discussed in Chapter 2, sphingosine is also important in 
the inhibition of Protein Kinase C. Unfortunately only small amounts of 
partially pure sphingosine and its derivatives can be extracted from 
plants and mammals. This fact is the driving force for organic chemists 
to set up some novel syntheses in which large amounts of sphingosine 
could be prepared in the laboratory, so that a variety of sphingolipids 
could be synthesised. 
Sphingosine is a 2-amino-1,3-diol with an E-double bond between 
C-4 and C-5, two chiral centres and a long alkyl chain. Its structure is 
basically made up of two parts: hydrophobic and hydrophilic moieties. 
Since there are two chiral centres present, there are four possible 
stereoisomers. Naturally occurring sphingosine has the (2S, 3R)-[D- 
erythro] -configuration. 
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The three approaches that have been largely,. used, for the 
synthesis of sphingosine involve: 1) the use of achiral materials to 
achieve synthesis of racemic material; 2) diastereoselective synthesis 
from simple chiral starting materials such as (S)-serine and sugar 
compounds; and 3) the use of versatile reactions such as Sharpless 
asymmetric epoxidation to achieve enantioselective synthesis. The 
most common disconnection (Scheme 4) is the breakage of the bond (b) 
as the aminodiol synthon is readily available from (S)-serine and many 
natural sugar compounds. Disconnection (a) remains most attractive 
and requires the synthesis of two new chiral centres in one or two 
steps. Asymmetric aldol reaction using a chiral auxiliary is frequently 
used to achieve the stereoselectivity. Racemic, diastereoselective, and 
enantioselective syntheses of sphingosine, in that order, are covered in 
the following review. The literature survey presented here covers the 
year 1952 onwards. 
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Scheme 4: Retrosynthesis of sphingosine 
3.2 Synthesis of Racemic Sphingosine 
This section reviews various ways in which the synthesis of 
racemic erythro-sphingosine and its derivatives were achieved. Most 
workers used an asymmetric synthesis to prepare racemic erythro- 
sphingosine except for the very early literature where the primary aim 
was probably to synthesise sphingosine, irrespective of its 
configuration. 
Grob and Gadient34 were the first group to synthesise racemic 
sphingosine and a derivative in 1952. Their synthesis is one of the 
shortest in the literature but they made no attempt to tackle the 
stereochemical problem and thus all four stereoisomers were formed. 
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Condensation of 2-pentadecynal (15) with. 2-nitroethanol gave all, four 
stereoisomers of 2-nitro-4-octadecyn-1,3-diol (16) (Scheme 5). The 
th re o -racemate . was separated from the erythro -racemate by 
chromatography. The nitro group was then reduced with zinc, and 
hydrochloric acid to the amino group. Partial reduction of the triple 
bond in the erythro-racemate with lithium aluminium hydride gave 
racemic erythro-sphingosine (17) whereas on prolonged exposure 
under hydrogen atmosphere, the triple bond was completely reduced to 

























Scheme 5: Synthesis of (±)-Z- and E-erythro-sphingosine and 
(L)-erythro-dihydrosphingosine by Grob and Gadient. 34 
An improved synthesis of racemic sphingosine was developed by 
Schmidt and co-workers starting with a C16 aß-unsaturated aldehyde 
(Scheme 6). 35,36 They had already established the reaction conditions, 
in which high diastereoselectivity would be obtained when the a- 
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aldehyde. 37 These conditions were then applied to the condensation of 
aC 16 aß -unsaturated aldehyde with the same anion which afforded 
exclusively the erythro-product (19). The stereospecificity may be due 
to the size of the disilylated amino group which disfavours the 
formation of the Z-enolate. The course of the reaction probably goes 
through a chair-like transition state which is held by the lithium ion. 
Reduction of the amino acid with lithium aluminium hydride followed 
by triacetylation gave racemic N, 0,0-triacetylsphingosine. It was 
important to carry out the acetylation step as this protected the amino 
group from being oxidised in air. 
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(±)- erythro-N, 0, O-Triacetylsphingosine 
(1s) 
Scheme 6: Synthesis of (±)-erythro-sphingosine by Schmidt et a1.35,36 
0 1sH27 
In contrast to the previous synthesis, Garigipati and Weinreb3 8 
developed a more efficient route which employed an intramolecular 
Diels-Alder reaction to construct the relative configuration on the cyclic 
system. Myristic aldehyde was converted in three steps into (Z, E) - 
carbamate (20), which upon treatment with thionyl chloride and 
pyridine afforded sulfinylcarbamate (21) (Scheme 7). Cycloaddition of 
the compound occurred at room temperature to give the Diels-Alder 
adduct (22). The bicyclic, product, upon treatment with 
phenylmagnesium bromide, underwent a 2,3-sigmatropic 
rearrangement via a five-membered ring transition state to give the 
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Scheme 7: Synthesis of (t)-erythro-sphingosine by Garigipati and Weinreb. 38 
In 1985 Cardillo et al. 39-41 managed to achieve another 
diastereoselective synthesis of racemic sphingosine, using the same 
starting material as Weinreb's group. The dienol was tranformed into 
its trischloroacetimidate (23). Regioselectivity of the cyclisation was 
uncertain, because compound (23) can either undergo a 5-exo or 6- 
endo closure in the presence of N-iodosuccinimide (Scheme 8). Since 
only the 6-membered oxazine ring was formed, the reaction must have 
been governed by an electronic factor. Cleavage of the oxazine followed 
by treatment with amberlyst A 26 in the carbonate form gave the 
corresponding unsaturated aziridine (24). Racemic erythro-N- 
acetylsphingosine was produced in two steps: protonation of the 
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the acetate form. Basic hydrolysis of racemic erythro-N- 
acetylsphingosine afforded racemic erythro-sphingosine. 
Scheme 8: Synthesis of (± )-eiythro-sphingosine by Cardillo et al. 39 41 
3 .3 Diastereoselective Synthesis of 
D-ervthro- phinl; osine 
This section reviews the various diastereoselective approaches 
that have been used to prepare D-erythro-sphingosine and its 
derivatives. The idea was to start the synthesis with homochiral 
starting material so that it could be used to control the stereochemical 
outcome of the formation of the new chiral centre. 
3.3.1 Diastereoselective Synthesis of D-erythro-Sphingosine 
using Carbohydrates 
Many carbohydrates are ideal homochiral starting materials in 
sphingosine syntheses. They are commercially available, inexpensive 
and their absolute configurations are known. In addition, their 
functional groups are useful for manipulation. 
The diastereoselective synthesis of D-erythro-sphingosine and its 
derivatives (Scheme 9) by Reist and Christie, 42,43 commences from 
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readily available 3-amino-3-deoxy-1,2: 5,6-di-O-isopropylidene-a-D- 
allofuranose (25) which was transformed in three steps into its di- 
protected aldehyde (26). Wittig condensation of the aldehyde with 
tetradecyltriphenylphosphonium bromide afforded Z- and E-isomers 
(27) as a mixture. Acid hydrolysis of the acetal followed by standard 
sodium periodate oxidation and reduction reactions gave the 
unsaturated diol (28). Hydrogenation of the diol using 10% palladium 
on charcoal reduced the the double bond completely as well as 
removing the benzyl group to afford D-erythro-dihydrosphingosine 
(29). Interestingly, when the ethyl carbamate (30) was used instead of 
benzyl carbamate, Wittig coupling in the presence of lithium salt gave 
only the E-isomer. Using standard deprotection steps as before, the 
corresponding diol (31) was formed. Basic hydrolysis of the crude 
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Scheme 9: Synthesis of D-erythro-sphingosine and D-erythro-dihydrosphingosine by 
Reist and Christie. 42,43 
A similar approach was adopted by Ogawa et al. using 1,2: 5,6-di- 
O-isopropylidene-a-D-glucofuranose as starting material (Scheme 
10). 44,45 Wittig coupling was applied to introduce the double bond. 
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The ratio of E-alkene to' its Z-isomer was 43: 57. The crucial difference 
between this approach and that of Reist and Christie, ý is that the former 
used irradiation in order to improve the E- and Z-ratio to 94: 6. The free 
secondary alcohol was converted into its mesylate before carrying out 
the three steps required for transforming the acetal into the diol. The 
diol was then protected as a macrocyclic structure (32). In order to 
establish the erythro-configuration, SN 2 displacement had to be 
performed on the mesylate group using sodium azide. Reduction of the 
azide, acylation and deprotection gave D-erythro-ceramide (33). 
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Scheme 10: Synthesis of D- erythro-ceramide by Ogawa et al. 44,45 
HN C23H27 
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Gigg and co=workers "made full use of oxazoline chemistry to 
prepare intermediates for the synthesis of sphingoglycolipids. The 
strategy of this approach (Scheme 11)46,47 involves cleaving a 
phenyloxazoline (34) to give a benzamide (35),, which cyclises with the 
mesylate to generate a new oxazoline (36). Through the course of 
cyclisation the erythro-configuration was established. The epoxide was 
made in. 4 steps. . 
Hydrolysis of the acetal followed by dimesylation and 
selective displacement of the primary mesylate by sodium benzoate 
gave the benzoate (37). The benzoate was readily converted into the 
oxirane (38) with sodium methoxide in chloroform-methanol. 
Alkylation with a Grignard reagent, followed by deprotection of the 
acetal gave the triol (39). This triol was then converted into the D- 
erythro-sphingosine phenyloxazoline derivative (40). 
Despite its length, the synthesis of (2S, 3R )- and (2S, 3S)- 
sphingosine developed by Obayashi and Schlosser48 is well designed. 
This is because the whole synthesis can be performed on a large scale 
without affecting the yields. D-(+)-Mannose was transformed into the 
bromodihydrofuran (41) (Scheme 12). This was the key intermediate 
which underwent dehalogenation in the presence of n-butyllithium and 
caused the 5-membered ring to collapse to generate the carbinol (42). 
Alkylation by the acetylide and SN2 displacement of the mesylate by 
lithium azide gave the azide with the desired stereochemistry. The last 
step involved reduction of the triple bond and the azide as well as 
deprotection. The success of this synthesis was heightened by the fact 
that threo-sphingosine was obtained via this route by using D-(+)- 
ribono-1,4-lactone as starting material. 
37 
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Scheme 12: Synthesis of erythro- and threo-sphingosine by Obayashi and 
Schlosser. 48 
In addition to the contribution made in the synthesis of racemic 
sphingosine, Schmidt and Zimmermann49,50 developed a route to D- 
erythro-sphingosine starting from D-galactose (Scheme 13). This sugar 
was converted into its 4,6-0 -benzylidene-D-galactose which upon 
treatment with sodium metaperiodate provided the desired 2,4-0- 
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benzylidene-D-threose (43). However, in the same year, Kiso et al. 5 1 
showed that 2,4-O-benzylidene-D-threose could be obtained from two 
different sugars., Wittig coupling of the 2,4-O-benzylidene-D-threose 
with hexadecanylidene triphenylphosphorane in the presence of 
lithium bromide gave exclusively the E-eiscosentriol (44). The 
mesylate of the alcohol was converted into the azide as before. 
Deprotection followed by reduction of the azide yielded D-erythro- 
sphingosine. 
In contrast to the above syntheses, Kamikawa et al. used 'a six- 
membered ring sugar, as opposed to five, as starting material and 
achieved diastereoselective synthesis of D-erythro-sphingosine (Scheme 
14). 52 Mercuric ý ion-assisted acid hydrolysis of 3,4,6-tribenzyloxy-D- 
galactal yielded hydroxy-E-enal (45). Reduction of the aldehyde gave 
the diol which was then protected as the diacetate (46). Coupling of 
dodecylmagnesium bromide cuprate with the allyl acetate gave the 
desired a -substitution product. Displacement of the acetate group to 
obtain the azide with complete inversion of the stereochemistry was 
carried out via three steps: methanolysis, mesylation and formation of 


















Scheme 13: Synthesis of D-erythro-sphingosine by Schmidt and 
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Scheme 14: Synthesis of D- erythro-sphingosine by Kamikawa et a1.52 
Adopting a new approach, Inazu et al. carried out the synthesis of 
D-erythro-sphingosine by starting from 2,3-O-isopropylidene-D- 
glyceric acid methyl ester (47), which when coupled with dimethyl 
methylphosphonate, generated the phosphonate (48) (Scheme 15). 5 3 
Wittig condensation with myristic aldehyde in the presence of caesium 
carbonate gave exclusively the E -product (49). High 
diastereoselectivity in the reduction of the unsaturated ketone was 
achieved with L-Selectride. Hydrolysis of the acetal followed by 
treatment of the triol with benzaldehyde afforded the six-membered 
ring acetal. Displacement of the free hydroxyl group by sodium azide 
with inversion of stereochemistry was achieved in the usual manner 
(mesylation and formation of the azide). Reduction of the azide 
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Scheme 15: Synthesis of D-erythro-sphingosine by Inazu et al. 53 
3.3.2 Diastereoselective Synthesis of D-e ry th ro -Sphingosinc 
using Serine 
Another homochiral building block which has made an important 
impact in the diastereo selective synthesis of D-erythro-sphingosine is 
(S)-serine. Use of serine as a 'starting material has an advantage over 
most sugars. There is no need to carry out the typical three steps 
which convert the threo-triol into its erythro-aminodiol as the amino 
group is already present in serine. 
Newman54 reported a short and highly stereoselective synthesis 
of D-erythro-sphingosine in 1973. (S)-Serine was converted into the 
aldehyde (50) by N-phthaloylation, O-acetylation, acid chloride 
formation and catalytic hydrogenation (Scheme 16). Addition of trans- 
pentadecenyldiisobutylalane to the aldehyde gave a 4: 1 mixture of 
erythro- and threo-isomers. The diastereoisomers were separated by 
chromatography. The conformation of the aldehyde controlled the 
43 
outcome of the diastereomeric mixture. Fortunately the preferred 
conformation, according to the proton NMR spectrum, was the one that 
gave predominantly the a ry th ro-isomer, when attacked by the 
organometallic reagent. 
Scheme 16: Synthesis of D-erythro-sphingosine by Newman. 54 
The approach adopted by Tkaczuk and Thornton55 was based on 
the sphingosine synthesis of Newman. (S)-Serine methyl ester56 was 
protected as an oxazoline which was then reduced to the aldehyde with 
diisobutylaluminium hydride (Scheme 17). Treatment of this aldehyde 
with E-pentadecenyldiisobutylalane gave the sphingosine oxazoline and 
its epimer as a 1: 1 mixture. These isomers could be separated 
chromatographically. Acid hydrolysis of the erythro-isomer followed 
by N-acylation with p-nitrophenyl oleate afforded the corresponding D- 
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Scheme 17: Synthesis of erythro- and threo- sphingosine derivatives by Tkaczuk and 
Thornton. 55 
Kozikowski and Wa57 were the first group to incorporate fluorine 
into sphingosine. Fluorine is a good replacement for an hydroxyl group 
because they are similar in size and fluorine can also act as a hydrogen 
bond acceptor. D-erythro-Sphingosine oxazoline was prepared using 
the procedure of Tkaczuk and Thornton. 55 Reaction of sphingosine 
oxazoline with 2-chloro-1,1,2-trifluorotriethylamine afforded the 
corresponding fluoro derivative (51) as well as the allylic 
CsFi5/ 
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rearrangement product (52) (Scheme 18). Since the fluoro derivative 
(51) was isolated as a single stereoisomer, the reaction must have 
occurred via an SN2 mechanism. Hydrolysis of the oxazoline gave E- 
threo-2-amino-3-fluoro-octadec-4-en-l-ol (53). 
Scheme 18: Synthesis of a fluorine-containing isostere of sphingosine by 
Kozikowski and Wa. 57 
A new improved procedure had been developed by Garner et al. 
for the synthesis of D-erythro-sphingosine from another stable 
protected serine aldehyde (Scheme 19). 58 The efficacy of this 
aldehyde as a chiral building block was also demonstrated by Herold, 5 9 
Liotta et al. 60 and Radunz et al. 61 N-BOC-(S)-Serine methyl ester was 
transformed into the aldehyde (54) by acetalisation and reduction with 
diisobutylaluminium hydride. Treatment with 1-pentadecynyllithium 
gave the corresponding erythro-sphingosine 2,2-dimethyloxazolidine 
and its epimer as a 9: 1 mixture. These diastereoisomers were readily 
separated chromatographically. Birch reduction followed by acid 
hydrolysis afforded D-erythro-sphingosine. However, on exposure to 
Lindlar hydrogenation cis-erythro-sphingosine was obtained. 
Interestingly, high threo-selectivity was observed on addition of 1- 
pentadecynyllithium to the aldehyde in the presence of anhydrous zinc 
bromide with dry ether as a solvent. It is noteworthy that the 2,2- 
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dimethyloxazolidine (55) and its epimer can be interchanged via a 
Mitsunobu inversion at the C-3 centre. 
N-BOC Serine 1) Dimethoxypropane__ 
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Scheme 19: Synthesis of D-erythro-sphingosine by Garner et a1., 58 Herold, 59 Liotta 
et a1.60 and 'Radunz et a1.61 
In contrast to the synthesis of Garner et al., Rapoport and 
Boutin62 took two steps to synthesise the ynol (56) instead of one. a'- 
Amino-ap -ynone was synthesised initially and then treated with 
sodium borohydride to achieve the diastereoselectivity (Scheme 20). 
N-Z-(S)-Serine was reacted with isobutylchloroform ate to generate a 
mixed anhydride which was then quenched with isoxazolidinc. N-Z-(S)- 
Serine isoxazolidide (57), being analogous to Weinreb's amide deserves 
to be mentioned. This amide can only react with one mole of the 
nucleophile, due to the lithium ion complexing to both oxygens, giving 
rise to a stable intermediate which cannot undergo further alkylation. 
Alkylation of the amide (57) with an excess of 1-pentadecynyllithium 
afforded the corresponding ap-ynone. Diastereoselective reduction of 









4: 1 mixture. Chromatography followed by Birch reduction afforded D- 
































syn : anti =1: 4 
Scheme 20: Synthesis of D-erythro-sphingosine by Rapoport and Boutin. 62 
3.4 Enantioselective Synthesis of Sphingosine 
Enzymic reaction, Sharpless asymmetric epoxidation and 
asymmetric aldol reaction are the three approaches that have been 
frequently employed to introduce the stereochemical centres in one 
step. Only a few groups have employed enzymes to achieve 
enantioselective synthesis. In most cases, epoxidation and the aldol 
reaction are more favoured. 
Earlier work of enantioselective synthesis of D-erythro- 
sphingosine via Sharpless asymmetric epoxidation was carried out by 
V as el la et al. 6 3,64 The enynol (58) was synthesised from 
epichlorohydrin as shown in Scheme 21. Sharpless asymmetric 
epoxidation of the enynol gave the desired epoxide and the free alcohol 
was then converted into a carbamate. This carbamate was then 




step in this synthesis was the regioselective intramolecular opening of 
the oxirane by the nitrogen anion of the carbamate to afford the 
erythro-carbamate (59). Treatment with lithium and ethylamine 
afforded selective reduction of the triple bond and debenzylation. Basic 
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Scheme 21: Synthesis of D- erythro-sphingosine by Vasella et a/. 63,64 
In an approach to (+)-aplidiasphingosine, Mori and Umemura 
prepared the key intermediate triene (60), from optically pure (R)- 
methyl citronellate in 16 steps (Scheme 22). 65 The triene (60) was 
epoxidised with tert-butylhydroperoxide in the presence of titanium 
(IV) isopropoxide and (+)-diethyl tartrate to give the epoxy alcohol 
(61). Cleavage of the oxirane with ammonia gave a (3: 1) mixture of 
diastereoisomers. Both isomers were purified by column 
chromatography. The absolute stereochemistry of the threo- 
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Scheme 22: Synthesis of (+)-aplidiasphingosine by Mori and Umemura. 65 
A new route was established by Katagawa et al. in which all 
sphingosine stereoisomers were synthesised from Z- and E-1,4- 
butenediol (Scheme 23). 66 Z-1,4-Butenediol, used to prepare D-threo- 
sphingosine, was converted into its (2R, 3 S)-epoxide in 4 steps: 
monoacylation of the diol, protection of the free alcohol, alkaline 
hydrolysis of the acetate to generate the allyl alcohol system and 
Sharpless epoxidation. Upon treatment with Ti(OiPr)2(N3)2, the 
epoxide was opened regioselectively to give the 1,3-diol (62). It was 
converted into the aldehyde (63) through successive reactions: 
diprotection of the diol, reduction of the azide, N-acetylation, selective 
deprotection and Swern oxidation. Wittig condensation of the aldehdye 
(63) with tetradecyltriphenylphosphonium bromide gave a mixture of 
Z- and E-isomers. The ratio of this mixture was improved in favour of 
the E-isomer by irradiation of the crude product in the presence of 
diphenyldisulfide. Removal of the protecting groups afforded D-threo- 
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sphingosine. Interestingly opening of the (2R, 3R)-epoxide with azide 
led to a mixture of 1,2-diol (64) and 1,3-diol (65) in the ratio of 1: 14. 
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Scheme 23: Synthesis of erythro- and threo-sphingosine by Katagawa et al. ss 
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Nicolaou et al. reported enantioselective synthesis of sphingosine 
using an asymmetric aldol reaction with an aß-unsaturated aldehyde 
(Scheme 24). 67 The strategy was based on the work of Evans and co- 
workers. 68 The oxazolidinone derivative (66) was transformed into its 
boron enolate and condensed with C16 aß-unsaturated aldehyde to 
afford a mixture of syn-adducts. The diastereoisomers were separated 
by column chromatography. SN2 displacement of the bromide with 
sodium azide gave the corresponding azide. Silylation of the secondary 
alcohol followed by reductive cleavage of the chiral auxiliary provided 
the monoprotected alcohol (67). Finally, D-erythro-sphingosine was 
obtained by desilylation and reduction of the azide. 
1) Bu2BOTf, NEt3 
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N Et3 NH2 
Scheme 24: Synthesis of D-erythro-sphingosine by Nicolaou et al. 67 
C 13H27 
The key step of the synthesis of Ito et al. 69 was to employ the 
chiral (aminoalkyl)ferrocenylphosphine-gold (I) complex to catalyse the 
asymmetric aldol reaction (Scheme 25). Reaction of C16 aß-unsaturated 
syn : anti = 95: 5 
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aldehyde with methyl isocyanoacetate (68) in the presence of this 
complex gave a quantitative yield of methyl 5-[(E)-l-pentadecenyl]-2- 
oxazoline-4-carboxylate consisting of anti- and syn-isomers in a ratio of 
89: 11. A chiral shift reagent, Eu(dcm)3, was used to calculate the 
enantiomeric excess. Hydrolysis and, reduction, followed by acetylation 
provided the D-threo-N- acetylsphingosine. Synthesis of D-erythro- 
sphingosine was readily achieved from the threo-isomer by carrying 
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Scheme 25: Synthesis of erythro- and threo- sphingosine by Ito et a!. 69 
Schollkopf et al. developed a new enantioselective synthesis of D- 
erythro-sphingosine via an asymmetric aldol reaction from the 
bislactim. ether of cyclo-(L-Val-Gly) (69) (Scheme 26). 70 Aldol addition 
of the lithiated derivative of the bislactim ether to an aß-unsaturated 
aldehyde normally gave exclusively the syn-adduct with high 
diastereoselectivity. However, when the C16 aß-unsaturated aldehyde 
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was used, a 1: 1 mixture' of syn-and anti-adducts was observed. The 
yield of the hydrolysis step was improved when the hydroxyl group 
was protected. Reduction of the ester followed by debenzylation with 
lithium and ethylamine afforded D-erythro-sphingosine. 
Scheme 26: Synthesis of D-erythro-sphingosine by Schollkopf et a1.70 
A .. _ lengthy enantioselective sphingosin- synthesis via enzymic 
reaction was reported by Findeis and Whitesides (Scheme 27). 71 
Fumarase (E. C. 4.2.1.2) was used to transform achiral chlorofumaric acid 
into L-threo-chloromalic acid by stereospecific hydration of the carbon- 
carbon double bond. Reduction of the diacid followed by acetalisation 
gave the corresponding hydroxy acetonide which, upon treatment with 
benzyl isocyanate gave the carbamate (70). , 
Deprotonation of the Nil 
resulted in a direct SN2 displcement of the chloride. The acetal was 
converted into its aldehyde (71) in 5 steps. Reaction of the aldehyde 
with lithiated phenyl n-tetradecanyl sulfone followed by acetylation 
yielded the acetoxy sulfone as a mixture of diastereoisomers, which on 
Na-Hg reduction produced predominantly the E-alkene. Debenzylation 
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Scheme 27: Synthesis of D-erythro-sphingosine by Findeis and Whitesides. 71 
3.5 Conclusion 
The importance of sphingosine is emphasised by the high number 
of papers published over the last 40 years. Since the work has been 
carried out worldwide, its -importance must 
be fundamental. . Although 
there are many different and reliable sphingosine syntheses, this area 
of research will remain active until the role of sphingosine derivatives 
becomes clear. Therefore organic chemists will continue to try to 
develop novel and more efficient syntheses, thus making sphingosine 
derivatives more readily available for biological evaluation. 
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CHAPTER FOUR 
Synthesis and Biological Evaluation of Phenylalaninol and 
(1S, 2S)-2-Amino-l-phenylpropane-1,3-diol Derivatives 
4.1 Introducton 
The initial aim of this project was to establish simple and reliable 
methods for carrying out acylation, methylation and dimethylation of a 
primary amino group in compounds which arc analogues of 
sphingosine. Various groups attached to the amino group of 
sphingosine have been shown to play an important role in the 
inhibition of both PKC and PAP enzymes. 2 6 N, N- Dimethy 1- 
sphingosine27 for instance was found to be a better inhibitor of PKC 
and PAP enzymes than sphingosine itself. Sphingosine was not 
employed as the starting material in our, work because of its cost. 
Cheaper alternatives were used instead. (R)-Phenylalaninol (72), (S)- 
phenylalaninol (73) - and (lS, 2S)-2-amino-l-phenylpropane-l, 3-diol 
(74) were used to establish the key reactions. They arc commercially 
available and were chosen because they have features in common with 
sphingosine such as functional groups in similar positions and a 
hydrophobic region. 
OH 
Ph' Y _OH Ph 
, 
OH 
NH2 . NH2 
(72) = (R)-Phenylalaninol 
(74) 







4.2 Synthesis of Phenylalaninol Analogues 
N-Acetylation 
The synthesis of these known compounds proved to be 
straightforward under standard conditions.? 2 (R )-N, 0- 
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Diacetylphenylalaninol (75) and its enantiomer (76) were prepared 
using acetic anhydride and pyridine in THE These compounds were 
isolated in greater than 80% yield. Being enantiomers, both have the 
same spectroscopic properties but different signs for the optical 
rotation. Their IR spectra showed strong absorptions at 1684 and 1772 
cm-1 due to the amide carbonyl and the ester carbonyl respectively. 
Their 1H NMR spectra showed two singlets at 1.96 and 2.10 
corresponding to the methyl groups. 
N-Methylation 
N-Methylation of the primary amine in compounds (72), (73) and 
(74) cannot be achieved selectively using methyl iodide and a base. 
The problem lies in the fact that the monomethylated products are 
likely to be more reactive than the starting material. The inductive 
effect of the methyl group makes the product able to react further to 
generate N, N-dimethylated and N, N, N-timethylated products. Even 
with the use of one equivalent of methyl iodide, the problem is still not 
resolved because as soon as the product is formed, it will compete with 
the starting material for methyl iodide. 
In order for mono-methylation to take place, the nitrogen of (S)- 
phenylalaninol (73) had to be protected as its butyloxycarbonyl 
derivative (Scheme 28). This protection was carried out as described? 3 
with di-tert-dibutyldicarbonate in dioxane and water. The product (77) 
was isolated in 96% yield after chromatography. The IR spectrum of 
the compound showed absorptions at 1686 and 3418 cm- 1 
corresponding to the carbamate carbonyl and the hydroxyl groups 
respectively. The BOC group gave a characteristic resonance in the 111 
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Scheme 28: Synthesis of (S)-N, O-dimethylphenylalaninol 
Coggins and Benoiton74 had prepared a variety of N-methylated 
derivatives from N-BOC derivatives using sodium hydride and methyl 
iodide in THE Methylation of (S)-N-BOC-phenylalaninol using these 
conditions gave the desired N-methylated methyl ether (78) in 5% 
yield. The IR spectrum of the amine showed a strong, absorption at 
2850 cm-1 due to the stretching of the CH. The 1H NMR spectrum 
showed two methyl singlets at 8 2.30 and 3.18 due to the N-methyl and 
O-methyl groups respectively. 
However this reaction also gave two unexpected products: the 
cyclic carbamate (79) and N-BOC-O-methylphenylalaninol (80). Since 
three equivalents of sodium hydride were used, the dianion of N-BOC- 
phenylalaninol could have formed initially as an intermediate (81) 
which can be methylated on the nitrogen and oxygen atoms. O- 
Methylation, in theory, was more favoured because the nitrogen site is 
sterically hindered by the tert-butyl group as well as being less 
58 
nucleophilic than the alkoxide. However, once the oxygen atom was 
methylated (82), the yield of the product (78) suggested that the 
nitrogen was reluctant to carry out further alkylation. When N- 
methylation occurred first, the nucleophilic oxygen , attacked either 
another mole of methyl iodide to give the product (78), or the 
carbamate carbon causing an expulsion of the tert-butoxide to afford 
the cyclic carbamate (79). The proposed mechanisms are shown in 
Scheme 29. The IR and 1H NMR spectra of N- BO C- O- methy 1- 
phenylalaninol were similar to those of (78). The IR spectrum of the 
cyclic carbamate showed absorption at 1750 em-1 corresponding to the 
stretching of the carbamate carbonyl bond. The 1H and 13C NMR 
spectra of the carbamate showed no resonance in the region expected 
for the methyl groups of the tert-butyl group. 
Scheme 29: Formation of N-methylated product and by-products 
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The final step was to deprotect the BOC group of (78) with 1M HCl 
in ethyl acetate to give (S)-N, O-dimethylphenylalaninol (83). The IR 
spectrum of the poduct showed a broad absorption ca. 3431 em-1 for 
the NH stretch, and the loss of the absorption corresponding to the 
carbamate carbonyl group. The IH and 13C NMR spectra also showed 
the disappearance of the BOC group. 
To minimise the above side reactions it was necessary to protect 
the hydroxyl group of N-BOC-phenylalaninol. It was protected as the 
tert-butyldimethylsilyl ether (84) (Scheme 30) which was prepared 
using imidazole and tert-butyldimethylsilyl chloride (TBDMSCI) and 
DMF. The yield of the reaction was 89%. The IR spectrum of (84) 
showed absorptions at 1089 and 840 cm-1 due to the stretching of the 
Si-O bond. The 1H NMR spectrum showed a singlet at 8 -0.03 due to the 
geminal dimethyl groups attached to the silicon, and a singlet at 8 0.88 
corresponding to the methyl groups of the tert-butyl group. 
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Scheme 30: Attempted synthesis of N-methylphenylalaninol 
Methylation of N-BOC-O-TBDMS-phenylalaninol (84) using sodium 
hydride and iodomethane was unsuccessful giving mainly the starting 
material. The conditions for this reaction were varied as shown in 
Table 1. As shown in Table 1, no success was achieved despite the 
range of solvents, temperature and time. 
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Table l 
Reagents Conditions Product 
MeI (7 equiv. ), room temperature, starting material, 80% 
NaH (1.5 e uiv. ), THE 24 h 
Mel (7 equiv. ), room temperature, starting material, 50% 
NaH (3 equiv. ), THE 24 h 
Mel (7 equiv. ), reflux 3 h, starting material and 
NaH (3 equiv. ), THE 24 h product 
MeI (7 equiv. ), room temperature, starting material, 70% 
NaH (1.5 e uiv. ), DMF 24 h 
Mel (7 equiv. ), reflux 3 h, starting material and 
NaH (3 equiv. ), DMF 24 h product 
Grieco and Bahsas7 5 reported a novel method for the N- 
methylation of a variety of amino acid derivatives and dipeptides via a 
retro aza Diels-Alder reaction, see Scheme 31. Two key features in this 
reaction make it an attractive method of N-methylation. Firstly, it 
proceeds without racemisation and also, only the amino group will react 
so protection of the hydroxyl group is not required. The reaction was 
reported to proceed via the acid-catalysed formation of the iminc 
adduct of the amino acid and formaldehyde, and subsequent trapping 
of this adduct via an aza Diels-Alder reaction. The retro aza Diels-Alder 
reaction then proceeded smoothly in the presence of trifluoroacetic 
acid. Triethylsilane reduced the liberated immonium ion to the N- 
methyl compound. 
Scheme 31: N-Methylation of amino acids and dipeptides via retro aza 
75 Diets-Alder reactions by Grieco and Bahsas. 
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Treatment of (S)-phenylalaninol (73) with formaldehyde, acetic 
acid and cyclopentadiene gave the corresponding aza Diels-Alder 
product (85) as a mixture of diastereoisomers (Scheme 32). These 
diastereoisomers did not need to be separated because they would give 
the same N-methylated product , on reduction. The expected 
absorptions, due to the stretching of O-H and C=C groups, were found at 
3401 and 1680 cm-1 respectively. The 1H NMR spectrum was complex 
but it was clear that the resonances at S 5.94 and 6.25 must be due to 
the alkene hydrogens. Fortunately, the 13C NMR spectrum of (85) was 
more informative. All the signals were accompanied by a smaller signal 
indicating that it was a diastereomeric mixture. The reduction step 
failed to generate the N-methylated compound. A variety of reducing 
agents was employed but none of them proved to be successful. This 
reaction was abandoned. 
Scheme 32: Attempted synthesis of N-methylphenylalaninol via a 
retro aza Diels-Alder reaction 
The last method employed to form the N-methylated product was 
reductive formylation of the amine. Meier and Ruechardt76 reported a 
general procedure for making N-acylated derivatives using carboxylic 
acids. In their procedures, salts were obtained when carboxylic acids 
were treated with ammonia or amines. The salts could be pyrolysed to 
62 
give amides. Treatment of (S)-phenylalaninol with excess formic acid 
and toluene under reflux gave the diformylated product (86)76 in 83% 
yield after purification by column chromatography (Scheme 33). The 
IR spectrum of (86) showed absorptions at 1668,1718 and 3400 em-1 
corresponding to the stretching of amide carbonyl, ester carbonyl and 
N-H respectively. The IH NMR spectrum showed a broad singlet at 8 
8.07 with a relative intensity of 2 due to the two hydrogens adjacent to 
the carbonyls. 
Scheme 33: Synthesis of N-methylphenylalaninol 
Reduction of the diformylated product (86) was carried out using 
lithium aluminium hydride in THE and gave the N-methylated product 
(87) in 74% yield after purification by column chromatography. The 
compound seemed to be pure by TLC but both its 1H and 13C NMR 
spectra showed that it was only partially pure. Further purification on 
silica column, chromatography was attempted but without any success. 
The impurity was not the starting material since the 1H NMR spectrum 
proved the reduction had gone to completion as the resonance at 6 8.07 
had disappeared. Also present in the lH NMR spectrum was a sharp 
singlet at 8 2.33 corresponding to the N-methyl group. This resonance 
was accompanied by a small sharp singlet at 8 2.28 probably due to the 
impurity. 
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N, N, -Dimethvlation 
Feldkamp et al. 77 reported a simple one-pot method for N, N- 
dimethylation via reductive amination. The reaction was reported to 
proceed via the acid-catalysed formation of the imine adduct of the 
primary amine and formaldehyde, which was subsequently reduced 
with hydrogen gas over a palladium and charcoal catalyst. Due to the 
fact that the N-methylated product still contained an N-H group, the 
reductive amination could be repeated a second time to yield a N, N- 
dimethylated derivative. Treatment of (S)-phenylalaninol with acetic 
acid, formaldehyde, hydrogen, palladium and charcoal afforded the 
known N, N-dimethylated product (88)78 (Scheme 34). The product 
was isolated in 54% yield after column chromatography. The IR 
spectrum showed an absorption at 3390 cm-1 corresponding to the 
hydroxyl group. The 1H NMR spectrum showed a sharp singlet at 8 
2.56 due to the methyl groups attached to the nitrogen. 
Scheme 34: Synthesis of N, N-dimethylphenylalaninol 
An unexpected product, (S)-3-methyl-4-benzyloxazolidine (89), 
was also isolated in this reaction. One possible way this by-product was 
generated is shown in Scheme 35. Since 4-benzyloxazolidine (90) did 
not form as a_ by-product- in this reaction, this may suggest that the 
reduction of the immonium ion was faster than the cyclisation of the 
alcohol to the imine. However, when the secondary immonium ion was 
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formed, the reduction was slower, and some of the secondary imine had 
cyclised to form (S)-3-methyl-4-benzyloxazolidine (89). The IR 
spectrum of this " compound only showed absorptions of C-H stretches. 
The 1H NMR spectrum showed a methyl singlet at S 2.47 due to the N- 
methyl group. Also an AB pattern was observed at 8 4.01 and 4.39 
with a geminal coupling constant of 4.4 Hz. These signals were slightly 
more deshielded than a typical 0-methyl group, suggesting that the CH2 
group must be sandwiched between an oxygen atom and an electron 
withdrawing group. Similar results were obtained when the other 
enantiomer (72) was subjected to the reaction conditions of Feldkamp 
et al. 77 
Scheme 35: Formation of N, N-dimethylphenylalaninol and by-product 
65 
N N, N-Trimethylation 
(S)-N, N, N-Trimethylphenylalaninol iodide (91)79 was prepared in 
61% yield by treatment of (88) with methyl iodide in diethyl ether 
(Scheme 36). The expected absorption due to the OH ' was found at 3200 
cm-1. The IH NMR spectrum showed a singlet at S 3.21 for the methyl 
groups attached to the nitrogen. Although small traces of impurities 
were present according to the 1H spectrum, compound (91) was 
sufficiently pure for biological testing. 
Scheme 36: Synthesis of N, N, N-trimethylphenylalaninol iodide 
4.3 Synthesis of (1S, 2S)-2-Amino-l-pl en o pane-1,3- 
diol Derivatives 
With the reaction conditions established for N-acetylation, N- 
methylation, N, N-dimethylation and N, N, N-trimethylation of an aminol, 
it was of great interest to see whether these conditions could be applied 
to (1S, 2S)-2-amino-l-phenylpropane-1,3-diol, an aminodiol. The extra 
hydroxyl group proved to be more problematic than anticipated. More 
side products were observed. N-Methylation using sodium hydride and 
methyl iodide proved to be unsuccessful as expected. In the case of 
reductive formylation, triformylation of the aminodiol occurred. 
Although apparently pure by TLC, both lH NMR and 13C NMR spectra 
showed that there were extra signals present. This mixture could not 
be purified further by column chromatography. It was decided to carry 
out the reduction with this partially purified product. The reduction 
step yielded a complex mixture from which the desired product could 
not be isolated. Although N-methylation of 2-amino-l-plhenylpropane- 
1,3-diol did not occur with the established reaction conditions, a new 
synthesis was devised to carry out N-methylation specifically on an 
aminodiol. It was the success of this synthesis that opened up a new 
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route by which N-methylsphingosine could be synthesised. Details of 
this method are discussed in Chapter 6. 
Out of the three established reaction conditions, N, N- 
dimethylation proved to be the most reliable. Treatment of (1S, 2S)-2- 
amino- 1-phenylpropane-l, 3-diol with acetic acid, formaldehyde, 
hydrogen gas, and a palladium and carbon catalyst afforded a complex 
mixture (Scheme 37). Fortunately, the known product (92)80 was 
purified by careful column chromatography. The O-H stretch was found 
at 3400 cm-1. The 1H NMR spectrum showed a sharp singlet at S 2.34 
with a relative intensity of 6 due to the methyl groups attached to the 
nitrogen. 
Scheme 37: Synthesis of (1 S, 2S)-2-dimethylamino-1-phenylpropane-1,3-diol 
4.4 Biological Testing of (R) and (S)-Phenylalaninol and 
(1S. 2S)-2-Amino-l-nhenylpropanc-l, 3-diol Analogy 'S I I 
The biological testing of some of these compounds' was carried out 
by Dr. Pamela Scott81 at the Department of Medical Oncology at the CRC 
Beatson Laboratories in Glasgow. Our initial aim was to study and 
compare the inhibitory effect of these derivatives with sphingosine on 
PAP enzymes. 
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4.5 Biological Assays 
Determination of N-ethylmaleimide (NEM)-sensitive PAP (PAPI) 
activity 
Each assay contained in a final volume of 0.1 ml: PAPI Cocktail 
(see below) (20 ml), H2O (45 ml), rat liver cytosol plasma membrane 
(PAPI) (10ml), 3H-phosphatidate /phosphatidyl-choline (3: 2) (20 ml), 
and drug (5m1). The assays were started by addition of the test 
compound. The incubation was carried out for 60 minutes at 37 oC 
after which time the reactions were stopped by addition of 
chloroform/methanol (19: 1) (2.2 ml) containing 0.08% olive oil and 
aluminium oxide (1 g). After centrifuging each test tube for 10 minutes 
to remove unreacted 3H-phosphatidate which precipitated with 
aluminium oxide, 1 ml of the top phase from each test tube was 
transferred to a scintillation vial which was then placed in a water bath 
at 90 OC so that the solvents would evaporate off. These vials now 
contained only the 3H-diacylglycerol and the radioactivity of each vial 
was measured in a Scintillation Counter (model 1600 TR; Canberra 
Packard). - The above experiment was carried out with three- different 
concentrations of each drug (0.2,0.6,1.2 mM), including propranolol as 
a reference and with 3 control assays that contained no enzyme. 
Determination of (NEM)-insensitive PAP (PAP2) activity 
Each assay consisted of PAP2 cocktail (see below) (20 ml), rat 
liver cytosol plasma membrane (45 ml), H2O (45 ml), 311-phosphatidate 
(20 ml) and drug (5 ml). The reactions were started by addition of the 
test compound and the incubations were terminated after 60 minutes 
at 37 oC by addition of chloroform/methanol (19: 1) (2.2 ml) containing 
0.08% olive oil. The unreacted 3H-phosphatidate was removed by 
adding aluminium oxide (1 g). The radioactivity of the 3H- 
diacylglycerol was measured. The above experiment was carried out 
with three different concentrations of each drug (0.2,0.6,1.2mM), 
including propranolol as a reference and with 3 control assays that 
contained no enzyme. 
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PAPI and PAP2 cocktails 
PAPI PAP2 
Dithiothreitol (DTT) 80 ml ------ 
Magnesium 30 ml ------- 
Tris/maleate buffer 
(pH 6.5) 
500 ml 500 nil 
N-ethylmaleimide 
(NEM) 
-------- 6.8 mg 
Triton X-100 ------- 500 ml 
Water 1390 ml 990 ml 
4.5.1 Results of Biological Assays 
The following Table 2 records the percentage of PAP inhibition for 
some of the compounds in the assays previously described. 
Table 2 
PAPI PAP2 
Compounds % inhibition % inhibition 
(mmol) (mmol) 
0.2 0.6 1.2 0.2 0.6 1.2 
OH 0 0 0 0 6 6 
/ H2 
(72) 
a off 0 5 3 6 3 5 
/ H2 N 
(73) 
HO HO 62 86 89 8 29 41 
C13H27 
(74) NH2 
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9 38 2 12 3 
(76) 
45 60 56 0 0 2 
(89) 










21 29 25 4 29 27 
(88) 
OH 23 42 38 0 0 0 
/ Me3N+ I' 
(91) 
OH 34 43 46 15 0 0 
OH 
(92) 
26 26 29 0 0 
(79) 0 
ro anolol 0 31 58 I l_ 0 0 3 
From the Table, it is clear that most of the analogues show little 
inhibition of PAP2 activity compared to N, N, N- trimethylatcd 
sphingosine but have some significant inhibitory effects on PAPI 
activity. Unfortunately, PAP2 is the enzyme that is involved in tumour 
promotion via signalling processes. The most promising inhibitors of 
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the PAPI enzyme were (R)- and (S)-4-benzyl-3-methyloxazolidine. 
(S)-4-Benzyl-3-methyloxazolidine (89) inhibited 45% of PAPI activity 
at 0.2 mmol. This compound was a better inhibitor than propanolol, a 
classical drug for the inhibition of PAP activities. (R) -4 -Benzyl-3- 
methyloxazolidine displayed similar inhibitory effects to propanolol on 
both PAP enzymes. Evidently (R)- and (S)-phenylalaninols showed 
little inhibitory effect on both PAP enzymes. Converting the primary 
amine into either its secondary amine or amide increased the inhibitory 
effects on both enzymes. By analogy with the corresponding 
quaternised sphingosine, N, N, N-trimethylphenylalaninol iodide was 
expected to be the most potent inhibitor of the compounds prepared. 
However, it did not inhibit PAP2 activity at all. Consequently, we could 
not conclude that increasing the bulkiness around the amine group 
would increase the inhibitory effect on both PAP enzymes. 
Also, it is difficult to relate these results from the cell-free PAP 
assays to what could happen in whole cells. Concentrations of the drug, 
substrate, enzyme and diacylglycerol in cells are much lower than the 
corresponding test tube assay. There are other factors that have to be 
taken into consideration. For instance the uptake of the drug by the 
cells and the purity of the enzymes. Unfortunately the enzymes used 
in the experiments are only partially pure which means that there are 
other enzymes present in the reaction that could interfere. Since the 
concentrations of phosphatidate and diacylglycerol are very low in the 
cells, it is better to examine the test compounds in a test tube assay 
initially to give some indication as to whether they have any affect on 
the PAP activitites. If a test compound from the selection shows 
promising inhibitory effects on the PAP enzymes, then a further assay 
could be used. 
In conclusion, a wide range of inhibition values was obtained 
from the above assays. There was no clear correlation between the 
inhibition and the bulkiness around the amino group. Nevertheless, in 
most cases increasing the bulkiness around the amino group did show 
an improvement in the inhibition. The results probably imply that the 
size around the amino group is not the only feature for the inhibition of 
PAP enzymes. A key feature which plays an important role in the 
inhibition of PAP and PKC enzymes may be the length of the 
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hydrophobic alkyl chain. We now directed our attention to the total 
synthesis of sphingosine. Once a reliable route had been established, it 
would be used to synthesise -a variety of sphingosine analogues. The 
detail of this work is discussed in Chapter 5. 
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CHAPTER FIVE 
Diastereoselective Synthesis of Sphingosine Analogues 
5.1 Introduction 
In the work described in Chapter 4, the main aim was to find the 
reaction conditions from which the amino group of sphingosine could be 
selectively methylated. Our next aim was to establish the methodology 
to synthesise sphingosine analogues with alkynyl chains of varying 
lengths. It was also of great interest to synthesise analogues of 
deoxysphingosine to check how such modifications would affect the 
inhibition of PKC. As previously mentioned in Chapter 3, 
diastereoselective and enantioselective approaches must be employed 
to synthesise optically active sphingosine. Most of our work was based 
on a diastereoselective' strategy. However, an attempt was also made to 
synthesis sphingosine via an enantioselective approach. The details of 
the enantioselective approach will be discussed in the next Chapter. 
(S)-Serine is the most frequently used starting material for the 
diastereoselective synthesis of sphingosine and is also the biological 
starting material for formation of sphingosine. As well as being cheap, 
it is also readily available in both enantiomeric forms. It had been 
reported41,42,54,58,59 that use of serinc provided a shorter synthetic 
route to sphingosine than use of sugars. For these reasons, serinc was 
chosen as the starting material for the following syntheses. 
5.2 Preparation of Acyclic Diprotected Scrinal 
Serine, like many amino acids, is highly insoluble in organic 
solvents. To improve its solubility and carry out selective reactions it 
has to be protected. All the reported sphingosine syntheses using 
serine as the starting material involve transforming it into its acctonidc 
serinal. Surprisingly, there is no evidence from the literature where 
acyclic diprotected serinal has been used for the synthesis of 
sphingosine. 
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Our aim was to establish reliable reaction conditions from which a 
substantial amount of acyclic diprotected serinal (93) could be 
prepared. This aldehyde would then be coupled with a selection of 
alkyne chains to give a range of sphingosine analogues. The rationale 
behind using acyclic diprotected serinal was to test whether or not it 
would improve the diastereoselective outcome. 
The preparation of the acyclic diprotected serinal (93) is outlined 
in Scheme 38. (S)-Serine was first protected as its methyl ester using 
methanol and hydrochloride gas. The known ester (94)82 was isolated 
as a white solid in 94% yield. The IR spectrum showed the ester 
carbonyl absorption at 1747 cm-1. The 1H and 13C NMR spectra were 
both in accord with literature spectra of serine methyl ester. 60 When 
serine methyl ester (94) was treated with triethylamine and di-tert- 
butyldicarbonate in dichloromethane, it gave the known carbamate 
(95)60 in 64% yield after column chromatography. The tent-butyl 
protons of (95) were present as a large singlet at S 1.42 in the 1H NMR 
spectrum. The carbamate carbonyl carbon showed clearly in the 13C 
NMR spectrum (S 260) and the C=O stretching mode was present at 
1712 cm-1 in the IR spectrum. 
Chromatography also afforded an unexpected product: the di-BOC 
protected serine methyl ester (96). This compound was isolated as a 
white solid in 10% yield, and its melting point confirmed the identity of 




























Scheme 38: Preparation of acyclic diprotected serinal 
Treatment of the monoprotected amino acid ester (95) with tert- 
butyldimethylsilyl chloride and imidazole in dry DMF at room 
temperature gave the diprotected ester (97) in 92% yield after 
purification by flash chromatography. The IR spectrum of this 
compound showed strong absorptions at 1752 and 1720 cm- 1 
corresponding - to the ester carbonyl and the carbamate carbonyl 
respectively. Absorptions at 1256 and 1088 cm-1 corresponded to 
stretching of the SiMe2 group and Si-O bond respectively. The 1H NMR 
spectrum showed two singlets at S 0.00 and S 0.01 due to germinal 
methyl groups. ý Also a singlet at 8 0.84 due to the methyl groups of the 
tert-butyl group. The signals of the silyl protecting group were 
distinctive in the 1H NMR spectrum. The geminal methyl groups are 
diastereotopic due to the chiral centre and give rise to two singlets at 8 
0.00 and 0.01. 
The reduction of the ester into the corresponding aldehyde (93) 
using DIBAL-H in toluene proved to be more difficult than first 
Me02C 
0H 
DMF / Imidazole 
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anticipated. A variety of reaction conditions was used and the results 
are shown in Table 3. 
Table 3 
DIBAL-H Solvent Time Temp oC Result 
1.1 equiv. DCM 0.5 h -78 mostly 
starting 
material 
2 equiv. DCM 2h -78 partial 
reduction 
2 equiv. DCM 2h Room temp alcohol 
1.1 equiv. toluene 1h -78 partial 
reduction 








It was found that using 1.5 equivalent of DIBAL-H in toluene 
produced the best result. No attempt was made to purify the aldehyde 
(93) from the alcohol using flash chromatography. Most amino 
carboxaldehydes are known to be unstable and can racemise on silica or 
if subjected to distillation conditions. 60 Therefore the partially pure 
aldehyde was used directly for the next step to ensure the integrity of 
the chiral centre. The yield of the reduction could be estimated from 
the lH NMR spectrum of the crude product. The aldehyde proton was 
distinctive in the 1H NMR spectrum showing a singlet at 5 9.59. The 
aldehyde carbonyl carbon showed up clearly in the 13C NMR spectrum 
(6 199) and the C=O stretching mode was present at 1725 cm-1 in the 
IR spectrum. 
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5.3 The Reaction of Acyclic Diprotected Scrinal with the 
Lithium Acetylide of Alkynes 
Addition of an excess of lithium acetylide of hex-1-yne to the 
aldehyde (93) gave a complex mixture (Scheme 39). TLC showed five 
spots, two of which were the starting materials. Two of the three 
remaining spots were very close to one another with large Rf values. 
These compounds (99) were too non-polar to be the desired carbinol 
(98). They were purified by careful column chromatography, and were 
found to have similar spectroscopic data. The IR spectra of (100) and 
(101) showed absorptions at ca 1248 and 1740 cm-1 corresponding to 
the SiMe2 group and the carbamate carbonyl respectively. Also there 
was no O-H absorption in the IR spectrum. While their 13C NMR spectra 
clearly indicated the presence of the carbamate carbonyl (S ca. 158), the 
O-tert-butyl group was absent in both IH and 13C NMR spectra. The 
only difference between their 1H NMR spectra was the signal at S ca. 
5.0. This signal was due to the proton adjacent to the carbamate 
oxygen. Although each signal was a doublet of triplets, the coupling 









Scheme 39: Attempted synthesis of the carbinol (98) 
OTBDMS 
LNHBOC 
In addition, two NMR homo-decoupling experiments were carried 
out to provide further structural information about these two 
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compounds ' (100) and (101). Irradiation of the signal of (100) at ca. 6 
3.56 caused the signals at 6 3.82 and 4.92 to collapse from a doublet of 
triplets to a triplet and from a triplet to a singlet respectively. Also 
homo-decoupling of the signal at ca. S 4.90 caused each of the signals at 
6 3.82 and 2.25 to collapse to a triplet. The reaction must have been 
successful or else the proton at 6 4.90 would not be coupled with the 
methylene protons (6 2.25) nearest to the triplet bond. Similar 
experiments were carried out on (101) and the same findings were 
observed. 
From the above observations, it was concluded that (100) and 
(101) must be the two diastereoisomers (99) formed in approximately 
equal amounts. Since there were no OH and O-tert-butyl groups 
present, the OH therefore must have cyclised with the carbamate. The 
mechanism of this reaction is shown in Scheme 40. The coupling of the 
acetylide of hex-1-yne with the aldehyde (93) resulted in the 
generation of an alkoxide ion which added to the carbamate carbonyl 
which then expelled the tert-butoxide group to give the cyclic 
carbamate mixture (99). 
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Scheme 40: Formation of the cyclic carbamate ring 
To differentiate between these two diastercoisomers, 111 NMR 
spectroscopy was employed as reported by Futagawa et al. 84 They 
found that the ring protons of the erythro-isomer of 2-oxazolidine 
derivatives and 2-phenyl-2-oxazoline derivatives always had a larger 
coupling constant than those of the threo-isomer. These findings are in 
agreement with use of the Karplus equation. The coupling constant for 
the erythro-isomer will have a larger value because it has a dihedral 
angle of ca. 00. Thus, the configurational identity of the threo- and 
erythro-isomers was assigned by analysis of the 1H NMR spectra of 
their 2-oxazolidone or 2-phenyl-2-oxazoline derivatives. The coupling 
constants for the ring protons of the diastercoisomers (99) were 3.3 and 
5.5 Hz. We assigned the isomer with the coupling constant of 5.5 Hz to 
be the erythro-form (101) and the isomer with the coupling constant of 
3.3 Hz to be the threo-isomer (100). 
79 
Although both diastereoisomers could be separated by careful 
column chromatography, the yield and the diastereoselectivity of this 
reaction were relatively poor. Therefore this route cannot be used 
generally to synthesise sphingosine analogues. In addition, when the 
reaction was scaled up, the reduction step only gave small traces of 
aldehyde. This problem coupled with the difficulty in purifying the 
acyclic diprotected serinal forced us to divert our attention to the 
synthesis of aß-ynone (102) using the diprotected serine methyl ester 
(97), since it is more stable than its aldehyde. The aß-ynone (102) 
might then be reduced diastereoselectively (Scheme 41). 
5.4 The Reaction of Acyclic Diprotected Serine Methyl Ester 














Scheme 41: Attempted synthesis of the aß-ynone (102) 
LNHBÖC 
Upon treatment of the ester (97) with the lithium acetylide of 
hex-1-yne it was expected that the ester would undergo a nucleophilic 
displacement to give the corresponding aß-ynone (102). Unfortunately 
this proved not to be the case. When the ester was treated with the 
lithium acetylide of hex-1-yne at -78 0C, only the starting material was 
obtained after the work up. The lack of success was probably due to 
the bulkiness of the protecting groups causing severe steric hindrance. 
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However, when the reaction was carried out at 0 0C, a mixture of the 
starting material and a side product were obtained. This side product 
will be discussed later in this chapter. In order to overcome the steric 
problem, different protecting groups were employed. 
The next step was based on a recent paper by Evans et al. 8 5 
detailing the transformation of N-CBZ-serine methyl ester into its cyclic 
diprotected form. Treatment of (95) with 2,2-dimethylpropane and 
PTSA as a catalyst produced the known acetonide ester (103)60 in 70% 
yield. The 2,2-dimethylpropropane acts as an acetone equivalent when 
treated under acidic conditions, see Scheme 42. These protecting 
groups should reduce the steric hindrance problem. 
Scheme 42: Formation of the oxazolidine ring system 
The IR spectrum of the oxazolidine (103) showed absorptions at 
1725 and 1702 cm-1 due to the ester carbonyl and carbarnate carbonyl 
respectively. No O-H absorption was observed in the IR spectrum. The 
1H NMR spectrum appeared more complex than the assigned structure 
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would indicate, see Diagram 8. The oxazolidine exists at room 
temperature as a mixture of rotamers. 86 The two ring methyl groups 
appeared as four separate signals at 6 1.43,1.46,1.57 and 1.60, two for 
each methyl group. The heights of these signals are proportional to the 
proportional of molecules in that particular rotameric form. All the 
signals,. appeared as pairs except for the methyl group of the ester 
which is a singlet. 
Treatment of the oxazolidine (103) with the lithium acetylide of 
hex-1-yne at -78 oC gave starting material, the desired aß-ynone (104) 
and a known by-product (105). 87 The aß-ynone (104) was isolated in 
17% yield after column chromatography. The IR spectrum showed 
absorptions at 1680 and 2225 cm-1 corresponding to the ketone 
carbonyl and the triple bond, respectively. The ketone carbonyl carbon 
showed up clearly in the 13C NMR spectrum (8 163.4). This value was 
low compared to the typical value for a ketone carbonyl because of the 
conjugation. 
Scheme 43: Synthesis of the aß-pone (104) 
The by-product isolated from the mixture was methyl 2-(tert- 
butyloxycarbonyl)aminoacrylate (105). This product was also found 
previously in the reaction of the acyclic diprotected ester with the 
lithium acetylide of hex-1-yne. It is UV active due to a conjugated 
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Diagram 8: 1H NMR spectrum of methyl (4S)-3-tcrt-butyloxycarhonyl- 
2,2-climcthyloxai. olicliiic-4-carhoxylatc (I03) 
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corresponding to the a ß-unsaturated ketone and carbamate carbonyl, 
respectively. Both III and 13C NMR spectra showed that only the ring 
system had been cleaved and the rest of the functional groups 
remained intact. Only five singlets were found in the 111 NMR 
spectrum. The two new singlets at S 6.08 and 6.10 were due to the 
olefinic protons. The formation of this by-product is shown in Scheme 
44. The acetylide anion of hex-l-yne could either act as a nucleophile 
or a base. When acting as a base, it deprotonated the a-hydrogen 
which subsequently caused the intermediate (106) to eliminate acetone 
to generate a stable conjugated compound (105). 
Scheme 44: Formation of the methyl 2-(tert-butyloxycarbonyl)aminoacrylato 
In order to try to prevent this by-product from being formed, the 
ester carbonyl was activated by a Lewis acid to enhance its reactivity, 
in the hope that the yield of the ynone would improve. However, 
addition of the Lewis acid to the reaction led to a complex mixture. The 
extra impurities resulted probably from the reaction of the nucleophilc 
with the carbamate carbonyl. The carbamate carbonyl would have 
been more activated by the Lewis acid than the ester carbonyl as it has 
a higher electron density. 
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Since addition of the Lewis acid caused more problems than 
expected, it was decided to transesterify the methyl ester (103) into the 
phenyl ester. The phenyl ester is obviously a more reactive ester as 
phenoxide is a better leaving group. If this did not prevent the 
formation of this by-product then the ester would have to be reduced 
to its aldehyde, which has been shown to be stable to silica. 86 
The standard method of transesterification using excess of phenol 
and PTSA with Dean-Stark conditions failed, to give any product and 
only the starting material could be isolated. Another method was tried. 
Upon treatment of the ester (103) with phenol and a tiny piece of 
lithium metal in dry DMF at 95 °C, the phenoxide anion should displace 
the methoxy group which would then abstract a proton from the phenol 
to give methanol and phenoxide anion. Thus lithium phenoxide should 
act as a catalyst and the equilibrium could be displaced by distilling off 
the methanol. Unfortunately, this proved not to be case. Treatment of 
the ester (103) with a catalytic amount of lithium phenoxide in DMF 
and phenol at 95 oC gave the methyl 2-(tert- 
butyloxycarbonyl)aminoacrylate (105). This product was isolated in 
95% yield. It came as a surprise that the phenoxide anion was able to 
deprotonate the 'cc-hydrogen as it is a relatively weak base. In 
conclusion, the a-hydrogen of the ester must be relatively acidic which 
causes the ring to collapse. Therefore alkynylation of the ester (103) 
was abandoned. 
5.5 The Use of the Acetonide of Serinal with the Lithium 
Acetylide of an Alkyne 
Garner et al. 86 had reported that the ester (103) could be 
transformed into its aldehyde (107) by carrying out the reduction with 
DIBAL in toluene at -78 °C. This aldehyde was found to be relatively 
stable and could be purified by column chromatography or distillation. 
The reduction of the ester (103) to the acetonide (107) ofserinal was 
achieved in 62% yield. Chromatography was carried out to purify the 
aldehyde. The IH NMR spectrum of (107) showed the aldehyde proton 
at 6 9.47 and 9.52. The 13C NMR spectrum showed the aldehyde 
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carbon at S 199.1 and 199.3. Due to the presence of rotameric isomers, 
all the signals were observed as pairs. 
At this point, this aldehyde (107) was adopted as the starting 
material for a new approach to the synthesis of sphingosine analogues. 












R=Cs, Clo 9 C13 
Scheme 45: Attempted synthesis of sphingosine analogues 
Careful dropwise addition of vinylmagnesium bromide to a stirred 
solution of (S)-N-(tert-butoxycarbonyl)serinal acetonide (107) was 
successful in producing a mixture of diastereoisomeric vinyl alcohols 
(108) which was isolated in 77% yield after chromatography. Attempts 
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to separate these diastereoisomers by flash chromatography failed. The 
signals for the alkene hydrogens were found at 5 5.1 for the terminal 
CH2 group and 5 5.7 for the alkene CH in the III NMR spectrum. The 
13C NMR spectrum was complex. The purity of these diastereoisomers 
was confirmed by microanalysis. 
If these diastereoisomers could have been separated, the erythro- 
isomer would have been subjected to ozonolysis to give the a-hydroxyl 
aldehyde (109). The E-double bond would then be introduced by 
Wittig reaction. By varying the Wittig reagents, a selection of 
sphingosine analogues would have been synthesised. Such an aldehyde 
would be most useful as an optically active building block for the 
synthesis of sphingosine analogues. 
In order to achieve the synthesis of sphingosinc analogues in the 
time constraints, the method of Garner et al. 58 was employed (Scheme 
46). They reported that condensation of the serinal acetonide (107) 
with the lithium acetylide of pentadec-1-yne gave good 
diastereoselectivity and both diastereoisomers were separable. 
Treatment of the acetonide aldehyde (107) with the lithium acetylide of 
pentadec-1-yne did indeed give the desired diastereoisomers (110) 
which were separated by careful column chromatography. The yield of 
the major product was 68%. The optical rotation was identical to the 
published values 8 for the erythro-isomer. The IR spectrum showed 
the carbamate carbonyl and OH absorptions at 1704 and 3277 cm- 1 
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Scheme 46: Attempted synthesis of sphingosine analogues 
The use of the methodology of Garner et al. was extended to 
prepare the erythro-isomers (111) and (112). After purification by 
column chromatography, erythro-isomer (111) was isolated in 58% 
yield. The IR spectrum , showed absorptions at 1693 and 3308 cm- 1 
due to the carbarmate carbonyl and OH respectively. The 1H NMR 
spectrum showed a broad doublet at 5 4.70 for the CH of the alcohol 
group, and a broad singlet at 8 3.90 for the -OH signal. The 13C NMR 
spectrum showed signals at 5 77.8 and 86.1 for the triple bond carbons. 
The erythro-isomer (112) was isolated in 63% yield after 
purification by column chromatography. This compound possessed 
spectroscopic data similar to other erythro-isomers. 
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The diastereoselectivity could be explained by assumption of a 
transition state according to the Felkin-Anh model. That is, the a- 
amino moiety is orthogonal to the plane of the carbonyl group. The 
nucleophile then approaches the carbonyl in the direction which gives 
the least steric interaction. Such an approach would favour the 
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Diagram 988: Felkin-Anh model ( not chelation controlled) 
OH 
H 
The next step was to reduce the triple bond partially using Birch 
conditions as reported. 5 8 Treatment of (110) with lithium and 
ammonia at -78 oC gave only small traces of the trans-product (113), 
when compared to the value of 68% from Garner's procedure. The 
conditions for the Birch reduction were varied as shown in Table 4. 
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Table 4 
Temp (°C) Solvent Time Result 
2.5 equiv. of -78 NH3 2h traces of 
sodium product 
3.0 equiv. of -78 NH3 3h traces of 
sodium product 
3.0 equiv. of -78 NH3 8h complex 
sodium mixture 
4.0 equiv. of -78 NH3 4h traces of 
sodium product 
2.5 equiv. of Reflux NH3 and THE 3h mainly 
sodium starting 
material 
2.5 equiv. of Reflux EtNH2 and 3 lh mainly 
sodium THE starting 
material 
2.5 equiv. of Reflux then EtNH2 and 3h at reflux complex 
sodium RT THE followed by mixture 
8hatRT 
Despite the variety of reaction conditions tested, none of them 
succeeded in producing a better yield of the trans-product (113). The 
lack of success was probably due to the lack of solubility of (110). 
When (111) was subjected to Birch reduction, the trans-product 
(114) was isolated in 10% yield after purification by column 
chromatography. The expected absorption due to the stretching of the 
C=C bond was found at 1645 cm-l- The 1H NMR spectrum showed a 
doublet of doublets at 6 5.34 for the olefinic proton nearest to the 
alcohol group and a doublet of triplets at 8 5.66 for the other olefinic 
proton. The coupling constant between the olefinic protons was found 
to be 15.4 Hz, suggesting it must be an E-double bond. Treatment of 
(114) with concentrated HC1 in ethyl acetate caused the compound to 
polymerise. Thus a milder deprotection step must be employed to 
prevent the compound from undergoing polymerisation. 
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Since the partial reduction of the triple bond to the E-double bond 
was not as straightforward as anticipated, it was decided to keep the 
triple bond in these sphingosine analogues. This would give us the 
benefit of seeing whether or not the E-geometry of the double bond 
was an essential criterion for PKC inhibition. 
In the typical deprotection of the NBOC-acetonide ring, there are 
two steps involved. Methanol and PTSA were used initially to open the 
ring followed by treatment with HC1 in ethyl acetate to cleave the BOC 
protecting group. The use of HCl in ethyl acetate was not ideal as 
previously found. Such strong conditions might cause polymerisation. 
It was found by accident that treatment of (110) with an excess of 
PTSA in methanol at room temperature for 48 h gave the known 
aminodiol (115)60 which was isolated as a yellow oil in 87% yield 
(Scheme 47). The IR spectrum showed absorptions at 2360 cm-1 due 
to the carbon to carbon triple bond. Another absorption at 3356 cm- I 
(very broad) indicating the OH and NH stretches was also found in the 
IR spectrum. Also no absorption was found for the carbamate carbonyl 
in the IR spectrum. Both IH NMR and 13C NMR spectra had no signals 
























Scheme 47: Synthesis of sphingosine analogues with a triple bond 
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This deprotection procedure was used to prepare the new 
compounds (2S, 3R)-2-amino-1,3-pentadec-4-ynediol (116) and (2S, 3R)- 
2-amino-1,3-octadec-4-ynediol (117). Both compounds exhibited 
similar spectroscopic data to compound (115). The molecular ions for 
all three aminodiols could not be detected because they lost water 
instantaneously when injected into the mass spectrometer. 
Aminodiols in general are relatively unstable and have a 
tendency to decompose when exposed to air. In order to prevent this 
from taking place, these compounds are normally protected as the 
corresponding triacetates. Treatment of (111) with triethylamine and 
acetic anhydride afforded the corresponding triacetate (118). The 
triacetate was isolated as a yellow oil in 21% yield. The IR spectrum 
showed absorptions at 1547,1659 and 1749 cm- I correlating to the 
amide carbonyl and ester carbonyls respectively. The IH NMR 
spectrum showed three singlets at 8 1.97,2.00 and 2.01 due to the a- 
methyl groups. The high resolution mass spectrum gave a value for the 
molecular ion of 339.2065 compared to the calculated value of 
339.2046. 
When (112) was exposed to triethylamine and acetic anhydride, 
the triacetate (119) was isolated as a white solid in 94% yield. The 1H 
NMR spectrum showed three singlets at 8 1.97,2.00 and 2.02 for the cc- 
methyl groups. The high resoluton mass spectrum gave a value for the 
molecular ion of 381.2532 in accordance with the theoretical value of 
381.2515. 
Liotta et al. 6 0 reported the synthesis of sphingosine from 
unprotected aminodiol (117) using either Birch reduction or lithium 
aluminium hydride reduction. Birch reduction of (117) proved to be 
unsuccessful. However, when (117) was treated with lithium 
aluminium hydride in dimethoxyethane at reflux, partially pure 
sphingosine (14) was isolated as an oil in 20% yield. Attempts to 
remove the impurity by column chromatography failed. The IR 
spectrum showed the C=C absorption at 1680 cm' 1. The IH and 13C 
NMR spectra were both in accord with the literature spectra of 
sphingosine. 60 
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In order to facilitate purification, it was decided to transform 
sphingosine into its known triacetate58 which should result in an easily 
purified crystalline derivative. The triacetylation of (14) using acetic 
anhydride and triethylamine proceeded in 70% crude yield to give an 
oil, which was partially purifed by flash chromatography. A further 
attempt to purify the triacetate by silica column chromatography 
caused it to decompose. Time constraints prevented further 
development of this route. 
5.6 Attempted nthesis of (R2-2-Amino-octadec-4E-en-l-ol 
A recent paper by Sibi et al. 89 detailed a general synthesis of 4- 
substituted oxazolidinones. Cleavage of the oxazolidinone ring would 
generate the corresponding aminol. Such a method was adopted for the 
synthesis of (R)-2-amino-octadec-4E-en-l-ol (120) as shown in Scheme 



































(S)-Serine methyl ester was first protected as its oxazolidin-2-one 
(121)89 using phosgene under basic conditions. The oxazolidin-2-one 
was isolated as an oil in 80% yield. The IR spectrum of (121) showed 
the presence of the ester carbonyl (1767 cm-1) and carbamate carbonyl 
(1740 cm-1) absorptions. The carbamate carbonyl carbon was evident 
in the 13C NMR spectrum and the correct molecular ion (in/z = 145) 
was present in the mass spectrum. 
The reduction of (121) to the known alcohol (122)89 was 
achieved in 63% yield using sodium borohydride in ethanol. 
Chromatography was required to purify the alcohol. The 1H NMR 
spectrum showed two sets of doublets of doublets at 6 3.60 for the 
methylene protons of the alcohol group. 
In order to transform the alcohol (122) into a better leaving 
group it was converted into the tosylate (123)89 by treatment with 
tosyl chloride in triethylamine. The product was isolated by flash 
chromatography in 64% yield. The IH NMR spectrum showed a singlet 
at 8 2.33 and an AA'BB' system at 6 7.73 due to the methyl group and 
the p-substituted benzene ring respectively. 
Chromatography -also gave the ditosylated product (124), not 
reported previously. 89 The product showed two methyl signals (at 8 
2.35,2.37) and two sets of AA'BB' systems (at 8 7.26-7.88) in the lH 
NMR spectrum. Microanalysis confirmed the purity of the compound. 
Akynylation of (123) with the lithium acetylide of pentadec- l- 
yne only led to the recovery of both starting materials. No 
improvement was achieved with the use of an extra equivalent of 
lithium acetylide. It appeared that once deprotonation had occurred, 
the salt precipitated and failed to react further. It was thought that the 
problem might be overcome by using a different organometallic 
reagent. However, the reaction was still not successful even with the 
use of an organocuprate. Several attempts were made but none proved 
to be successful. The lack of success was probably due to the fact the 
cuprate did not form in the reaction mixture. Transmetallation of the 
lithium acetylide of an alkyne into its cuprate is known to be a difficult 
process. 90 
However, addition of the lithium acetylide of pentadec-1-yne to a 
stirred, solution of the ditosylated product (124) was successful in 
producing compound (125) in a yield of 23% (Scheme 49). The IR 
spectrum of (125) showed an absorption at 2236 cm-1 corresponding to 
the carbon to carbon triple bond stretch. The 13C NMR spectrum 
clearly showed the triple bond carbons at S 72.3 and 90.9. High 
resolution mass spectrometry gave a molecular ion of 461.2575 in 
accordance with the theoretical value of 461.2599. There was not 
enough compound (125) made to continue the synthesis and time 















Scheme 49: Towards (R)-2-amino-octadec-4 E-en-1-ol (120) 
(CH2) 1 2CH 3 
To synthesise optically active sphingosine, a diastereoselective or 
enantioselective approach must be employed. In this chapter, we have 
tried to devise a novel synthesis of sphingosine via a diastereoselective 
route. Unfortunately there were several drawbacks, such as the 
difficulty in 'separating' the diastereoisomers of (108) and the Birch 
reduction of the triple bond in (117), which could not be overcome. 
Instead of continuing to try to find better conditions for the Birch 
reduction, an alternative approach to synthesis of sphingosine 
analogues was attempted and is discussed in the next Chapter. 
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CHAPTER SIX 
Enantioselective Synthesis of Sphingosine Analogues 
6.1 Introduction 
Our next aim was to devise enantioselective routes by which 
optically active aminodiol compounds with one or more alkyl groups 
attached to the amino group could be synthesised. (1 R, 2S)-2-N- 
Alkylamino-1-phenylpropane-1,3-diol (126) and N, N-dialkylamino-l- 
phenylpropane-1,3-diol (127) were the chosen targets. These 
compounds have features in common with sphingosine, such as 
functional groups in similar positions and a hydrophobic region. Once 
the preparations of these aminodiols were established, their routes 
would then be applied to the total synthesis of monomethylatcd (128) 
and dimethylated sphingosine (129). As discussed in Chapter 4, 
monoalkylation of (1S, 2S)-2-amino-l-phenylpropane-1,3-diol could not 
be carried out using standard methods and as for the dialkylation it 
occurred only in poor yield. Therefore to synthesise (1R, 2S)-2-N- 
alkylamino-1-phenylpropane-1,3-diol and N, N-dialkylamino-l- 
phenylpropane-1,3-diol enantiselectively would be a bonus. 
OH 
OH 
R2 ý R1 
(126); R1 = alkyl group; R2 =H 
(127); R1 = R2 = alkyl group 
C 13H27 OH 
R3 R4 
(128); R3 = alkyl group; R4 =H 
(129); R3 = R4 = alkyl group 
6.2 Attempted Enantioselective Synthesis of (1 R, 2S)-2- 
Diethylamino-l-phenylpropane-1,3-diol 
Rayner and his co-workers reported91 a novel method for 
preparing 2,3-diaminoalcohols via Lewis acid induced rearrangement of 
2,3-epoxyamines (Scheme 50). The procedure deserves a mention 
OH 
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because the stereochemical outcome was controlled. The initial step 
utilised Sharpless asymmetric epoxidation to prepare optically active 
2,3-epoxyalcohol (130) which was then transformed into its tosylate 
(131) by treatment with triethylamine and tosyl chloride. The tosylate 
was then displaced by diethylamine to afford the corresponding 2,3- 
epoxyamine (132). Treatment of (132) with trimethylsilyl 
trifluoromethanesulfonate caused the nitrogen lone pair to attack the 
epoxide ring regioselectively to give the aziridinium 
trifluoromethanesulfonate (133). The less hindered position (C-1) of 
(133) was regiospecifically attacked by a nucleophile which is normally 
an amine, to give a protected diaminol (134). If the nucleophile was 
water then the final product would be an aminodiol instead of a 
diaminol. This was basis for the attempted enantioselective synthesis 
of the dialkylated aminodiol (127). 




R1 = Pr, R2 = H, R3, R4 = (CH2)5 
R1 = Pr, R2 = H, R3, R4 = CH2Ph 






























To synthesise the N, N-dialkylamino- l-phenylpropane-l, 3-diol 
(127), (E)-3-phenylpropen-2-ol was chosen as the starting point for the 
synthesis, as outlined in Scheme 51. Sharpless asymmetric epoxidation 
of (E)-3-phenylpropen-2-ol by the published procedure92 gave the 
desired epoxide (135) which was isolated in 64% yield after purification 
by column chromatography. The IR spectrum of the epoxide showed 
absorptions at 3342 and 1256 cm-1 due to the OH and C-O respectively. 
Its 1H NMR spectrum showed a doublet at S 3.90 for the CH nearer to 
the phenyl ring and a multiplet at S 3.23 for the other epoxide CH. The 
13C NMR spectrum also showed the presence of the two CH groups at 6 
55.6 and 62.6 and high resolution mass spectrometry gave a molecular 
ion of 150.0680 in accordance with a theoretical value of 150.0683. An 
experiment was not carried out to confirm the optical purity of the 2,3- 
epoxy alcohol (135) using the Mosher method. It was assumed, at this 
stage, that the enantiomeric excess for the Sharpless asymmetric 
epoxidation was the same as the value quoted in the literature for the 
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The, 2,3-epoxyalcohol (135) was then transformed into its known 
tosylate. (136)92 by treatment with tosyl chloride and triethylamine. 
The tosylate was isolated as white crystals in 80% yield. The IH NMR 
spectrum of (136) showed a singlet at 8 2.44 for the methyl group and 
an AA'BB' system at 5 7.28-7.80, for -the. p-substituted benzene ring. 
The high resolution mass spectrum of (136) gave a molecular ion of 
304.0769 in accordance with a theoretical value of 304.0782. 
Treatment of. the tosylate (136), with diethylamine and potassium 
iodide in dry DMF afforded a complex mixture. This mixture was 
purified by flash chromatography to give the new 2,3-epoxyaniine 
(137) in 22% yield. The IR spectrum of the compund still showed the 
presence of the epoxide ring. Its 1H NMR spectrum showed a triplet at 
8 0.97 for the . methyl groups and a multiplet at 
8 2,51 for the 
methylene protons. The epoxide CH groups were also found in the 
expected region of the 1H NMR spectrum and high resolution mass 
spectrometry gave a value for the molecular ion of 205.1500 compared 
with a theoretical value of 205.1517. 
The key step was the Lewis acid induced rearrangement of the 
2,3-epoxyamine (137) to give the corresponding 2- 
trimethylsiloxymethylaziridinium ion which would then be opened 
regioselectively by water to form the aminodiol (138). The 
rearrangement followed by the opening of the ring should provide the 
erythro-configuration. However, when the epoxyamine (137) was 
treated with trimethylsilyl trifluoromethanesulfonate for 30 minutes 
before water was introduced, work up gave a complex mixture. 
Although it could not be purified by column chromatography, the III 
NMR spectrum of the mixture suggested that the epoxide ring had been 
opened. The epoxide cleavage was, also evident in the 13C NMR 
spectrum. Chemical shifts of the CH groups suggested that the epoxide 
ring was opened not by the nitrogen lone pair but by the water 
molecule to give the corresponding amino-2,3-diol (139). From the 
spectroscopic evidence, the intermediate 2-trimethylsiloxymethyl- 
aziridinium ion, had not been generated. Another attempt was carried 
out where the 2,3-epoxyalcohol was stirred with trimethylsilyl 
trifluoromethanesulfonate for 10 hours before the nucleophile was 
introduced. After the work-up, a complex mixture was again isolated. 
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The IH and 13C NMR spectra of the crude product were almost identical 
to the previous spectra. The route` was abandoned due to the difficulty 
in performing the key step. 
6.3 Synthesis of (1R, 2S -2-Ethylamino-l-plýenvln.. ropa11s- 
1.3-diol 
It is known that 2,3-epoxyalcohols are useful intermediates in the 
synthesis of carbohydrates, and related compounds. 93 In a recent 
report94 by Roush and Adam, 2,3-epoxyalcohols were transformed into 
their 2-amino-1,3-diols, see Scheme 52. They reported that the 
reaction of the 2,3-epoxyalcohols with an isocyanate, followed by 
deprotonation of the carbamate (140) with sodium hydride, generated a 
nitrogen nucleophile which would then open the epoxide ring 
regioselectively to afford the cyclic carbamate (141). Basic hydrolysis 
of (141) gave the 2-amino-1,3-diol (142). 
Scheme 52: Synthesis of monomethylated 2-amino-1,3-diol (142) by Roush and 
Adam. 93 
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In the procedure of Roush and Adam, every step gave a yield of 
at least 80% and the cyclisation of the nitogen anion with the epoxide 
ring was highly regiospecific. These two characteristics of the 
procedure made it ideal for the synthesis of (1R, 2S)-2-ethylamino-1- 
phenylpropane-1,3-diol (145). The synthesis of (1R, 2S)-2-ethylamino- 
1-phenylpropane-1,3-diol is shown in Scheme 53. Treatment of 
(2R, 3R)-2,3-epoxy-3-phenylpropan-l-ol (135) with ethyl isocyanate 
and triethylamine afforded the carbamate (143) in 93% yield after 
column chromatography. The IR spectrum of this compound showed an 
absorption at 1689 cm-1 due to the carbamate carbonyl. Its 11-1 NMR 
spectrum showed a triplet at 5 1.05 for the methyl group and a quartet 
at S 3.05 for the methylene protons of the ethyl group. The 13C NMR 
spectrum clearly showed the presence of the carbamate carbonyl at 6 
155.9. 
Scheme 53: Synthesis of monomethylated 2-amino-1,3-diol. 
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The epoxyalcohol (135) was assumed to be optically active and-, at 
this point it was decided that we should carry out a range . of 
experiments to find out if the epoxycarbamate (143) was still optically 
active too. The optical rotation was -found to be + 54.5 and further 
experiments were carried out to find out the optical purity of (143). 
The initial experiment was to examine the 1H NMR spectrum of the 
compound after addition of 3% (by mole) and 6% of the chiral shift 
reagent europium - (III) tris[3-(heptafluoropropylhydroxymethylene)- 
(+)-camphorato] (146). There was no splitting of any signals but they 
had moved downfield as a result of paramagnetic properties of the 
europium atom. Another IH NMR experiment was carried out, this time 
with a different chiral shift reagent, (+)-2,2,2-trifluoro-l-(9-anthryl)- 
ethanol (147). Again no splitting of the signals was observed in the 111 
NMR spectrum. 
These NMR experiments with chiral shift reagents were not 
sufficient proof that the epoxycarbamate (143) was a single 
enantiomer. The last experiment involved the use of chiral column gas 
chromatography. Only one compound was observed. These 
experiments established that the optical purify of this compound must 
be greater than 95%. 
The next step was the reaction of ' the epoxycarbamate (143) with 
sodium hydride in THE This provided the erythro-hydroxycarbamate 
(144) in 80% yield after' recrystallisation. Its optical rotation was -52.5 
in contrast to value of +54.5 for (143). The IR spectrum of (144) 
showed absorptions at 1760 and 3300 cm-1 due to the carbamate 
carbonyl and OH respectively. Ring strain of the cyclic ring caused the 
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carbamate carbonyl stretch to shift to a higher frequency. Its 
III NMR 
spectrum suggested that the epoxide ring was cleaved. The 
13C NMR 
spectrum showed that the carbonyl carbon was deshielded slightly 
(from 5 155.8 to 158). The compound gave a correct elemental 
composition. 
Roush and Adam suggested that the cyclisation of the nitrogen 
anion with the epoxide ring was highly regiospecific giving only the 
carbamate with the five-membered ring. 94 We decided to investigate 
whether or not such regioselectivity was observed in our experiment. 
It is likely that there is hardly any difference in the spectroscopic data 
between the carbamate with the five- (144) and six-membered ring 
(148). 
Since both compounds are isomers, microanalysis and mass 
spectrometry provided little help. In theory, the most valuable piece of 
spectroscopic data which should establish whether it was a carbamate 
with a six- or a five-membered ring is from IR spectra. The carbamate 
carbonyl stretch for different ring sizes should be different. Such 
absorption could be used to distinguish clearly between the carbamate 
carbonyl groups of five- and six-membered rings. However, a 
literature search provided little evidence for the existence of an 
absorption frequency for a six-membered carbamate. Thus IR 
spectrometry is not ideal to be used to establish whether the cyclic 
carbamate was a five- or six-membered ring. The 
1H NMR spectrum of 
(144) might be the solution providing that the CH next to the alcohol 
group coupled with the OH. A D20 exchange experiment was carried 
out. The 1H NMR spectrum of (144) showed only one signal was 
affected. It could be concluded that the signal must be the CIi next to 
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the alcohol group. On D20 exchange, this signal was resolved from a 
multiplet to a doublet. This suggested that the compound must be the 
carbamate with a five-membered ring otherwise the CH next to the 
alcohol group would have remained a multiplet on D20 exchange, if it 
was in the six-membered ring 
The last step of the synthesis of (1R, 2S)-2-ethylamino-l- 
phenylpropane-1,3-diol (145) was hydrolysis of the hydroxycarbamate 
(144). Hydrolysis was effected using lithium hydroxide in a mixture of 
water and ethanol to give the 2-ethylamino-1,3-diol (145) in 93% yield. 
The IR spectrum of this compound showed absorptions at 3448,3286 
and 3083 cm-1 due to the NH and two OH groups respectively and the 
compound gave a correct elemental composition. 
Compound (145) was recrystallised in a conical flask from 
analytical grade ethyl acetate and hexane giving small cubic crystals. 
These were submitted to Miss K. McCormark (University of Glasgow) for 
X-ray crystallographic analysis. The displacement ellipsoid structure of 
this compound is shown in Diagram 10. 
As expected the molecule has several hydrogen bonding 
interactions (Diagram 11). The oxygen and hydrogen atoms of the 
hydroxyl groups, and the nitrogen and hydrogen atoms of the amino 
group are all involved in H-bonding. Each functional group is H-bonded 
to two other identical molecules. The unit cell of the crystal is depicted 
in Diagram 12. 
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Diagram 10: The displacement ellipsoid structure of (1 R, 2S)-2- 
ethylamino- I -phcnylpropane- l . 3-diol (145) 
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S. 
Diagram 12: The unit ccll of (1/1,2S)-2-cthylam ino-I-phcnyIII ropane- 
I, 3-dial (145) 
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Since the overall yield for the synthesis of (1R, 2S)-2-ethylamino- 
1-phenylpropane-1,3-diol was excellent, it was decided to apply the 
procedure of Roush and Adam to the synthesis of N-ethylsphingosine. 
However, this methodology required the use of an allyl alcohol as a 
starting material. Therefore, the ene-allyl alcohol (149) required for 
the synthesis of N-ethylsphingosine had to be prepared from 
tetradecanal (153). This material is commercially available, but was 
found to be too impure and difficult to purify because of its instability. 
Therefore fresh material had to be prepared from tetradecanoic acid 
(150). The preparation of (149) and its use in the synthesis are 





































Scheme 54: Attempted synthesis of N-ethylsphingosine 
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To prepare the hydroxydiene (149), tetradecanoic acid was 
treated with dry HC1 in methanol to afford the known methyl ester 
(151)95 in 95% yield. The IR spectrum of the methyl ester (151) 
showed a absorption at 1744 cm-1 due to the ester carbonyl. Its III 
NMR spectrum showed a singlet at 8 3.53 corresponding to the methoxy 
group and the high resolution mass spectrum gave a value for the 
molecular ion of 242.2237 compared with a theoretical value of 
242.2245. 
Reduction of the methyl ester (151) with lithium aluminium 
hydride gave the known alcohol (152)96 in 94% yield. The expected 
absorption due to the stretching of the OH was found at 3421 cnl' 1. 
The 1H NMR spectrum of (152) . showed a triplet at 
6 3.52 for the 
methylene protons nearest to the hydroxyl group. 
Swern oxidation of (152) to the known aldehyde (153)97 was 
achieved in 84% yield using dimethylsulfoxide, oxalyl chloride and 
triethylamine. Flash chromatography was required to purify the 
aldehyde. The IR spectrum showed an absorption at 1720 cm-1 for the 
aldehyde carbonyl. The aldehyde was evident from signals at 8 9.70 in 
the 1H NMR spectrum, and at 8 202.1 in the 13C NMR spectrum. 
Wittig condensation was then required to convert the aldehyde 
into the known diene methyl ester (154)38. The first step involved 
deprotonation of methyl (E)-4-dimethylphosphono-2-butenoatc 
followed by coupling with the aldehyde to afford the diene methyl 
ester. The diene methyl ester was isolated in 62% yield. The IR 
spectrum of the diene methyl ester (154) showed absorptions at 1650 
and 1718 cm-1 for the C=C and (xß-unsaturated ester carbonyl. Its 111 
NMR spectrum showed a singlet at 8 3.70 for the methoxy group and a 
multiplet at 6 5.81 - 7.72 for the alkene hydrogens. Due to the 
complexity of this multiplet, the coupling constants could not be 
estimated. The 13C NMR spectrum showed that it was only partially 
pure and consisted of a mixture of (2E, 4Z)- and (2E, 4E)-isomers. These 
isomers could not be separated using column chromatography and had 
to be used directly in the next step with the possibility that the 
products of the next step would give a better separation on TLC. 
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The reduction of (154) to the known alcohol (149)3 8 was 
achieved in 80% yield using lithium aluminium hydride. The expected 
OH stretch was ` found at 3318 cm-1. The IH NMR spectrum showed a 
doublet at 5 4.05 for the methylene protons nearest to the hydroxyl 
group. The splitting patterns of alkene protons were complex and so 
the coupling constants could not be determined. A small trace of the 
(2E, 4Z)-isomer was shown by the 13C NMR spectrum. Further attempts 
to separate these isomers by column chromatography failed. 
Nevertheless the mixture was used in the next reaction. 
Asymmetric epoxidation of the hydroxydiene (149) gave the new 
E-ene-epoxyalcohol (155) in 5% yield using Sharpless conditions. The 
IR spectrum of (155) showed absorptions at 1245,1645 and 3200 cm-1 
due to the C-O, C=C and OH respectively. The epoxide protons were 
observed in the 1H NMR spectrum as a multiplet at 8 3.03 for the 
epoxide proton nearest to the hydroxyl group and a double of doublets 
at S 3.30 for the other epoxide proton. Also present in the 111 NMR 
spectrum were a double doublets of triplets at 8 5.11 for the alkene 
proton adjacent to, the epoxide, and a doublet of triplets at 8 5.89 for 
the other alkene proton. The coupling constant between the alkene 
protons was found to be 15.4 Hz indicating it must be a E-double bond. 
The reaction also gave the new Z-ene-epoxyalcohol (156) which 
was isolated in 10% yield. There was little spectroscopic difference 
between (155) and (156) apart from their 1H NMR coupling constants. 
The alkene protons of the Z-ene-epoxyalcohol were found to have a 
coupling constant of 11 Hz. A homo-decoupling experiment was carried 
out on the E-isomer (155) to ensure that the epoxidation did indeed 
occur at the allylic double bond. Irradiation of the signal at 8 5.89 
caused the signal (saturated methylene protons) at 8 2.01 to collapse 
from a multiplet to a triplet. This decoupling, however, had no effect on 
the methylene protons adjacent to the hydroxyl group. Thus it could be 
concluded that Sharpless asymmetric epoxidation must have occurred 
at the allylic double bond. The same finding was also observed for the 
Z-isomer. 
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Although the enantioselective route was successful in the 
synthesis of (1R, 2S)-2-ethylamino-l-phenylpropane-1,3-diol (145), the 
route to the corresponding N-ethylsphingosine came to a halt at the 
Sharpless epoxidation stage. The yield was poor for the Sharpless 
asymmetric epoxidation because the starting material had a tendency 
to crystallise out of the reaction mixture at low temperature. But from 
room temperature to 0 °C, the starting material readily dissolved in 
dichloromethane. Unfortunately, it was necessary to carry out the 
Sharpless asymmetric epoxidation around -30 oC in order to achieve 
the best selectivity and to ensure the formation of the titanium 
complex. Such a problem has to be overcome as this is the key step of 
the synthesis. One possible solution may be to perform the epoxidation 
with a co-solvent. However, time constraints prevented further 
development of this route towards N-ethylsphingosine. We believe that 
the success of this synthesis probably relies solely on improving the 
yield of the Sharpless epoxidation as the three remaining steps appear 
straightforward. 
6.5 Biological Testing of a Selection of Sphingosine Analogues 
A selection of compounds was tested in vitro on two different 
cancer lines by Dr A. T. McGown at the Paterson Institute in 
Manchester. These cell lines were human ovarian carcinoma and 
chronic myelogenous leukaemia. Table 5 records the IC5 0 values of 
these compounds. Comparison of IC50 values for both assays show that 
the order of potency increases when the hydrophobic part is an alkyl 
chain. Compounds (115), (116) and (117) were the most potent for 
both cell lines having IC50 values of about 1µM. 
Table 5 
IC50 values (µ M) 
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Further testing was carried out by Dr McGown on the most active 
alkynes (115), (116) and (117). They were tested in vitro on mouse 
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P388 lymphoid neoplasm with a high PKC expression, a P388 cell line 
with a low PKC expression (ca. 10%) resistant to bryostatin (Br/D) and a 
humun ovarian carcinoma resistant to adriamycin (A2780ADR). The 
results shown in Table 6 demonstrate that these alkynes (115), (116) 
and (117) are effective against a range of cancer cell lines with IC5 0 
values of about 1µM. In addition, decreasing the PKC expression (ca. 
10%) 'in the P388 cell line decreases the IC50 values of compounds 
(116) and (117) by five fold, indicating that these compounds are 
exerting some effect on PKC. 
Table 6 
IC50 values (µ M) 
P338 Br/D A2780ADR 
CH 6 
(116) 
6.56 1.5 0.63 
CH 7 
(117) 
7.87 1.18 0.69 
CH 8 
(115) 
1.53 0.59 1.13 
D-erythro- 
s hin osine 
3.8 4.4 1.13 
6.6 Future Work 
Since the three sphingosine analogues containing a triple bond 
showed very promising cytotoxic effects on different cancer lines, it will 
be of great interest to synthesise the corresponding N-methylated 
compounds to see how such a modification will affect the anti-cancer 
activity. As discussed in Chapter 4, N-methylation of the aminodiol 
proved to be more difficult than first anticipitated. Such a problem 
may be overcome by using the retro aza Diels-Alder procedure. The 
main attraction of this procedure was the fact that the reaction could 
proceed in the presence of other functional groups. Although (S)-N- 
methylphenylalaninol could not be synthesised using this procedure 
because of the mixture of products obtained in the reduction step, we 
believe that once the conditions and reagents for this reduction have 
been established, this procedure will be a powerful way to carry out N- 
methylation. 
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Sphingosine was only produced in small amount in the reduction 
step of the diastereoselective synthesis. It was too low to be used to 
synthesise sphingosine analogues. The yield of the reduction step must 
be improved. As for the enantioselective approach, the problem was 
with the insolubility of the starting material for the Sharpless 
epoxidation. Achieving enantioselective synthesis was more desirable 
than the diastereoselective synthesis because the final product of the 
enantioselective approach would be N-alkylsphingosine instead of 
sphingosine itself. The alkyl group of N-alkylsphingosine could be 
varied simply by using different isocyanates in the carbamate 
formation step. It would be desirable to have a route in which N- 
methylsphingo sine could be synthesised, providing an alternative to the 
usual N-methylation of sphingosine. 
The synthesis of deoxysphingosine slowed to a halt until (S)-3-(4- 
toluenesulfonyl)-4-(4-tolu en esulfonyloxymetlhyl)oxazolidin-2-one 
(124) was discovered. The use of (124) in the alkynylation step was 
encouraging even though the yield was not that good. Unfortunately 
there was insufficient product to be used for the last step which would 
be the Birch reduction. 
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CHAPTER SEVEN 
Experimental to Chapters 4-6 
7.1 General 
Melting points (m. p. ) were measured with a Gallenkamp apparatus. 
Infra-red (IR) spectra were obtained on a Perkin Elmer 983 
spectrophotometer or a Perking Elmer PU 9800 PT-IR 
spectrophotometer. 1H and 13C NMR spectra were obtained on a 
Bruker WP200-SY spectrometer operating at 200MHz and 50MIHz 
respectively. All coupling constants quoted arc measured in Hz. The 
numbering schemes shown are used for case of asssigning the NMR 
spectra. Mass spectra (MS) were recorded on AEI MS 12 or MS902 
spectrometers. Thin layer chromatography (TLC) was carried out on 
silica gel G plates of 0.25mm thickness developed with hexane - ethyl 
acetate unless stated otherwise and compounds were detected with 
vanillin, iodine or by ultra-violet radiation. Column chromatography 
was carried out on silica gel, 70-230 mesh with the same solvent 
system. 
7.2 Experimental to Chapters 4 
(S)-N. O-DiacetXlphenylalaninol (7 ) 72 
13 
Pyridine (1.3 g, 16.6 mmol) and acetic anhydride (1.69 g, 16.6 mmol) 
were added sequentially to a solution of (S)-phenylalaninol (1.0 g, 6.62 
mmol) in dry THE (20 ml). After the reaction mixture was stirred at 
room temperature for 10 h, it was diluted with ethyl acetate (40 ml) 
and washed with 1M hydrochloric acid (3 x 30 ml) and then with 
saturated sodium bicarbonate solution (3 x 30 ml). The organic layer 
was dried with magnesium sulfate and concentrated to give white 
needles (1.3 g, 84%); mp 112-113 OC {lit., 72 114-115 oC}; Rf 0.6 (ethyl 
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acetate); [aID22 -13.0 (c 1 in acetone) {lit., 
72 [a]D22 -13 (c 1 in acetone)); 
8H (200MHz, CDC13) 1.96 (3H, s, 13-H3), 2.10 (3H, s, 11-H3), 2.85 (211, 
ABX, 3-H2, J 4.6,11.4 Hz), 4.10 (2H, ABX, 1-H2, J 6.4,13.7 Hz), 4.38 (111, 
m, 2-H), 5.67 (1H, br d, NH), 7.26 (5H, m, aromatic H); 5c (50 MHz, CDC13) 
20.8 (C-13), 23.3 (C-11), 37.4 (C-3), 49.4 (C-2), 64.7 (C-1), 126.7 (C-7), 
128.5 (C-5 and -9 or C-6 and -8), 129.1 (C-5 and -9 or C-6 and -8) 
136.9 (C-4), 169.8 (C-12), 171.0 (C-10); vmax (KBr disc)/cm-1 1772 
(COO), 1684 (CON), 1271,1261,1045,1033; m/z 235 (M+, 1.5%), 176 
(14.6, M- OCOCH3) 134 (9.6, M- OCCH3, - NHCOCH3), 120 (20.9), 102 
(51.2), 84 (72.9), 60 (100%); (found M+, 235.1211. Calc. for C 13H 17NO3, 
235.1280). (Found: C, 66.13; H, 7.36; N, 5.90. Calc. for C 13H 17NO3: C, 
66.00; H, 7.20; N, 5.90 %). 
(R)-N. 0-Diacetyll2henylalaninol (75)72 
13 
The title compound was prepared in the same way as for the (S) - 
isomer except that (R)-phenylalaninol (1.0 g, 6.62 mmol) was used. The 
compound was isolated as white needles (1.3 g, 84%); mp 113-114 OC 
{lit., 72 114-115 °C]; Rf 0.6 (ethyl acetate); [a]D22 +13.0 (c 1 in acetone) 
{lit., 72 [a]D22 +13 (c 1 in acetone)); 8H (200MHz, CDC13) 1.96 (3H, s, 13- 
H3), 2.10 (3H, s, 11-H3), 2.85 (2H, RX, 3-H2, J 4.5,11.4 Hz), 4.10 (2H, 
AB X, 1-H2, J 6.3,13.5 Hz), 4.38 (IH, m, 2-H), 5.67 (IH, br d, NH), 7.26 
(5H, m, aromatic H); 6c (50 MHz, CDC13) 20.8 (C-13), 23.3 (C-11), 37.4 (C- 
3), 49.4 (C-2), 64.7 (C-1), 126.7 (C-7), 128.5 (C-5 and -9 or C-6 and -8), 
129.1 (C-5 and -9 or C-6 and -8), 136.9 (C-4), 169.8 (C-12), 171.0 (C- 
10) ; vm ax (KBr disc)/cm-1 1772 (COO), 1684 (CON), 1271, 
1261,1045,1033; m/z (M+, 1.3%), 176 (14.6, M- OCOCH3) 134 (9.6, M- 
OCCH3, - NHCOCH3 ), 120 (21.9), 102 (51.2), 84 (74.9), 60 (100%); (found 
M+, 235.1214. Calc. for C 13 H 17 NO3,235.1208). (Found: C, 66.19; 11, 




Dioxan (12 ml) and di-tert-butyldicarbonate (2 g, 8.6 mmol) were 
added to a solution of (S)-phenylalaninol (1.0 g, 6.62 mmol) in water 
(25 ml) with continuous stirring at room temperature for 18 h. The 
solvents were then removed with ethanol in vactto and the residue was 
chromatographed (ethyl acetate-hexane; 1: 3) to give an oil (1.66 g, 
97%); Rf 0.4 (ethyl acetate-hexane; 1: 1); 6ii (200MHz, CDC13) 1.41 (911, s, 
11-, 12- and 13-H3), 2.80 (2H, d, 3-H2, J 7.2 Hz), 2.89 (111, br s, 01l), 
3.56 (2H, ABX, 1-H2, J 3.7,11.0 Hz), 3.86 (IH, m, 2-H), 4.76 (111, br d, 
NH), 7.26 (5H, m, aromatic H); 8c (50 MHz, CDC13) 28.2 (C-11, -12 and 
-13), 37.8 (C-3), 50.5 (C-2), 65.0 (C-1), 79.3 (C-14), 126.5 - 129.2 
(aromatic CH), 137.2 (C-4), 155.1 (C-10); vmax (film) / cm-1 3418hr (011), 
2914,1686 (OCON); m/z 251 (M+, 0.3%)178 (10.9, M- OC4 H9), 160 
(19.2, M- COOC4H9), 91 (42.7, M- OHCH2CHNH000C4119), 57 (100%); 
(found M+, 251.1530. Calc. for C14H21N03,251.1521). 
(S)-2-[(tert-Butyloxycar y amino)-N-metliyl]Q 
methylphenylalaninol (78) 
(using the procedure of Coggins and Benoiton74) 
11 
Sodium hydride (95%, 0.35 g, 21.6 mmol) was added to a stirred 
solution of N-BOC-phenylalaninol (77) (1.8 g, 7.17 mmol) and 
iodomethane (4 ml, 21.2 mmol) in dry THE (20 ml). After the mixture 
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was stirred for 15 h at room temperature, the mixture was poured into 
ice water and extracted with ethyl acetate (3 x 40 ml). The combined 
extracts were dried with magnesium sulfate and concentrated under 
reduced pressure to afford a yellow oil. TLC (ethyl acetate-hexane; 1: 1) 
showed three spots with Rf values of 0.4,0.6 and 0.7. Purification of 
the oil by column chromatography eluting with ethyl acetate-hexane 
(1: 4) gave (S)-3-methyl-4-benzyloxazolin-2-one (79), N-tert- 
butyloxycarbonyl-O-methylphenylalaninol (80), and the title 
compound. 
The title compound was obtained as a yellow oil (0.1 g, 5%); Rf 0.7; 811 
(200MHz, CDC13) 1,. 3 (9H, s, 11-, 12- and 13-H3), 2.30 (3H, s, 16-113), 
2.71 (2H, m, 3-H2), 3.16, (2H, m, 1-H2), 3.18 (3H, s, 15-113), 3.81 (111, m, 
2-H), 7.12 (5H, m, aromatic H); 5C (50 MHz, CDC13) 28.3 (C-11, -12 and 
-13), 33.8 (C-16), 37.7 (C-3), 51.5 (C-15), 58.7 (C-2), 72.5 (C-1), 79.4 (C- 
14) 126.2 (C-7), 128.4 (C-5 and -9 or C-6 and -8), 129.3 (C-5 and -9 or 
C-6 and -8), 138.2 (C-4), 155.0 (C-10); vmax (film) / cm-1 2850,1745 
(OCON); m/z 206 (9.1, M- OC4H9), 188 (23.5, M- COOC4H9), 134 (11.2, 
M- N(CH3)COOC4H9, - CH3); (found M+ - 0C4119,206.1179. Calc. for 
C 12H 16NO2,206.1181). 
(S)-3-Methyl-4-benzyloxazolin-2-one (79) was obtained as white 
needles (0.30 g, 21%). 
m. p. 90 oC; Rf 0.4; [a]D22 -58.1 (c 1.5 in CHC13); 811 (200MHz, CDC13) 2.75 
(2H, m, 3-H2), 2.77 (3H, s, 11-H3), 3.82 (2H, m, 1-H2), 4.02 (11-1, nl, 2-11), 
7.11 (5H, m, aromatic H); SC (50 MHz, CDC13) 29.4 (C-11), 38.2 (C-3), 58.2 
(C-2), 66.52 (C-1), 126.2 (C-7), 128.4 (C-5 and -9 or C-6 and -8), 129.3 
(C-5 and -9 or C-6 and -8), 135.5 (C-4), 158.42 (C-10); vmA,, (KBr disc) / 
cm-1 1750 (OCON); m/z 191 (M+, 0.8), 117 (1.2), 100 (100, M- 
C6H5CH2), 91 (13.9, M- CHCH2OO0NMe); (found M+, 191.0956. Calc. for 
C 11 H 13 NO2,191.0946). (Found: C, 69.26; H, 6.98; N, 7.14. Calc. for 
C11H13N02: C, 69.11; H, 6.77; N, 7.32%). 
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(S)-N-tert-Butyloxycarbonyl-O-methylphenylalaninol (80) was obtained 
as a yellow oil (1.1 g, 57%). 
O/15 
0 
Rf0.6; 5H (200MHz, CDC13) 1.3 (9H, s, 11-, 12- and 13-H3), 2.71 (211, m, 
3-H2), 3.16 (2H, ABX, 1-H2, J 3.7,11.2 Hz), 3.18 (3H, s, 15-H3), 3.81 (1H, 
m, 2-H), 4.92 (1H, br d, NH), 7.11 (5H, m, aromatic H); 5c (50 MHz, CDC13) 
28.3 (C-11, -12 and -13), 37.7 (C-3), 51.5 (C-15), 58.7 (C-2), 72.5 (C-1), 
79.7 (C-14), 126.2 (C-7), 128.3 (C-5 and -9 or C-6 and -8), 129.3 (C-5 
and -9 or C-6 and -8), 138.2 (C-4), 155.0 (C-10); vmax (film) / cm- 1 
1745 (OCON); m/z 192 (18.9, M- OC4H9), 174 (5.9, M- COOC4H9), 134 
(14.9, M- HNCOOC4H9, - CH3); (found M- OC4H9,192.1018. Calc. for 
C11H14NO2,192.1024). 
(S)-N. 0-Dime thyýýhenylýlaninol ($I1 
0 
10 
A solution of (S)-2-[(tert-butyloxycarbonylamino)-N-methyl]-O- 
methylphenylalaninol (78) (0.1 g, 38.4 mmol) in 1M HCl in ethyl 
acetate (30 ml) was stirred at room temperature for 5 h. The reaction 
mixture was diluted with ethyl acetate (20 ml), washed with 1M 
sodium hydroxide (2 x 50 ml), dried with magnesium sulfate and 
concentrated to give the title compound (0.04 g, 78%) as a yellow oil; Rf 
0.4 (ethyl acetate); [a]D22 -1.4 (c 1.7 in ethanol); Stt (200MHz, CDC13) 
2.38 (3H, s, 11-H3), 2.56 (1H, br s, NH), 2.72 - 2.81 (3H, m, 1-H2 and 2- 
H), 3.23 (2H, m, 3-H2), 3.29 (3H, s, 10-H3), 7.26 (5H, m, aromatic H); 8c 
(50 MHz, CDC13) 33.9 (C-11), 37.3 (C-3), 58.8 (C-10), 60.6 (C-2), 73.2 (C- 
1), 126.1 (C-7), 128.5 (C-5 and -9 or C-6 and -8), 129.2 (C-5 and -9 or 
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C-6 and -8), 138.7 (C-4); Vmax (KBr disc) / cm-1 3431m (NH); m/z 179 
(M+, 3.0%), 134 (50, M- NHCH3, - CH3), 81 (100, M- C6H5CH); (found 
M+, 179.1320. Calc. for C11H17NO, 179.1320). 
S)-N-tert-Butvloxvcarbon I mcinvitiuvrnncnviaianina 
LU4 
(using the procedure of Corey et a!. )98 
N-BOC-phenylalaninol (77) (3.24 g, 13.0 mmol), imidazolc (1.3 g, 20.0 
mmol), and tert-butyl-dimethylsilyl chloride (2.35 g, 14.3 mmol) in dry 
DMF were placed in a 250 ml round bottom flask. The reaction was 
stirred for 1h then 1M hydrochloric acid (30 ml) was added . The 
aqueous layer was extracted with ethyl acetate (3 x 30 ml). The 
combined extracts were dried with magnesium sulfate and 
concentrated under reduced pressure to give an oily solid (4.2 g, 89%); 
Rf0.6 (ethyl acetate-hexane; 1: 2); 811 (200MHz, CDC13) -0.03 (611, s, 15- 
and 16-H3), 0.88 (9H, s, 17-, 18- and 19-CH3), 1.43 (911, s, 11-, 12- and 
13-H3), 2.76 (2H, d, 3-H2, J 8.0 Hz), 3.41 (2H, m, 1-112), 3.52 (111, in, 2- 
H), 4.73 (1H, br d, NH), 7.13 (5H, m, aromatic H); SC (50 MHz, CDC13) -5.5 
(C-15 and -16), 18.1 (C-20), 25.7 (C-17, -18 and -19), 28.3 (C-11, -12 
and -13), 37.3 (C-3), 53.0 (C-2), 62.9 (C-1), 79.1 (C-14), 121.5 (C-7), 
134.6 (C-5 and -9 or C-6 and -8), 134.8 (C-5 and -9 or C-6 and -8), 
138.2 (C-4), 155.4 (C-10); vmax (film) / cm-1 2953,1695 (OCON), 1256 
(Si(CH3)2), 1056,840 (SiO); m/z 292 (2.1, M- OC4H9), 251 (100, Mli - 
Si(CH3)2C(CH3)3), 173 (50.1), 90 (87.6); (found M- OC4H9,292.1690. 
Calc. for C 16H26SiNO2,292.1684). 
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Attempted preparation of (S)-2-[(tert-butylox cay rbon lamino)-N- 
methyl]-O-tert-butyldimethylsilylphenylalaninol 
(using the procedure of Coggins and Benoiton74) 
0 
Sodium hydride (95%, 0.1 g, 4.2 mmol ) was added to a solution of (S)- 
N-BOC-O-TBDMS-phenylalaninol (84) (1 g, 2.7 mmol) in dry DMF under 
nitrogen. Once the hydrogen gas had stopped evolving, methyl iodide 
(1 g, 7.0 mmol) was added dropwise to the resulting mixture. After the 
addition was complete, the flask was stirred overnight at room 
temperature. Ethyl acetate (50 ml) was added followed by water (30 
ml). The aqueous layer was extracted with ethyl acetate (4 x 30 nil) 
and the combined extracts were washed with brine (3 x 30 ml), water 
(3 x 30 ml), dried, filtered and concentrated to give a yellow oil. TLC 
and all spectral properties were identical to N-BOC-O-TBDMS- 
phenylalaninol (84). This reaction was repeated several times under 
different conditions, all of which were unsuccessful. Table 1 
summarises the outcomes. 
Azabicyclic lic (2.2.1) heptene (85 
(using the procedure of Grieco and Bahsas75) 
4 
121 
Cyclopentadiene (1.3 g, 19.6 mmol) was added to a stirred solution of 
(S)-phenylalaninol (1 g, 6.62 mmol), trifluoroacetic acid (0.75 g, 6.62 
mmol) and formaldehyde (37%, 1.2 g, 13.2 mmol) in water (30 ml). 
After 1h at room temperature, the hetrogenous mixture was washed 
with hexane and neutralised with saturated sodium bicarbonate 
solution. The resulting solution was then extracted with methylene 
chloride (3 x 40 ml). The combined organic extracts were dried over 
magnesium sulfate and concentrated to give an oil which was purified 
by column chromatography eluting with methylenc chloride/ 
methanol/ ammonium hydroxide (96: 3: 1) to afford the title compound 
(1.0 g, 67%); the 1H NMR spectrum was complex; Sc (50 MFiz, CDC13) 
42.8 (C-2), 47.5 (C-6), 51.1 (C-8), 51.5 (C-5), 52.1 (C-1), 61.4 (C-7), 
128.3 (C-13), 129.3 (C-11 and -15 or C-12 and -14), 130.2 (C-11 and 
-15 or C-12 and -14), 130.4 (C-3 or -4), 136.8 (C-3 or -4), 137.3 (C-15); 
Vmax (film) / cm-1 3401,1680., 
Attempted synthesis of (S -N-methylphenylalaninol 
OH 
Trifluoroacetic acid (0.25 g, 2.18 mmol) and triethylsilane (0.50 g, 4.4 
mmol) were added to a solution of (121) (0.5 g, 2.18 mmol) in 
chloroform. The reaction, mixture was stirred at room temperature 
under nitrogen. After 20 h, the solvent was removed under pressure. 
The crude product was redissolved in chloroform (50 ml), treated with 
1M HCl (50 ml) and washed with ether (3 x 30 ml). The aqueous layer 
was neutralised with saturated sodium bicarbonate solution and 
extracted with methylene chloride (3 x 50 ml). The organic extracts 
were dried over magnesium sulfate and concentrated to give a complex 
mixture. 
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(S)-N. O-Diformylphenylalaninol 86176 
0 
Formic acid (1.2 g, 31 mmol) was added to a solution of (S) - 
phenylalaninol (1 g, 6.6 mmol) in toluene (10 ml) and the mixture was 
heated at 90 - 98 oC for 13 h. After cooling to room temperature, the 
mixture was diluted with ethyl acetate (20 ml) and washed with 
saturated sodium bicarbonate solution and then brine. The organic 
layer was dried with magnesium sulfate, filtered and concentrated 
under reduced pressure to give a yellow oil which was 
chromatographed (ethyl acetate-hexane; 1: 1) to afford a white solid (1 
g, 83%); mp 98 - 99 °C; Rf0.3 (ethyl acetate-hexane; 1: 1); 51; (200M1iz, 
CDC13) 2.91 (2H, d, 3-H2), 4.16 (2H, d, 1-H2), 4.54 (111, in, 2-11), 6.17 
(1H, br d, NH), 7.20 (5H, m, aromatic H), 8.07 (2H, br s, 10-11); 3c (50 
MHz, CDC13) 37.1 (C-3), 47.9 (C-2), 65.1 (C-1), 126.9 (C-7) 128.5 (C-5 
and -9 or C-6 and -8), 129.2 (C-5 and -9 or C-6 and -8), 136.4 (C-4), 
160.7 - 160.9 (C-10 and -11); vmax (KBr disc) / cm-1 3400,1718 (OCO), 
1668 (CON); m/z 207 (M+, 4.2%), 162 (100, M- OCOH), 133 (18.3, M- 
000H, - CHO), 115 (7.4, M- OCOH, - NHCHO), 91 (80, M- 




Lithium aluminium hydride (0.55 g, 14.4 mmol) and dry THE (30 nil) 
were placed in a flame dried three-necked flask. A solution of (S)-N, O- 
diformylphenylalaninol (86) (1 g, 4.8 mmol) in dry THE (20 nil) was 
then added to the suspension at 0 °C. The reaction mixture was stirred 
for 1h at this temperature and then quenched by addition of saturated 
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ammonium chloride solution (50 ml). The resulting mixture was 
extracted with ethyl acetate (3 x 50 ml), dried with magnesium sulfate, 
filtered and concentrated to give a yellow oil. The oil was partially 
purified by flash chromatography eluting with ethyl acetate-ethanol 
(9: 1) to afford the title compound (0.65 g, 74%). 
(IS 2S)-N. O. O-Triformyl-2-amino-l-phenylpropanc-1.3-diol (157)76 
0 
0 
Formic acid (1.4 g, 3.0 mmol) was added to a solution of (IS, 2S)-2- 
amino-1-phenylpropane-1,3-diol (1 g, 6.0 mmol) in toluene (10 ml) 
and the mixture was heated at 90 - 98 oC for 13 h. After cooling to 
room temperature, the mixture was diluted with ethyl acetate (20 ml) 
and washed with saturated sodium bicarbonate solution and then brine. 
The organic layer was dried with magnesium sulfate, filtered and 
concentrated under reduced pressure to give a yellow oil which was 
chromatographed (ethyl acetate-hexane; 1: 1) to afford an oil (1.3 g, 
86%); Rf 0.4 (ethyl acetate-hexane; 1: 1); Stt (200MHz, CDC13) 3.80 (111, 
dd, 1-H, J 5.4,11.4 Hz), 4.10 (1H, dd, 1-H, J 6.3,11.0 Hz), 4.67 (111, m, 2- 
H), 5.93 (1H, d, 3-H, J 6.9 Hz), 7.25 (5H, m, aromatic H), 8.73,7.95,8.02 
(3H, 3xs, 10-, 11- and 12-H); 8c (50 MHz, CDC13) 49.7 (C-2), 62.0 (C-1), 
73.0 (C-3), 126.0 (C-5 and -9 or C-6 and -8) 128.2 (C-5 and -9 or C-6 
and -8), 128.9 (C-7), 135.5 (C-4), 159.3,160.3,161.4 (C-10, -11 and 
-12); Vmax (KBr disc) / cm-1 1718 v. 
b (OCO), 1668 v. b (CON); ni/z 251 
(M+, 0.5%), 177 (5.8), 132 (14.7), 107 (23.8), 71 (100); (found M+, 
251.0808. Calc. for C12H13N05,251.0810). 
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Lithium aluminium hydride (0.68 g, 20 mmol) and dry THE (30 ml) 
were placed in a flame dried three-necked flask. A solution of (157) (1 
g, 4.0 mmol) in dry THE (20 ml) was then added to the suspension at 0 
0C. The reaction mixture was stirred for 1h at this temperature and 
then quenched by addition of saturated ammonium chloride solution 
(50 ml). The resulting mixture was extracted with ethyl acetate (3 x 50 
ml), dried with magnesium sulfate, filtered and concentrated to give a 
complex mixture. 
(S)-N. N-Dimethylphenylalanino (88) 
(using the procedure of Feldkamp et al. 77) 
OH 
Formaldehyde' (36%, 0.8 g, 8.0 mmol) was added to a solution of (S) - 
phenylalaninol (1 g, '6.7 mmol), palladium/carbon catalyst (10%, 0.1g) 
and glacial acetic acid (0.8 g, 13.4 mmol) in water (30 ml). Nitrogen gas 
was bubbled through the reaction mixture for 5 min before hydrogen 
gas was introduced. The reaction was stirred for 10 h after which the 
catalyst was removed through Celite. The residue was diluted with 
diethyl ether and slowly made basic with 2M sodium hydroxide 
solution. The ether layer was separated and the aqueous layer was 
extracted with diethyl ether (3 x 30 ml). The combined extracts were 
dried with magnesium sulfate and concentrated under reduced 
pressure to give a yellow oil. TLC (ethyl acetate-pet ether; 1: 1) showed 
two spots with Rf values of 0.2 and 0.5. Purification of the oil by 
column chromatography eluting with ethyl acetate-pet ether (1: 1) 
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afforded the title compound and (S)-3-methyl-4-benzyloxazolidine 
(89). 
The title compound was obtained as a yellow oil (0.65 g, 54%); Rf 0.2; 
[a]D22 -1.8 (c 1.56 in ethanol) {lit., 
78 [a]p22 -2.1 (c 1.56 in ethanol)); 51; 
(200MHz, CDC13) 2.56 (6H, s, "10 and 11-H3), 2.81 (2H, m, 3-H2), 3.2 (3H, 
m, 1-H2 and 2-H), 3.81 (1H, br s OH), 7.12 (5H, m, aromatic H); 8C (50 
MHz, CDC13) 30.5 (C-3), 40.1 (C-10 and -11), 60.3 (C-1), 66.8 (C-2), 
126.1 (C-7) 128.4 (C-5 and -9 or C-6 and -8), 128.9 (C-5 and -9 or C-6 
and -8), 139.38 (C-4); Vmax (film) / cm-1 3390,2936,778; in/z 179 
(M+, 0.1%), 148 (7.7, M- (CH3)2, - H), 133 (2.1), 88 (21.7), 59 (100); 
(found M+, 179.1328. Calc. for C 11 H 17NO, 179.13 10). 
(S)-3-Methyl-4-benzyloxazolidine (89) was obtained as a white soild 
(0.2 g, 17%). 
Rf 0.5; [a]D22 -2.4 (c 1.7 in ethanol); 8H (200MHz, CDC13) 2.47 (311, s, 10- 
H3), 2.52 (1H, m, 2-H), 2.82 (2H, m, 3-H2), 3.62 (2H, m, 1-H2), 4.01 (111, 
d, 11-H, J 4.4 Hz), 4.39 (1H, d, 11-H, J 4.4 Hz), 7.13 (5H, m, aromatic 11); 
He (50 MHz, CDC13) 38.7 (C-3), 40,0 (C-10), 66.8 (C-2), (C-1), 88.2 (C-11), 
126.1 (C-7) 128.4 (C-5 and -9 or C-6 and -8), 128.9 (C-5 and -9 or C-6 
and -8), 138.7 (C-4); vmax (KBr disc) / cm-1 2944,2856,2792; mgthz 177 
(M+, 0.2%), 147 (1.4, M- OCH2), 91 (13, M- N(CH3)CH2OCH2CH, 86 (100, 
M- C6H5CH2); (found M+, 177.1138. Calc. for C11H15NO, 177.1154). 
(R)-N. N-Dimethylphenylalaninol (158) 
(using the procedure of Feldkamp et al. 77) 
The title compound was prepared in the same way as the S- isomer 
except that (R)-phenylalaninol (1 g, 6.7 mmol) was used. TLC also 
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showed two spots with the same Rf values as the S-isomer. The 
mixture was purified by column chromatography eluting with ethyl 
acetate-pet ether (1: 1) to afford partially pure (R) -3 -methyl -4- 
benzyloxazolidine and the title compound. 
The title compound was obtained as a yellow oil (0.70 g, 64%); Rf 0.2; 
[a]D22 +1.9 (c 1.56 in ethanol) {lit., 78 [(X]D22 +2.1 (c 1.56 in ethanol)); 811 
(200MHz, CDC13) 2.56 (6H, s, 10 and 11-H3), 2.81 (2H, m, 3-112), 3.2 (4H, 
m, 1-H2, OH and 2-H), 7.12 (5H, m, aromatic H); 6c (50 MHz, CDC13) 30.5 
(C-3), 40.1 (C-10 and -11), 60.3 (C-1), 66.8 (C-2), 126.1 (C-7) 128.4 (C-5 
and -9 or C-6 and -8), 128.9 (C-5 and -9 or C-6 and -8), 139.38 (C-4); 
umax. (film) / cm-1 3390,2936,778; m/z 179 (M+, 0.1%), 148 (7.7, M- 
(CH3)2, - H), 133 (2.1), 88 (21.7), 59 (100); (found M+, 179.1328. Calc. 
for C 11 H 17NO, 179.1310). 
(R)-3-Methyl-4-benzyloxazolidine (159) was obtained as a yellow solid 
(0.25 g, 21%). 
Rf0.5; [a]D22 +2.3 (c'1.7 in' ethanol); 8H (200MHz, CDC13) 2.47 (311, s, 10- 
H3), 2.52 (1H, m, 2-H), 2.82 (2H, m, 3-H2), 3.62 (2H, m, 1-112), 4.01 (111, 
d, 11-H, J 4.4 Hz), 4.39 (1H, d, 11-H, J 4.4 Hz), 7.13 (5H, m, aromatic H); 
5C (50 MHz, CDC13) 38.7 (C-3), 40.0 (C-10), 66.8 (C-2), (C-1), 88.2 (C-11), 
126.1 (C-7) 128.4 (C-5 and -9 or C-6 and -8), 128.9 (C-5 and -9 or C-6 
and -8), 138.7 (C-4); vmax (KBr disc) / cm-1 2944,2856,2792; in/z 177 
(M+, 0.2%), 147 (1.4, M- OCH2), 91 (13, M- N(CH3)CH2OCH2CH, 86 (100, 
M- C6H5CH2); (found M+, 177.1138. Calc. for C11H15NO, 177.1154). 
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(IS 2S) 2-Dimethylamino-1-phenylpropane-1.3-diol (92) 
(using the procedure of Feldkamp et al. 77) 
OH 
Formaldehyde (36%, 0.72 g, 7.2 mmol) was added to a solution of (1S, 
2S)-2-amino- 1-phenylpropan-1,3-diol (1 g, 6.0 mmol), palladium/ 
carbon catalyst (10%, 0.1 g) and glacial acetic acid (0.72 g, 12 mmol) in 
water (30 ml). Nitrogen gas was bubbled through the reaction mixture 
for 5 min before hydrogen gas was introduced. The reaction was 
stirred for 10 h after which the catalyst was removed through Celite. 
The residue was diluted with diethyl ether and slowly made basic with 
2M sodium hydroxide solution. The ether layer was separated and the 
aqueous layer was extracted with diethyl ether (3 x 30 ml). The 
combined extracts were dried with magnesium sulfate and 
concentrated under reduced pressure to give a yellow oil. Purification 
of the oil by flash chromatography eluting with ethyl acetate afforded 
the title compound (0.3 g, 26%) as a yellow oil; Rf0.1 (ethyl acetate); 811 
(200MHz, CDC13) 2.34 (6H, s, 10- and 11-H3 ), 2.46 (IH, m, 2-H), 3.16 
(2H, m, 1-H2), 4.15 (3H, br d, 3-H, 3-OH, 1-OH), 7.13 (5H, m, aromatic 
H); 8c (50 MHz, CDC13) 41.1 (C-10 and -11), 57.7 (C-1), 70.8 (C-2 and -3), 
126.9 (C-7), 128.3 (C-5 and -9 or C-6 and -8), 128.5 (C-5 and -9 or C-6 
and -8), 141.9 (C-4); Vmax (film) / cm-1 3400,3300,2930; ni/z 195 
(M+, 0.4%), 164 (12.7, M- CH2OH), 134 (3.6, M- CH2OH, - (CH3)2,89 
(51), 58 (100, M- HN(CH)(CH3)2); (found M+, 195.1281. Calc. for 
C 11 H 17NO2,195.1259). 
N. N. N-Trimethyll2henylalaninol iodide (91)79 
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A solution of N, N-dimethylphenylalaninol (88) (1 g, 5.64 mmol) and 
methyl iodide (1.69 g, 11.3 mmol) in diethyl ether (30 ml) was stirred 
for 24 h at room temperature. The solid was filtered and washed with 
diethyl ether (3 x 40 ml) to give a yellow solid (1.1 g, 61%); 811 (200MHz, 
CD3 OD) 3.33 (9H, s, 11-, 12- and 13-H3), 3.67 (2H, m, 3-H2), 4.06 (IH, 
m, 2-H), 4.80 (3H, m, 1-H2, -OH), 7.13 (5H, m, aromatic H); 6c (50 MHz, 
CD3 OD) 31.9 (C-3), 53.1 and 53.7 (C-10, -11 and -12), 57.7 (C-1), 77.1 
(C-2), 128.2 (C-7), 129.8 (C-5 and -9 or C-6 and -8), 130.1 (C-5 and -9 
or C-6 and -8), 137.3 (C-4); vmax (film) / cm-1 3348; in/z 148 (43.9, M 
- C2H601), 133 (1.2), 119 (3.3), 88 (100); (found M- C2H601,148.1106. 
Cale. for C 10H 14N, 148.1104). 
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7.3 Experimental to Chapter 5 
(S)-Serine methyl ester hydrochloride (94)82 
3 OH 
+I ý Cl H3N C O2M4e 
1 
Hydrochloride gas was bubbled through a solution of (S)-serine (10 g, 
95.2 mmol) and methanol (150 ml) until all the serine had dissolved. 
After stirring the solution at room temperature for 5 h, methanol was 
evaporated off under reduced pressure to afford the title compound 
(14.0 g, 94%) as a white solid. The white solid was stored in a 
desiccator under vacuum overnight with pellets of potassium hydroxide 
to ensure the complete removal of HCI. St; (200MHz, D20) 3.57 (3H, s, 
4-H3), 3.73 (1H, dd, 3-H, J 3.6,12.5 Hz), 3.85 (IH, dd, 3-H, J 4.0,12.5 
Hz), 4.01 (1H, t, 2-H, J 3.8 Hz); Sc (50 MHz, D20) 50.3 (C-4), 51.3 (C-3), 
56.0 (C-2), 167.9 (C-1); Vmax (KBr) / cm-1 3417,2958,1747. (Found: C, 
30.8; H, 6.4; N, 9.0. Calc. for C4H10NC10: C, 30.73; H, 6.52; N, 8.92%). 






Di-tert-butyldicarbonate (17.8 ml, 77.2 mmol) was added to a solution 
of triethylamine (18 ml, 12.9 mmol) and (S)-serine methyl ester 
hydrochloride (94) (10 g, 64.3 mmol) in dry dichloromethane (100 ml). 
After the reaction mixture was stirred for 10 h at room temperature, it 
was diluted with dichloromethane (50 ml) and washed with water (3 x 
50 ml). The organic layer was dried with magnesium sulfate and 
concentrated to give a yellow oil. This was purified by column 
chromatography (hexane-ethyl acetate; 9: 1) to give the title compound 
(9 g, 64%) and (S)-N-tert-butyloxycarbonyl-O-tert-butyloxycarbonyl- 
serine methyl ester (96) (2 g, 11%). 
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The title compound was isolated as a clear oil; Rf0.1 (hexane-ethyl 
acetate; 9: 1); [a]D22 -6.0 (c 3.6 in CHC13) {lit., 
58 [(XID22 -6.5 (c 3.6 in 
CHC13) ); 8H (200MHz, CDC13) 1.37 (9H, s, 6-, 7- and 8-H3), 3.37 (1 H, br t, 
OH), 3.78 (3H, s, 9-H3), 3.81 (2H, m, 3-H2), 4.29 (IH, m, 2-H), 5.61 (IH, 
d, NH); Sc (50 MHz, CDC13) 28.2 (C-6, -7 and -8), 52.5 (C-9), 55.8 (C-2), 
63.0 (C-3), 80.1 (C-5), 155.8 (C-4), 171.5 (C-1); vmax (film) / cm-1 3400, 
2978,1713 br (OCON and CO2Me); m/z 160 (23, M- CO2Me), 146 (21.5, 
M- OC4H9), 133 (79), 104 (32), 88 (39), 60 (100); (found M- CO2M e, 
160.0985. Calc. for C7H14N03,160.0973). 
(S)-N, O-Di-tert-butyloxycarbonylserine methyl ester (96) was isolated 
as a white solid; mp 94 oC (lit., 83 94.5 °C) 
0 3/'' 12 
2 
O4 Ný CO2Me 
H19 
1 
Rf0.3 (hexane-ethyl acetate; 9: 1); [a]D22 -33.0 (c 1.1 in CHC13); 811 
(200MHz, CDC13) 1.42 (6-, 7- and 8-H3 or 12-, 13- and 14-H3), 1.44 (6-, 
7- and 8-H3 or 12-, 13- and 14-H3), 3.74 (3H, s, 1-H3 ), 4.25 (IH, dd, 2- 
H, J 3.5,10.9 Hz), 5.30 (1H, d, NH); 8C (50 MHz, CDC13) 27.6 (C-6, -7 and 
-8 or C-12, -13 and -14), 28.2 (C-6, -7 and -8 or C-12, -13 and -14), 
52.6 (C-9), 52.8 (C-3), 66.3 (C-2), 80.2 (C-5 or -11), 82.7 (C-5 or -11), 
153.2 (C-4 or C-10), 156.2 (C-4 or C-10) 171.3 (C-1); vmax (Kßr disc) / 
cm-1 2933,1740,1712,1526; m/z 260 (0.8, M- C02Mc), 205 (1.1, M- 
(C4H9)2), 146 (5.3), 104 (19.2), 57 (100); (found M+, 206.1507. Ca1c. for 
C 12H 22N O 5,260.1498). (Found: C, 52.6; H, 7.8; N, 4.3. Calc. for 













A solution of compound. (95) (1 g, 4.57 mmol), imidazolc (0.62 g, 9.14 
mmol) and tert-butyldimethylsilyl chloride (0.9 g, 5.94 mmol) in dry 
DMF (30 ml) was stirred at room temperature for 15 h. The mixture 
was then diluted with ethyl acetate (100 ml) and washed with brine (5 
x 50 ml). The organic layer was dried with magnesium sulfate, filtered 
and concentrated to a crude oil. The oil was purified by flash 
chromatography eluting with hexane-ethyl acetate (9: 1) to give a clear 
oil (1.4 g, 92%); Rf 0.8 (ethyl acetate-hexane; 1: 2); 511 (200MI1z, CDC13) 
0.00 (3H, s, 9- or 10-H3), 0.01 (3H, s, 9- or 10-113), 0.84 (911, s, 11-, 12-, 
and 13-H3), 1.43 (9H, s, 6-, 7- and 8-H3), 3.71 (311, s, 15-113), 3.76 (111, 
dd, 3-H, J 3.0,10 Hz), 4.00 (1H, dd, 3-H, J 2.5,10 Hz), 4.34 (111, m, 2-11), 
5.34 (1H, br d, NH); Sc (50 MHz, CDC13) -5.7 (C-9 or -10), -5.6 (C-9 or 
-10), 18.1 (C-14), 25.6 (C-11, -12 and -13), 28.2 (C-6, -7 and -8), 52.1 
(C-15), 55.5 (C-2), 63.6 (C-3), 79.7 (C-5), 155.3 (C-4), 171.3 (C-1); v,,,,, x 
(film) / cm-1 2970,1752 (COOMe), 1720 (OCON), 1256 (SiMe2), 1088, 
840 (SiO); m/z 260 (13.5, M- OC4H9), 220 (55.4), 176 (4.7), 89 (100); 
(found M- OC4H9,260.1312. Calc. for C11H22NO4Si, 260.1318). 
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Si- 9 
A stirred solution of compound (97) (1.4 g, 4.2 mmol) in anhydrous 
toluene (30 ml) was cooled to -78 oC and diisobutylaluminium hydride 
(1.5M, 4.8 ml, 7.1 mmol) was added dropwise, keeping the internal 
temperature below -70 °C. After the mixture had been stirred at -78 
oC for a further 2 h, saturated ammonium chloride solution (30 nil) was 
added. The mixture was poured into cold 1M FICI (50 nil) and 
extracted with ethyl acetate (3 x 50 ml). The combined extracts were 
washed with brine (2 x 50 ml), dried with magnesium sulfate, filtered 
and concentrated to afford a crude oil. This oil was sufficiently pure 
and had to be used directly for the next step; Rf0.75 (Hexane-ethyl 
acetate; 2: 1); SH (200MHz, CDC13) 0.00 (6H, s, 9- and 10-113), 0.81 (911, s, 
11-, 12- and 13-H3), 1.41 (9H, s, 6-, 7- and 8-H3), 3.90 (311, in, 2-11 and 
3-H2), 5.40 (1H, br d, NH), 9.59 (1H, s, 1-H); 5C (50 MHz, CDC13) -5.6 (C-9 
and -10), 18.1 -(C-14), 25.6 (C-11, -12 and -13), 28.2 (C-6, -7 and -8), 
61.3 (C-3), 61.5 (C-2) 79.7 (C-5), 155.2 (C-4), 199.3 (C-1); v, nax (film) / 
cm-1 1725 (CHO), 1720 (OCON), 1250 (SiMe2), 1090,839 (SiO). 
















BuLi (1.5M, 4 ml, 6.0 mmol) was added to a solution of 1-hexyne (0.54 
g, 6.6 mmol) in dry THE (30 ml) at -78 °C. After stirring at -78 OC for 
30 min, (S)-2-[(tert-butyloxycarbonyl)amino]-3-tert-butyldimethyl- 
silyloxypropanal (93) (1 g, 3.3 mmol) in anhydrous TIIF (10 ml) was 
added dropwise. The resulting mixture was stirred at this temperature 
for a further 2h and then allowed to warm up to room temperature 
overnight. Saturated ammonium chloride solution (40 nil) was added 
and the mixture was extracted with ethyl acetate (3 x 50 nil). The 
combined organic extracts were washed with brine (3 x 50 nil), dried 
with magnesium sulfate, filtered and concentrated to give a yellow oil. 
The mixture of diastereoisomers was separated by careful 
chromatography eluting with hexane-ethyl acetate (9: 1). 
(4S, 5R)-4-tert-Dimethylsilyloxymethyl-5-(1-hexynyl)oxazolidine-2-one 








H 4321 CH2CH2CH2CH3 
Rf 0.3 (hexane-ethyl acetate; 9: 1); [a]n22 -43.0 (c 1.1 in CIICI3); 511 
(200MHz, CDC13) 0.00 (6H, s, 11- and 12-H3), 0.82 (1211, ni, 1-, 14-, 15- 
and 16-H3), 1.39 (4H, m, 2- and 3-H2), 2.14 (211, dt, 4-11, J 1.8,6.6 11z), 
3.56 (2H, d, 10-H2, J 3.3 Hz), 3.82 (IH, m, 9-H), 5.20 (111, dt, 7-11, J 1.9 
and 7.7 Hz), 6.42 (1H, br s, NH); SC (50 MHz, CDC13) -5.5 (C-11 and -12), 
13.5 (C-1), 18.1 (C-13), 18.3,21.8 (C-2 and -3), 25.7 (C-14, -15 and 
-16), 30.1 (C-4), 55.9 (C-9), 63.4 (C-10), 68.1 (C-7), 72.0,91.1 (C-5 and 
-6), 158.4 (C-8); vmax (film) / cm-1 1740,1248 (SiMc2), 1092 (SiO); In/Z 
254 (35, M- C4H 9 ), 224 (30, M- C4 H 9, - C2 H 6), 210 (60), 168 (40), 
115 (3.5), 75 (100); (found M- C4H9,254.1243. Ca1c. for C121I20NO3Si, 
254.1212). 
(4S, 5S)-4-tert-Dimethylsilyloxymethyl-5-(1-hexynyl)oxazolidine-2-one 
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HN, P0 
Rf0.25 (hexane-ethyl acetate; 9: 1); [aID22 -11.2 (c 1.4 in C11C13); 8E1 
(200MHz, CDC13) 0.00 (6H, s, 11- and 12-H3), 0.82 (1211, m, 1-, 14-, 15- 
and 16-H3), 1.40 (4H, m, 2- and 3-H2), 2.25 (211, dt, 4-11, J 1.8,6.9 11z), 
3.56 (2H, d, 10-H2, J 4.7 Hz), 3.82 (IH, m, 9-H), 4.90 (111, dt, 7-11, J 1.9 
and 5.2 Hz), 6.42 (1H, br s, NH); 8c (50 MHz, CDC13) -5.5 (C-I I and -12), 
13.5 (C-1), 18.1 (C-13), 18.3,21.8 (C-2 and -3), 25.6 (C-14, -15 and 
-16), 30.2 (C-4), 60.9 (C-9), 63.5 (C-10), 68.3 (C-7), 75.8,89.2 (C-5 and 
-6), 158.8 (C-8); Vmax (film) I cm-1 1740,1248 (SiMc2), 1092 (SiO); m /Z 
254 (46.7, M- C4H9), 210 (78), 168 (36.9), 115 (3.5), 75 (100); (found 
M- C4H9,254.1203. Calc. for C12H2ONO3Si, 254.1212). 
Meth a unvi-z. -anncuwiox ' c. 1'LS2ililitlý- ý ! 
10 
carboxylate. (103)86 
A solution of (S)-N-tert-butyloxycarbonylserine methyl ester (95) (3 g, 
13.7 mmol) in anhydrous benzene (150 ml) with 2,2-dimethoxypropane 
(2.5 ml, 20.5 mmol) and p-toluenesulfonic acid (0.3 g) was heated 
under Dean-Stark conditions for 2 h. The deep yellow coloured reaction 
mixture was poured into saturated sodium bicarbonate solution (100 
ml) and extracted with ether (3 x 50 ml). The combined organic 
extracts were washed with water (2 x 50 ml), dried with magnesium 
sulfate, filtered and concentrated to afford a crude oil. The oil was 
purified by column chromatography to give the title compound (2.5 g, 
70%) as a light yellow oil; Rf 0.4 (hexane-ethyl acetate; 4: 1); [ec]o22 -46.0 
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(c 1.3 in CHC13) {lit., 58 [(X]D22 -46.7 (c 1.3 in CHC13)); 5I1 (200MIIz, 
CDC13) 1.34 (5H, s, 9-, 10- and 11-H3), 1.43 (511, s, 9-, 10- and 11-113 & 
5- or 6-H3), 1.46 (2H, s, 5- or 6-H3), 1.57 (IH, s, 5- or 6-113), 1.60 (211, 
s, 5- or 6-H3), 3.69 (3H, s, 12-H3), 4.04 (2H, m, 3-112), 4.30 (0.511, dd, 2- 
H), 4.40 (0.5H, dd, 2-H); SC (50 MHz, CDC13) 24.2,24.8,25.0,25.9 (C-5 
and -6), 28.1 (C-9, -10 and -11), 52.1,52.2 (C-12), 59.1 (C-2), 65.9,66.1 
(C-3), 80.1,80.7 (C-8), 94.3,94.9 (C-4), 155.1 (C-7), 171.2,171.6 (C-12); 
Vmax (film) / cm-1 3065,2978,1725 (COOMe), 1702 (OCON); iu/z 244 
(8.6, M- CH3), 200 (2.0, M- CO2Me), 186 (5.1, M- 0C4119), 144 (100), 
100 (1.1), 84 (84); (found M- CH3,244.1171. Calc. for C1l I11$ NO5, 
244.1185). 
(4S)-3-tert-Butyloxycarbonyl-2.2-dimcthyl-4-hcx-5- 
Xnvlcý arbonyloxazolidinc (104) 
10 11 
17 
BuLi (1.5M, 4 ml, 4.6 mmol) was added dropwise at -78 oC to a solution 
of 1-hexyne (0.4 g, 5 mmol) in dry THE (20 ml). The solution was 
stirred for 30 min before a solution of methyl (4S)-3-tert- 
butyloxycarbonyl-2,2-dimethyloxazolidine-4-carboxylate (103) (1 g, 
3.9 mmol) in dry THE (10 ml) was added. The resulting solution was 
stirred at -78 oC for a further 4 h. Saturated ammonium chloride 
solution (20 ml) was added and the organic layer was separated. The 
aqueous layer was extracted with ethyl acetate (2 x 30 1111) and the 
combined extracts were dried with magnesium sulfate and 
concentrated to give an oil. The oil was purified by column 
chromatography eluting with hexane-ethyl acetate (6: 1) to give the title 
compound, starting material and methyl 2-(1 a rt - 
butyloxycarbonyl)aminoacrylate (105). 
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The title compound was isolated as *a yellow oil (0.2 g, 17%); Itf 0.3 
(hexane-ethyl acetate; 3: 1); 6H (200MHz, CDC13) 0.81 (311, t, 17-113), 1.35 
(19H, m, 15-H2,16-H2,5-, 6-, 8-, 9- and 10-113), 2.30 (211, t, 14-112), 
4.04 (2H, m, 3-H2), 4.28 (0.6, dd, 2-H, J 3.9,7.1 I-1z), 4.47 (0.411, app. t, 
2-H); 6c (50 MHz, CDC13) 13.3 (C-17), 18.7,21.8 (C-15 and -16), 24.1, 
24.9,25.0,26.0 (C-5 and -6), 28.0,28.3 (C-9, -10 and -11), 29,4 (C-14), 
65.2,65.6 (C-3), 66.5 (C-2), 80.6 (C-8), 80.8 (C-12), 95.2 (C-13), 155.9 
(C-7), 163.4 (C-1); vmax (KBr disc) / cm-1 2200,2705,1680. 
Methyl ,, 2-(tert-butyloxycarbonyl)aminoacrylatc (105)87 was isolated 
as a clear oil (0.15 g, 19%). 
Rf0.7 (hexane-ethyl, acetate; 3: 1); 811 (200MHz, CDC13) 1.35 (911, s, 6-, l- 
and 8-H3),. 3.75 (3H, s, 9-H3), 5.65 (1H, br d, N1l), 6.08 (111, d, 3-11, j 1.5 
Hz), 6.08 (1H, br s, 3-H); Sc (50 MHz, CDC13) 28.2 (C-6, -7 and -8), 52.8 
(C-9), 80.3 (C-5), 118.1 (C-3), 155.9 (C-4), 164.4 (C-1) ; v1y, x (Kllr disc) / 
cm-1 1680,1750. 
First attempted preparation of phenyl (45)-3-tart-huty o Upadmay. L 
2.2-dimethyl oxazolidinc-4-car oxyjate. 
\ _n ývirX 
0 
A solution of methyl (4S)-3-tert-butyloxycarbonyl-2,2- 
dimethyloxazolidine-4-carboxylate ' (103) (0.5 g, 1.9 mmol) in 
anhydrous benzene (150 ml) with phenol (0.5 g, 5.7 mmol) and 1p- 
toluenesulfonic acid (0.3 g) was heated under Dean-Stark conditions for 
6 h. The deep yellow coloured reaction mixture was poured into 
saturated sodium bicarbonate solution (100 ml) and extracted with 
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ether (3 x 50 ml). The combined organic extracts were washed with 
water (2 x 50, ml), dried with magnesium sulfate, filtered and 
concentrated to afford a crude oil. TLC analysis and NMR spectra were 
identical to those of starting material. 
Second attempted nrenaration of C 
2.2-dimethyloxazolidine-4-carhox, late 
Lithium (13 mg, 0.9 mmol) was added to a solution of phenol (0.36 g, 
3.8 mmol) An dry DMF (25 ml). A solution of (4S)-3-tert- 
butyloxycarbonyl-2,2-dimethyloxazolidinc-4-carboxylatc (103) (0.5 g, 
1.9 mmol) in DMF (5 ml) was then added. The reaction was set tip as a 
distillation. The resulting solution was heated at 95 OC for 4 It and then 
allowed to cool down to room temperature. The mixture was poured 
into ethyl acetate (30 ml) and water (30 ml). The organic layer was 
separated and the aqueous layer was washed with ethyl acetate (3 x 30 
ml). The combined organic extracts were washed with brine (4 x 50 
ml), dried with magnesium sulfate and concentrated to give an oil. The 
oil was purified by flash chromatography cluting with hexane-ethyl 
acetate (5: 1) to give methyl 2-(tert-butyloxycarbonyl)aminoaerylate 




A stirred solution of (4S)-3-tert-butyloxycarbonyl-2,2- 
dimethyloxazolidine-4-carboxylate (103) (2.2 g, 8.5 mmol) in 
anhydrous toluene (30 ml) was cooled to -78 oC and 
diisobutylaluminum hydride (1.5 M, 9.6 ml, 14.5 mmol) was added 
dropwise, keeping the internal temperature below -70 °C. After the 
mixture had been stirred at - 78 oC for a further 2 h, methanol (20 ml) 
was slowly added with the internal temperature kept below -70 oC. 
The reaction mixture was poured into ice cold 1M lICI (50 nil) and 
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extracted with ethyl acetate (3 x 50 ml). The combined organic 
extracts were washed with brine (3 x 50 ml), dried with magnesium 
sulfate, filtered and concentrated to afford a yellow oil. This oil was 
purified by flash chromatography (hexane-ethyl acetate; 4: 1) to give 
title compound (1.2 g, 62%) as a clear oil; Rf 0.36 (hexane-ethyl acetate; 
4: 1); [a]D22 -90.5 (c 1.34 in CHC13) (lit., 
58 [aID22 -91.7 (c 1.34 in CIICI3)); 
St; (200MHz, CDC13) 1.36 (5H, s, 9-, 10- and 11-H3), 1.39 (511, s, 9-, 10- 
and 11-H3 & 5- or 6-H3), 1.43 (2H, s, 5- or 6-113), 1.44 (111, s, 5- or 6- 
H3), 1.48 (2H, s, 5- or 6-H3), 4.01 (2H, m, 3-112), 4.11 (0.511, m, 2-11), 
4.27 (0.5H, m, 2-H), 9.47 (0.5H, d, 1-H, J 2.3 Hz), 9.52 (0.511, (1,1-11, J 2.3 
Hz); 8c (50 MHz, CDC13) 23.7,24.5,25.6,27.0 (C-5 and -6), 28.1 (C-9, -10 
and -11), 63.3,63.8 (C-3), 64.6 (C-2), 80.9,81.2 (C-8), 94.7,94.7 (C-4), 
155.1,155.4 (C-7), 199.1,199.3 (C-1); vmax (film) / cnt-1 3072,2976, 
1725 (CHO), 1720 (OCON); m/z 200 (10.5, M- CIlO), 156 (1.3,1`"t - 
OC4H9), 146 (53), 100 (66), 84 (100), 72 (14.2); (found M- CH O, 
200.1278. Calc., for C1OH18NO3,200.1287). 
3-tert-Butvlox carno -4- 
dimeth, yloxazolidine (108) 
10 
A solution of compound (107) (1.2 g, 5.2 mmol) in anhydrous TIIi (30 
ml) was added dropwise over 30 min into vinyl magnesium bromide 
(1M, 7.9 ml, 7.9 mmol) at -78 OC. The resulting, mixture was stirred at 
this temperature for a further 1h before saturated ammonium chloride 
solution (30 ml) was added. The organic layer was separated and the 
aqueous layer was extracted with ether (3 x 30 ml). The combined 
organic extracts were washed brine (30 ml), dried with magnesium 
sulfate, filtered and concentrated to leave an oil. Purification by 
column chromatography (hexane-ethyl acetate; 3: 1) afforded the title 
compound (1.1 g, 77%) as a clear oil; Rf 0.28 (hexane-ethyl acetate; 4: 1); 
SH (200MHz, CDC13) 1.38 (15H, m, 5-, 6-, 9-, 10- and 11-113), 3.90 (311, 
m, 2-H, 3-H2), 4.21 (1H, br s, 1-H), 5.10 (2H, m, 13-112), 5.7 (111, in, 12- 
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H); the carbon spectrum was complex; Vmax (KBr disc) / cnr1 3415, 
1740,1696; m/z 200 (3.1, M- C4H9), 184 (4.2, M- OC4119), 144 (20), 
57 (100); (found M- C4H9,200.0938. Calc. for C9H 14NO4,200.0923). 
(Found: C, 60.7; H, 8.9; N, 5.4. Calc. for C13H23N04: C, 59.92; 11,8.88; N, 
5.29%). 
General procedure 1 for alkynylation of aldehydc (107) 
(using the procedure of Garner et nl. 58) 
BuLi (1.5M, 0.014 mmol) was added to a -23 oC solution of the alkyne 
(0.015 mmol) in dry THE (100 ml) under nitrogen. The resulting 
suspension of lithium acetylide was stirred at the same temperature for 
a further 1h and then a solution of the aldehyde (107) (0.01 mmol) in 
dry THE (20 ml) was added. The reaction was complete (monitored by 
TLC) after 2h at this temperature and then was quenched by addition 
of saturated ammonium chloride solution (50 ml). The organic layer 
was separated and the aqueous layer was extracted with ether (3 x 30 
ml). The combined organic layers were washed with brine (2 x 50 ntl), 
dried with magnesium sulfate, filtered and concentrated to give a 
yellow oil. TLC in hexane-ethyl acetate (4: 1) showed formation of both 
diastereoisomers. The major diastereoisomer was separated by careful 
chromatography eluting with hexane-ethyl acetate (9: 1). 












Following general procedure 1, the title compound was prepared with 
these reagents: BuLi (1.5M, 4 ml, 4.1 mmol), 1-nonyne (0.81 g, 6.6 
mmol), aldehyde (107) (1 g, 4.4 mmol). The compound was isolated as 
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a clear oil (0.9,58%); Rf 0.36 (ethyl acetate-hexane; 1: 4); [aID22 -40.2 (c 
2.4 in CHC13); 5H (200MHz, CDC13) 0.81 (3H, t, 20-H3), 1.18 (1011, m, 15- 
H2 to 19-H2), 1.42 (15H, m, 5-, 6-, 9-, 10- and 11-H3), 2.12 (211, dt, 14- 
H2, J 1.7 and 6.8 Hz), 3.90 (IH, br s, OH), 4.10 (211, m, 3-112), 4.40 (111, 
m, 2-H), 4.70 (1H, br d, 1-H, J 8.2 Hz); 8c (50 MHz, CDC13) 214.0 (C-20), 
18.5,22.4,28.4,28.7 (C-15 to C-19), 25.2,25.6 (C-5 and -6), 28.2 (C-9. 
-10 and -11), 31.6 (C-14), 60.3 (C-2), 63.8 (C-1), 64.9 (C-3), 77.7,86.1 
(C-12 and -13), 80.9 (C-8), 94.7 (C-4), 155.1 (C-7); vmax (filet) / cm- 1 
3308 (OH), 2932 2233,1693 (OCON); m/z 297 (2.8, M11 - C4119), 200 
(27.4), 144 (29.6), 100 (100); (found MH - C4119,297.1931. Calc. for 
C 16H27NO4,297.1940). 
-tert-Butylox, ycarbon, yl-4-[(1 R)- 1-hý 
dimethyloxazolidine (112) 
HO", --'\l 
rl v, ý- 
N_ il _O 
17 23 
22 
General procedure 1 was used with the following reagents: BuLi (1.5M, 
4 ml, 4.1 mmol), 1-dodecyne (1.1 g, 6.6 mmol), aldehyde (107) (1 g, 4.4 
mmol). The compound was isolated as a light yellow oil (1.1 g, 63%); Rf 
0.38 (hexane-ethyl acetate; 4: 1); [a ID 22 -37.8 (c 1.3 in C11C13 ); 811 
(200MHz, CDC13) 0.80 (3H, t, 23-H3), 1.15 (16H, in, 15-112 to 22-112), 
1.45 (15H, m, 5-, 6-, 9-, 10- and 11-H3), 2.13 (2H, m, 14-112), 3.86 (111, 
br s, OH), 4.03 (2H, m, 3-H2), 4.56 (IH, m, 2-H), 4.70 (111, br d, 1-11, J 8.2 
Hz); 8c (50 MHz, CDC13) 14.0 (C-23), 18.6,22.5,28.5,28.8,29.0,29.2, 
29.5,30.8 (C-15 to C-22), 25.4 (C-5 and -6), 28.6 (C-9, -10 and -11), 
31.8 (C-14), 62.7 (C-2), 63.9 (C-1), 64.9 (C-3), 77.7,86.1 (C-12 and -13), 
80.9 (C-8), 94.8 (C-4), 15.3 (C-7); vmax (film) / cm-1 3245,2945,2270, 
1695; m/z 339 (4.9, MH - C4H9), 280 (6.3), 200 (73.9), 156 (3.8), 144 










General procedure 1 was used with the following reagents: IluLi (1.5M, 
4 ml, 4.1 mmol), 1-pentadecyne (1.4 g, 6.6 mmol), aldehyde (107) (1 g, 
4.4 mmol). The compound was isolated as a light yellow oil (1.3 g, 68%); 
Rf 0.4 (hexane-ethyl acetate; 4: 1); [a]D22 -41.2 (c 1.4 in CI1C13) {lit., ref7, 
[a]D22 -40.1 (c 1.4 in CHC13)}; SH (200MHz, CDC13) 0.91 (311, t, 26-113), 
1.21 (22H, m, 15-H2 to 25-H2), 1.45 (15H, m, 5-, 6-, 9-, 10- and 11-113), 
2.15 (2H, br dt, 14-H2, J 1.6 and 6.7 Hz), 3.90 (1H, br s, 011), 4.20 (211, m, 
3-H2), 4.49 (1H, m, 2-H), 4.70 (1H, br d, 1-H, J 8.3 11z); Sc (50 N111z, 
CDC 13) 14.0 (C-26), 18.7, * 22.6,28.5,28.8,29.1,29.3,29.5,29.6,31.5, 
31.9 (C-15 to C-25), 25.3 (C-5 and -6), 28.6 (C-9, -10 and -11), 31.8 (C- 
14), 62.7 (C-2), 64.0 (C-1), 65.0 (C-3), 78.4,87.2 (C-12 and -13), 81.0 (C- 
8), 94.8 (C-4), 155.8 (C-7); vmax (film) / cm-1 3277 (011), 2856,2243, 
1704 (OCON); m/z 381 (1.2, M- C4 H9), 200 (22.4), 144 (33.8), 100 
(100); (found M- C4H9,381.2883. Calc. for C221139NO4,381.2879). 
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A solution of (4S)-3-tert-butyloxycarbonyl-4-[(1R)-1-hydroxy-2- 
nonynyl]-2,2-dimethyloxazolidine (111) (1 g, 2.8 mmol) in dry Till' (10 
ml) was added to a blue solution of Li (0.04 g, 5.6 mmol) in ammonia 
(50 ml) at -78 0C. After it was stirred at -78 oC for 4 h, the reaction 
was quenched at -78 oC with saturated ammonium chloride solution 
(20 ml) and the ammonia was allowed to evaporate at room 
temperature overnight. The residue was redissolved in ethyl acetate 
(100 ml), washed with 1M HC1 (3 x 50 ml), dried with magnesium 
sulfate and concentrated to give a yellow oil. The oil was purified by 
careful chromatography eluting with (hexane-ethyl acetate; 9: 1) to give 
the title compound as a yellow oil (0.1 g, 10%) and starting material (0.6 
g); Rf0.38 hexane-ethyl acetate, (4: 1); Stt (200Mflz, CDC13) 0.81 (311, t, 
20-H3), 1.18 (10H, in, 15-H2 to 19-H2), 1.42 (1511, in, 5-, 6-, 9-, 10- 
and 11-H3), 2.20 (2H, m, 14-H2), 4.00 (4H, m, 011,2-11,3-112), 5.34 (111. 
dd, 12-H, J 5.6 and 15.5 Hz), 5.66 (1H, dt, 13-H, J 6.6,15.4 IN); SC (50 
MHz, CDC13) 14.1 (C-20), 22.6,29.1,29.2,31.8 (C-15 to C-19), 25.7,26.2 
(C-5 and -6), 28.7 (C-9, -10 and -11), 32.4 (C-14), 62.3 (C-2), 65.2 (C-3), 
74.1 (C-1), 81.1 (C-8), 94.4 (C-4), 128.0 (C-12), 133.4 (C-13), 155.4 (C- 
7); vmax (film) / cm-1 3301,1704,1645. 
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A solution of (4S)-3-tert-butyloxycarbonyl-4-[(1 R)-1-Iiydroxy-2- 
pentadecynyl]-2,2-dimethyloxazolidine (110) (1 g, 2.8 mmol) in dry 
THE (10 ml) was added to a blue solution of Li (0.04 g, 5.6 mmol) in 
ammonia (50 ml) at -78 OC. After it was stirred at -78 oC for 4 Ii, the 
reaction' was quenched at -78 oC with saturated ammonium chloride 
solution (20 ml) and the ammonia was allowed to evaporate at roost 
temperature overnight. The residue was redissolved in ethyl acetate 
(100 ml), washed with 1M HC1 (3 x 50 ml), dried with magnesium 
sulfate and concentrated to give a yellow oil. NMR spectroscopy of the 
crude product showed that the major component was starting material 
but there was a small trace of trans-double bond product formed. 
General procedure 2 for d oie r C ona 
dimethyloxazolidine 
(lit. procedure58 was modified) 
02 .ý ý_ 
The 3-tert-butyloxycarbonyl-2,2-dimethyloxazolidine (1 mmol) was 
dissolved in methanol (40 ml) and toluene-p-sulfonic acid (4 mmol) 
was added to the solution. ' The reaction mixture was stirred at room 
temperature for 48 h after which methanol was removed under 
reduced pressure. The crude oil was redissolved in ethyl acetate (100 
ml), and the solution was washed with saturated sodium bicarbonate 
solution (3 x 50 ml), brine (2 x 50 ml), dried with magnesium sulfate 
and concentrated to give the aminodiol. 
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(2S. 3R)-2-Amino-1.3-dodec-4-yncdio (116) 
OH 
General procedure 2 was used with the following reagents: Tolucne-lp- 
sulfonic acid (1.4 g, 6.4 mmol), (4S)-3-tert-butyloxycarbonyl-4-[(1 R)- l- 
hydroxy-2-nonynyl]-2,2-dimethyloxazolidine (111) (0.5 g, 1.4 mntol), 
methanol (50 ml). The compound was isolated as a clear yellow oil (0.3 
g, 87%); Rf 0.1 (ethyl acetate-ethanol; 9: 1); [a]o22 -22.6 (c 0.7 in C11C13); 
SH (200MHz, CDC13) 0.80 (3H, t,, 12-H3), 1.20 - 1.40 (1011, m, 7-112 to II- 
H2), 2.14 (2H, t, 6-H2, J 6.1 Hz), 2.82 (IH, m, 2-H), 3.90 (411, br s, 011,011, 
NH2), 3.60 (2H, br d, 1-H2, J 4.8 Hz), 4.32 (1H, br d, 3-11, J 4,711z); SC (50 
MHz, CDC13) 14.0 (C-12), 18.6,22.4,28.4,28.7 (C-7 to C-11), 31.6 (C-6), 
56.9 (C-2), 63.1 (C-i), 64.3 (C-3), 78.4,87.2 (C-4 and -5); vn, ax (KBr disc) 
/ cm-1 3356 v. br, 2932,2360; m/z 196 (1.2 MH - 1120), 100 (100), 83 
(26.5), 
, 
60 (7.8); (found MH - H2O, 196.1732. Calc. for C 121122N O, 
196.1701). 
(2S. 3R)-2-Amino-1.3-pentadcc-4-ynediot (1,7) 
15 
13 
Following general procedure 2, the title compound was prepared with 
these reagents: Toluene-p-sulfonic acid (1.73 g, 6.4 mmol), (4S)-3-tert- 
butyloxycarbonyl-4-[(1R)-1-hydroxy-2-dodeynyl]-2,2-ditncthyloxazo- 
lidine (112) (0.7 g, 1.8 mmol), methanol (50 ml). The compound was 
isolated as a white solid (0.41 g, 89%); Rf 0.1 (ethanol-ethyl acetate; 
1: 9); [a]D22 -8.8 (c 1.1 in CHC13); 8H (200MHz, CDC13) 0.80 (311, t, 15-113). 
1.18 - 1.40 (16H, m, 7-H2 to 14-H2), 2.13 (2H, t, 6-H2, J 7.0 11z), 2.82 
(1H, m, 2-H), 3.45 (4H, br s, OH, OH, NH2), 3.68 (211, br d, 1-112, J 5.0 11z), 
4.32 (1H, m, 3-H); 6c (50 MHz, CDC13) 14.0 (C-15), 18.6,22.5,28.5,28.8, 
29.0,29.2,29.5,30.8 (C-7 to C-14), 31.8 (C-6), 57.0 (C-2), 62.9 (C-1). 
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64.2 (C-3), 78.3,87.1 (C-4 and -5); Vmax (film) / cm-1 3357v. br, 2973, 
2338; m/z 238 (0.9, MH -H20), 100 (100), 9.3 (12.7), 8.3 (14.0); (found 
MH - H2O, 238.2166. Calc. for C15H28NO, 238.2171). 
(2S. 3R)-2-Amino-1.3-octadec-4-, nediol 115) 
OH 
General procedure 2 was employed with the following reagents: 
Toluene-p-sulfonic acid (2.1 g, 8.8 mmol), (4S)-3-tert-hutyloxy. 
carbonyl-4- [(1R)-1-hydroxy-2-pentadecynyl]-2,2-dimethyloxazolidinc 
(110) (1.0 g, 2.2 mmol), methanol (50 ml). The compound was isolated 
as a yellow solid (0.6 g, 92%); Rf0.1 (ethyl acetate-ethanol; 9: 1); [(X]1)22 
-6.1 (c 0.7 in CHC13); SH (200MHz, CDC13) 0.81 (311, t, 18-113), 1.25 (2211, 
m, 7-H2 to 17-H2), 2.14 (2H, t, 6-H2), 2.83 (111, br s, 2-11), 3.18 (411, hr 
s, OH, OH, NH2), 3.62 (2H, br d, 1-H2), 4.32 (111, br s, 3-11); SC (50 Mltz, 
CDC13) 14.1 (C-18), 18.7,22.6,28.6,28.9,29.1,29.3,29.5,29.6 (C-7 to C- 
17), 31.9 (C-6), 56.9 (C-2), 63.2 (C-1), 64.4 (C-3), 78.3,87.4 (C-4 and -5); 
Vmax (KBr disc) / cm-1 3398,3280,3100,2232; m/z 280 (2.1, h1 - C113), 
279 (0.3, M- H2O), 153 (2.1), 102 (100), 85 (68); (found h1 - N113, 
280.2390. CaIc. for C 18H32O2,280.2402). 
(2S. 3R -2-Acetamino-l. 3-diacetoxydodec-4-vile( 





A solution of (2S, 3R)-2-amino-1,3-dodec-4-ynediol (116) (0.3 , g, 1.4 
mmol), acetic anhydride (0.7 ml, 7 mmol) and 4-dimethylamino- 
pyridine (0.03 g) in triethylamine (20 ml) was stirred at room 
temperature- for '8 h. The excess of triethylamine was removed under 
reduced pressure and the residue was redissolved in ethyl acetate (50 
ml). The organic layer was washed with 1M HCI (3 x 50 nil), saturated 
sodium bicarbonate solution (3 x 50 ml), brine (50 nil), dried with 
magnesium sulfate and concentrated to give an oil which was purified 
by flash chromatography eluting with hexane-ethyl acetate (5: 1) to 
afford the title compound as an yellow oil (0.1 g, 21%)-, Rf0.35 (hexanc- 
ethyl acetate; 1: 1); 8H (200MHz, CDC13) 0.80 (311, t, 12-113), 1.45 (1011, in, 
7-H2 to 11-H2), 1.97,2.00,2.01 (9H, 3 s, 14-, 16- and 18-113), 2.18 (211, 
br dt, 6-H2, J 2.0,7.1 Hz), 4.01 (IH, dd, 1-H, J 5.8,11.3 11z), 4.25 (111, dd, 
1-H, J 6.8,11.3 Hz), 4.48 (1H, m, 2-H), 5.46 (111, dt, 3-11, J 2.0,3.8 11x), 
5.71 (1H, br d, NH); 6c (50 MHz, CDC13) 14,0 (C-12), 16.6,22.5,28.2, 
28.6,28.8 (C-7 to C-11), 20.7,20.8,23.3 (C-14, -16 and -18), 31.6 (C-6), 
50.6 (C-2), 62.5 (C-1), 63.8 (C-3), 74.2,89.2 (C-4 and -5), 169.6,169.9, 
170.2 (C-13, -15 and -17); vmax (KBr disc) / cm-1 3282,2360,1747, 
1659,1547; m/z 339 (M+, 0.9%), 296 (1.5), 280 (5.4), 144 (23.4), 103 
(39.7), 84 (100); (found M+, 339.2065. Cale. for C1 8H29NO5,339.2046). 
(2S. 3R)-2-Acetamino-1.3-diacctoxxpcntadcc-4-, ync (119) 
0 
13 
A solution of (2S, 3R)-2-amino-1,3-pentadec-4-yncdiol (117) (0.5 g, 2.0 
mmol), acetic anhydride (1 ml, 10 mmol) and dimethylaminopyridinc 
(0.05 g) in triethylamine (25 ml) was stirred at room temperature for 8 
h. The excess of triethylamine was removed under reduced pressure 
and the residue was redissolved in ethyl acetate (50 nil). The organic 
layer was washed with 1M HC1 (3 x 50 mnl), saturated sodium 
bicarbonate solution (3 x 50 ml), brine (50 ml), dried : with magnesium 
sulfate and concentrated to give an oil. The oil was triturated with 
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hexane (20 ml) to afford the title compound as a white soild (0.72 g, 
94%); mp 98-99 OC; [a]D22 -48.1 (c 1.2 in CHC13); 811 (200MHz, CDC13) 
0.80 (3H, t, 15-H3), 1.35 (18H, m, 7-H2 to 14-H2), 1.97,2.01,2.02 (911,3 
s, 17-, 19- and 21-H3), 2.15 (2H, dt, 6-H2, J 2.0,7.1 llz), 4.05 (111, dd, 1- 
H, J 5.8,11.3 Hz), 4.25 (111, dd, 1-H, J 6.4,11.3 liz), 4.45 (111, m, 2-11), 
5.48 (1H, dt, 3-H, J 2.0,3.8 Hz), 5.98 (1H, br d, NH); 5C (50 MHz, CDC13) 
13.9 (C-15), 18.6,22.6,28.2,28.8,28.9,29.2,29.3,29.4 (C-7 to C-14), 
20.7,20.9,23.1 (C-17, -19 and -21), 31.8 (C-6), 50.6 (C-2), 62.3 (C-1), 
65.8 (C-3), 73.5,89.0 (C-4 and -5), 169.5,170.0,170.7 (C-16, -18 and 
-20); Vmax (KBr disc) / cm-1 3290,2370,1747,1660,1545; m/z 381 
(M+, 0.4%), 338 (4.7), 322 (4.4), 278 (3.0), 144 (90.1), 102 (100); (found 




A solution of (2S, 3R)-2-amino- 1,3-octadec-4-ynediol (115) (0.3 g, I 
mmol) and lithium aluminium hydride (0.11 g, 3 mmol) in DMZs (20 ml) 
was heated under reflux for 10 h and then allowed to cool down to 
room temperature. The reaction was quenched by careful addition of 
saturated ammonium chloride solution (20 ml) followed by ethyl 
acetate (30 ml). The organic layer was separated and the aqueous layer 
was extracted with ethyl acetate (3 x 30 ml). The combined organic 
extracts were washed with brine (30 ml), dried with magnesium 
sulfate, filtered and concentrated to afford a yellow oil. Purification of 
the oil by flash chromatography eluting with ethanol-ethyl acetate (1: 9) 
afforded the title compound as a yellow oil (60 mg, 20%); Rf0.0 (ethyl 
acetate-ethanol; 9: 1); 6H (200MHz, CDC13) 0.81 (3H, t, 18-113), 1.13 (2211, 
m, 7-H2 to 17-H2), 1.94 (2H, m, 6-H2), 2.73 (IH, m, 2-I1), 3.65 (111, dd, 
1-H, J 3.3,11.4 Hz), 3.75 (IH, dd, 1-H, J 4.4,11.2 Hz), 4.23 (111, in, 3-11), 
4.47 (4H, br s, OH, OH, NH2), 5.38 (IH, dd, 4-H, J 5.8,15.3 11z), 5.72 (111, 
dt, 5-H, J 6.7,15.2 Hz); 6c (50 MHz, CDC13) 14.8 (C-18), 22.6,29.0,29.2, 
29.3,29.4,29.6,31.9 (C-7 to C-17), 32.4 (C-6), 48.1 (C-2), 59.7 (C-I), 
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71.8 (C-3), 128.1 (C-4 or ' -5), 133.7 (C-4 or -5); vmax (KBr disc) / cm-1 
3470,1680; m/z 264 (0.7, MH - H2O), 124 (14.8), 102 9100), 82 (15.4); 
(found MH - H2O, 264.2664. Calc. for C18H34N, 264.2691). 
N. O O-Triacetyl-D-erythro-sphingosine (160)58 
24 
A solution of D-erythro-sphingosine (14) (60 mg, 0.2 mmol), acetic 
anhydride (0.2 ml, 2 mmol) and 4-dimetllylaminopyridine (0.05 g) in 
triethylamine (25 ml) was stirred at room temperature for 8 h. The 
excess of triethylamine was removed under reduced pressure and the 
residue was redissolved in ethyl acetate (50 ml). The organic layer was 
washed with 1M HC1 (3 x 50 ml), saturated sodium bicarbonate 
solution (3 x 50 ml), brine (50 ml), dried with magnesium sulfate and 
concentrated to give an oil. The oil was partially purified by flash 
chromatography eluting with hexane-ethyl acetate (4: 1) to afford the 
title compound (60 mg, 70%); Rf 041 (hexane-ethyl acetate; 4: 1); 811 
(200MHz, CDC13) 0.78 (3H, t, 18-H3), 1.18 (22H, m, 7-H2 to 17-112), 2.04 
(1H, m, 6-H2,20- 22- and 24-H3), 2.89 (1H, m, 2-H), 3.99 (2H, m, 1-112), 
5.22 (2H, m, 3-H and 4-H), 5.70 (1H, dt, 5-H, J 6.7,15.3 Hz); 8C (50 Mliz, 
CDC13) 14.0 (C-18), 20.1,23.0,23.1 (C-20, -22 and -24), 22.6,28.6,29.1, 
29.3,29.4,29.5,29.6,30.9,31.9 (C-7 to C-17), 32.2 (C-6), 56.6 (C-2), 
63.7 (C-1), 74.3 (C-3), 124.4 (C-4), 136.8 (C-5), 170.1,170.9 (C-19, -21 
and -23). Attempted further purification on a silica column caused the 
title compound to decompose. 
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(S)-Serine methyl ester hydrochloride (95) (10 g, 64.3 mmol) and 
potassium hydrogen carbonate (6.7 g, 66.8 mmol) were dissolved in 
water (110 ml) and the solution was stirred at room temperature for 10 
min. Potassium carbonate (9.4 g, 67.8 mmol) was added to the solution 
which was then cooled to 0 °C. A solution of phosgene in toluene (2M, 
44 ml, 85.4 mmol) was added dropwise and the resulting solution was 
stirred for 2h at 0oC. The solvent was removed under reduced 
pressure to leave a white solid which was extracted with 
dichloromethane (3 x 100 ml). The extracts were dried with 
magnesium sulfate and concentrated to give a clear oil (7.5 g, 80%); Rf 
0.45 (ethyl acetate); [a I D22 -18.6 (c 4.3 in CH2C12); 6n (200MHz, CDC13) 
3.73 (3H, s, 6-H3), 4.39 (1H, dd, 3-H, J 4.8,9.6 Hz), 4.52 (111, dd, 3-I1, J 
4.8,9.1 Hz), 4.67 (1H, app. t, 2-H, J 9.6 Hz), 6.88 (1H, br s, Nil); 8C (50 
MHz, CDC13) 51.3 (C-2), 52.1 (C-6), 65.2 (C-3), 157.8 (C-4), 169.3 (C-1); 
Vmax (KBr disc) / cm-1 3323, ' 1767,1740; m/z 145 (M+, 5.4%), 87 (5), 
86 (100); (found M+, 145.0380. Calc. for C5H7NO4,145.0375). 
4-Hvdroxymethvloxazolidin-2-one (122 
HO 1_2__, 3 
HN, 4iO 
89 
Sodium borohydride (1.36 g, 35.7 mol) was added in portions to a 
solution of compound (121) (5 g, 34.2 mmol) in ethanol (100 nil) at 0 
O C. The reaction mixture was allowed to warm to room temperature. 
After it was stirred for 3h at this temperature, saturated aqueous 
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ammonium chloride solution (30 ml) was added. The white solid was 
filtered off and the filtrate was concentrated to give a white paste. The 
white paste was purified by flash chromatography eluting with 
methanol-ethyl acetate (1: 4) to afford the title compound as a white 
solid (2.5 g, 63%); Rf0.28 (ethyl acetate-hexane; 9: 1); 811 (200MHz, D20) 
3.60 (2H, 2x dd, 1-H2), 4.01 (1H, m, 2-H), 4.19 (1H, dd, 3-H, J 5.1,8.7 
Hz), 4.45 (1H, t, 3-H, J 8.7 Hz); 8c (50 MHz, D20) 54.4 (C-2), 63.2 (C-i), 




° \ 8 
HN 
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Tosyl chloride (6.3 g, 32.8 mmol) was added at 0 OC to a solution of the 
compound (122) (2.5 g, 21.3 mmol) in dry triethylamine (20 ml). The 
reaction was stirred at room temperature overnight after which 
triethylamine was removed under reduced pressure. The solid was 
redissolved in dichloromethane (100 ml), washed with 1M HCl (2 x 50 
ml) and the organic layer was dried with magnesium sulfate, filtered 
and concentrated to give a yellow oil. The oil was purified by column 
chromatography to give the title compound and (S) -3- (4 - 
toluenesulfonyl)-4-(4-tolu en esulfonyloxymethyl)oxazolidin-2-one 
(124). 
The title compound was obtained as a crystalline solid (3.5 g, 64%); mp 
97 oC (lit., 99 96-99 °C); Rf0.28 (methanol-ethyl acetate; 1: 9); [aID22 +6.0 
(c 0.54 in CHC13); SH (200MHz, CDC13) 2.33 (3H, s, 1-H3), 4.04 (411, in, 8. 
and 10-H2), 4.37 (IH, m, 9-H), 6.33 (IH, br s, NH), 7.27 (2H, d, 2- and 4- 
H), 7.73 (2H, d, 5- and 7-H); Sc (50 MHz, CDC13) 21.6 (C-1), 50.8 (C-9), 
66.4 (C-8 or -10), 69.7 (C-8 or -10), 127.9 (C-2 and -4), 130.3 (C-5 and 
-7), 131.7 (C-3), 145.6 (C-6), 159.3 
(C-11); vmax (KBr disc) / cm-1 3445, 
3300,1770. (Found: C, 48.7; H, 4.86; N, 5.16. Calc. for Cl IH 13 NS 05 : C, 
48.65; H, 4.63; N, 5.02%). 
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(S) -3- (4- to 1u en es u1 fo nyl) -4- (4-to! u en es u1 fo nyl ox y methyl) ox az 01 din -2- 




Rf0.40 (methanol-ethyl acetate; 1: 9); [a]D22 -50.1 (c 1 in CHC13); 811 
(200MHz, CDC13) 2.35 (3H, s, 1- or 18-H3), 2.37 (3H, s, 1- or 18-113), 
4.15 (2H, 2x dd, 10-H2, J 2.9,9.9 Hz), 4.24 (2H, m, 8-H2), 4.56 (211, m, 
9-H), 7.26 (4H, app. t, 2-, 4-, 14- and 16-H), 7.66 (2H, d, 5- and 7-H or 
13- and 17-H), 7.78 (2H, d, 5- and 7-H or 13- and 17-H); 8C (50 MHz, 
CDC13) 20.9 (C-1 or -18), 21.6 (C-1 or -18), 54.7 (C-9), 65.0 (C-10), 68.8 
(C-8), 127.8 (C-2 and -4 or C-14 and -16), '128.3 (C-2 and -4 or C-14 
and -16), 129.9 (C-5 and -7 or C-13 and -17), 130.1 (C-5 and -7 or C-13 
and -17), 131.7 (C-3 or -15), 134.1 (C-3 or -15), 145.7 (C-6 or -12), 
146.0 (C-6 or -12), 151.7 (C-11); Vmax (KBr disc) / cm-1 2930,1774, 
1363. (Found: C, 50.8; H, 4.5; N, 3.3. Calc. for C18H19N07S2: C, 50.71; 11, 
4.40; N, 3.20%). 
Attempted preparation of (R)-4-(2-hexadecynyl)oxazoli din-2-one 
BuLi (1.5M, 3 ml, 4.6 mmol) was added dropwise at -78 OC to a solution 
of 1-pentadecyne (1.3 ml, 4.6 mmol) in dry THE (30 ml). The solution 
was allowed to warm to room temperature and stirred for 30 min 
before cooling back down to -78 °C. Cul (0.45 g, 2.4 mmol) was then 
added. After the grey suspension was stirred for 2h at - 78 °C, a 
solution of compound (123) (0.5 g, 1.8 mmol) in dry THE was added 
dropwise via a dropping funnel. This suspension was stirred at -78 oC 
for 30 min and then at room temperature overnight. The organic 
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solvent was removed under reduced pressure. The resulting blue 
solution was extracted with ethyl acetate (3 x 50 ml), and the combined 
extracts were dried with magnesium sulfate and concentrated to give 
an oil. All spectral data were identical to those of starting material. 
(R)-3-(4-Toluenesulfonyl-4-(2-hexadecynyl)oxazoli din-2-onc (125) 
26 24 
23 ý, 25 17 
22 ý\ ý; 18 ý ý14 12 
. .. ziýý/ 5` ii4 13 i?. OÖ 
3 
BuLi (1.5M, 0.64 ml, 0.96 mmol) was added dropwise at -78 OC to a 
solution of 1-pentadecyne (0.3 ml, 0.96 mmol) in dry THE (20 ml). The 
solution was allowed to warm to room temperature and stirred for 30 
min before cooling back down to -78 °C. A solution of compound (124) 
(0.2 g, 0.48 mmol) in dry THE (10 ml) was added to this mixture. The 
resulting solution was stirred at -78 OC for 2h and at room 
temperature overnight. Saturated ammonium chloride solution (20 nil) 
was added and the organic layer was separated. The aqueous layer was 
extracted with ethyl acetate (2 x 30 ml) and the combined extracts 
were dried with magnesium sulfate and concentrated to give an oil. 
The oil was purified by column chromatography eluting with hexane- 
ethyl acetate (2: 1) to give the title compound as a yellow oil (50 mg, 
23%); Rf 0.4 (hexane-ethyl acetate; 2: 1); 5H (200MHz, CDC13) 0.80 (3H, t, 
1-H3), 1.18 (22H, m, 2-H2 to 12-H2), 2.20 (4H, m, 13- and 16-H2), 2.37 
(3H, s, 26-H3), 2.93 (IH, m, 17-H), 3.91 (IH, dd, 18-H, J 6.1,1.2 Hz), 4.10 
(IH, dd, 18-H, J 4.7,1.2 Hz), 7.26 (2H, d, 22- and 24-H), 7.75 (2H, d, 21- 
and 25-H); 8C (50 MHz, CDC13) 14.0 (C-1), 18,6,22.6,27.4,28.7,28.9, 
29.2,29.3,29.5,30.9 (C-2 to C-12), 31.1 (C-13 or -16), 31.9 (C-13 or 
-16), 36.8 (C-17), 64.1 (C-18), 72.3 
(C-14 or -15), 90.9 (C-14 or -15), 
127.9 (C-22 and -24), 129.7 (C-21 and -25), 134.4 (C-23), 144.7 (C-20), 
152.9 (C-19); Vmax (KBr disc) / cm-1 2927,2236,1715; m/z 461 (M+, 
1.6%), 349 (20), 306 (30.8), 276 (7.6), 235 (100), 210 (20), 155 (100); 
(found M+, 461.2575. Calc. for C26H39NO4S, 461.2599). 
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7.4 Experimental to Chapter 6 
(2R. 3R) 2.3-Epoxy-3-phenylpropan-1-01(135)92 
A flame-dried four-necked flask fitted with a thermometer and two 
dropping funnels was charged with (-)-diethyl tartrate (0.46 g, 2 ntmol) 
and dichloromethane (250 ml). After the mixture was cooled to -20 °C, 
activated powdered 4A molecular sieves (1.5 g), titanium 
tetraisopropoxide (0.38 g, 1.4 mmol) and tert-butylhydroperoxide (11 
ml of 5-6 M solution in decane; ca. 55 mmol) were added sequentially. 
The mixture was stirred at -20 oC for 1h and was then treated with a 
solution of freshly distilled (E)-3-phenylpropen-2-ol (3.5 g, 26 mmol) in 
dichloromethane (10 ml). After 3h at -20 °C, the reaction was 
quenched with a 10% solution of sodium hydroxide saturated with 
sodium chloride. Before removing the cold bath, ether (20 nil) was 
added and the stirred mixture was allowed to warm up to 10 oC, 
whereupon magnesium sulfate (1 g) and Celite (0.1 g) were added. The 
mixture was then filtered through Celite, washed with diethyl ether and 
concentrated to give a yellow oil. The oil was purified by column 
chromatography eluting with hexane-ethyl acetate; (2: 1) to give white 
crystals (2.5 g, 64%); mp 50-51 oC (lit., 92 51-53 OC); Rf 0.3 (hcxane- 
ethyl acetate; 2: 1); 5H (200MHz, CDC13) 3.16 (1 H, br s, OH), 3.23 (1 H, m, 
2-H), 3.75 (IH, dd, 1-H, J 4.2 and 12.8 Hz), 3.90 (IH, d, 3-H, J 2.2 Hz), 
4.00 (1H, dd, 1-H, J 2.2 and 12.8), 7.25 (5H, m, aromatic H); 8C (50 MHz, 
CDC13) 55.6 (C-2), 61.3 (C-1), 62.6 (C-3), 125.7 (C-5 and -9 or C-6 and 
-8), 127.6 (C-7), 128.4 (C-5 and -9 or 
C-6 and -8), 136.7 (C-4); vmax (KBr 
disc) / cm-1 3442 (OH), 1256; m/z 150 (M+, 7.1%), 132 (28.2, M- H2O), 
119 (28.7), 91 (100, M- CHOCH2OH); (found M+, 150.0683. Calc. for 
C9H 1002,150.0680). (Found: C, 72.0; H, 6.7. Calc. for C9H 1002: C, 71.72; 
H, 6.76%). 
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(2R. 3R)-1-((P-Tolucnesulfonyl)oxY]-2.3-cPoxy-3-12licnylpronanc (136) 
(using the procedure of Awad et n1.100) 
Tosyl choride (2.8 g, 14.6 mmol) was added to a solution of (2R, 3R)-2,3- 
epoxy-3-phenylpropan-1-ol (135) (2 g, 13.3 mmol) in triethylamine 
(20 ml). After it was stirred overnight at room temperature, the 
reaction mixture was diluted with saturated aqueous ammonium 
chloride solution (30 ml) and extracted with ethyl acetate (3 x 30 ml). 
The combined extracts were dried with niagnesiuni sulfate, filtered and 
concentrated to a white solid. Recrystallisation from hexane-ethyl 
acetate gave white crystals (3.2 g, 80%); mp 68 OC (lit., ref 68-69 oC); Rf 
0.8 (hexane-ethyl acetate; 2: 1); Stt (200MHz, CDC13) 2.44 (311, s, 16-113), 
3.23 (1H, m, 2-H), 3.75 (IH, d, 3-11, J 1.9 Hz), 4.14 (111, dd, 1-11, J 5.5 and 
11.5 Hz), 4.34 (1H, dd, 1-H, J 3.6 and 11.5 Hz), 7.28 (511, in, aromatic 11, 
11- and 15-H), 7.80 (2H, d, 12- and 14-11); 8c (50 MHz, CDC13) 21.6 (C- 
16), 56.3 (C-2), 59.5 (C-3), 69.5 (C-1), 125.6 - 132.5 (aromatic CII), 
135.4 (C-4), 136.1 (C-13), 145.2 (C-10); vmux (KBr disc) / cni-1 2945, 
1356 (S020), 1175,960; nz/z 304 (M+, 2.0%), 155 (47.2, M- 
SO2OC6H5CH3), 133 (21.9), 91 (100); (found M+, 304.0782. Cale. for 
C 16H 16SO4,304.0769). 
22 R. 3R -1-(N. N-Diethylamino)2.3-cepoxy-3-phenyl ro anc (137) 
(using the procedure of Rayner et A9 1) 
A flame dried three-necked flask under nitrogen was charged with 
(2R, 3R)-1-[(p-toluenesulfonyl)oxy]-2,3-epoxy-3-plhenylpropane (136) 
(2 g, 6.6 mmol), potassium iodide (1.2 g, 7.3 mmol) and dry 
dimethylformamide (20 ml). Diethylamine (0.96 g, 13.2 mmol) was 
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then added dropwise to the mixture. After it was stirred overnight at 
room temperature, the mixture was poured into ice water and extracted 
with ethyl acetate (3 x 20 ml). The combined extracts were washed 
with saturated sodium bicarbonate solution, dried with magnesium 
sulfate and concentrated to give an oil. Purification of the oil by flash 
chromatography eluting with ethyl acetate afforded a yellow oil (0.3 g, 
22%); Rf 0.05 (hexane-ethyl acetate; 2: 1); 811 (200MHz, CDC13) 0.97 (611, 
t, 11- and 13-H3), 2.51 (5H, m, 10- & 12-112 and 1-11), 2.81 (111, dd, 1- 
H, J 4.1 and 11.5 Hz), 3.05 (IH, m, 2-H), 3.52 (111, d, 3-11, J 1.9 11r. ), 7.22 
(5H, m, aromatic H); 5C (50 MHz, CDC13) 10.1 (C-11 and -13), 45.9 (C-10 
and -12), 53.4 (C-1), 55.4 (C-2), 59.8 (C-3), 123.9 (C-5 and -9 or C-6 and 
-8), 126.4 (C-7), 126.8 (C-5 and -9 or C-6 and -8), 135.7 (C-4); vniax 
(film) / cm-1 2934,1203; n: /z 205 (M+, 0.6%), 91 (8.3), 86 (100, M- 
C6H5CHCH), 72 (10.7, M- C6H5CHCHCH2); (found M+, 205.1517. Calc. for 
C 13H 19NO, 205.1466). 
phenylpropanc-l . 3-diol 
(using the procedure of Rayner et a!. 91) 
Trimethylsilyl trifluoromethanesulfonate (0.24 g, 1.1 mmol) was added 
to a solution of (2R, 3R)-1-(N, N-dicthylamino)-2,3-epoxy-3- 
phenylpropane (137) (0.2 g, 0.9 mmol) in dry dichloromethanc (10 ml) 
at -78 oC under nitrogen. After 30 min, water (1 nil) was added to the 
solution which was then allowed to warm to room temperature and 
stirred for 24 h. Ethyl acetate (30 ml) and water (20 nil) were added. 
The organic layer was separated, washed with saturated sodium 
bicarbonate solution, dried with magnesium sulfate and concentrated to 
give an oil. NMR spectroscopic analysis indicated a complex mixture 
but the epoxide ring was opened. 
156 
(2R. 3R)- l -[(N-Ethylaminocarbonyl)oxy]-2.3-epoxyphcnylpropanc (143) 
(using the procedure of Roush et al. 94) 
11 
10 N 12, 
H 
Freshly distilled ethyl isocyanate (1.68 ml, 21.3 nlnlol) was added to a 
solution of (2R, 3R)-2,3-epoxy-3-phenylpropan-l-ol (135) (2 g, 13.3 
mmol) and triethylamine (3.8 ml, 26.6 mmol) in dry dichloromethane 
(20 ml). After it was stirred overnight at room temperature, the 
reaction mixture was diluted with saturated aqueous ammonium 
chloride solution (20 ml) and extracted with ethyl acetate (3 x 30 nll). 
The combined extracts were washed with brine, dried with magnesium 
sulfate, filtered and concentrated. The resulting crude poduct was 
purified by column chromatography cluting hexane-ethyl acetate (4: 1), 
to give the title compound (2.3 g, 93%) as a white solid which proved to 
be > 95% optically pure by chiral column gas chromatography and use 
of shift reagents (+)-2,2,2-trifluoro-l-(9-anthryl)-ethanol and tris[3- 
(heptafluoroproylhydroxmethylene)-(-)-canlpllorato], europium (111) 
derivative; mp 46 °C; Rf0.4 (hexane-ethyl acetate; 4: 1); [aID22 + 54.5 (c 
0.29 in CHC13); Stt (200MHz, CDC13) 1.05 (311, t, 12-113), 3.05 (311, in, 11- 
H2 and 2-H), 3.70 (1H, d, 3-H, J 1.9 Hz), 4.01 (111, dd, 1-11, J 5.8 and 12.3 
Hz), 4.53 (1H, dd, 1-H, J 3.0 and 12.2 Hz), 7.19 (51I, in, aromatic 11); 8c 
(50 MHz, CDC13) 15.1 (C-12), 35.9 (C-11), 56.2 (C-2), 59.8 (C-3), 64.3 (C- 
1), 125.7 (C-5 and -9 or C-6 and -8), 128.4 (C-7), 128.5 (C-5 and -9 or 
C-6 and -8), 136.3 (C-4), 155.9 (C-10); Vn, ax (KBr disc) / cm-1 3316 
(CONH), 2972,1689 (OCON); nm/z 226 (M+, 0.6), 150 (7.5%, M- 
CONCH2CH3), 134 (8.8), 107 (100, M- C6115C1011). 91 (66.7); (found 
M+, 221.1050. Cale. for C 12H 15N03,221.1050). (Found: C, 65.2; 11,6.7; 
N, 6.3. Calc.. for C 12H 15N03: C, 65.12; H, 6.60; N, 6.33%). 
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2S. 3R)-3-Ethyl-4-(1-hydroxybcnzyl)-2-oxazol idinonc (14 
(using the procedure of Roush et xl. 94) 
Sodium hydride (95%, 0.88 g, 36 mmol) was added to a solution of 
(2R, 3R)-1-[(N-ethylaminocarbonyl)oxy]-2,3-epoxyphenylpropane (143) 
(2 g, 9 mmol) in dry THE (30 ml). After the reaction mixture had been 
stirred for 6 h, it was quenched by addition of saturated aqueous 
ammonium chloride solution (30 ml) and extracted with ethyl acetate 
(3 x 30 ml). The combined extracts were dried with magnesium sulfate 
and concentrated to give crystalline crude product. Recrystallisation 
from ethyl acetate-hexane afforded light brown needles (1.6 g, 80%); 
mp 98.5 OC; Rf0.1 (hexane-ethyl acetate; 4: 1); [a]D22 - 52.5 (e 0.84 in 
CHC13); 81; (200MHz, CDC13) 0.98 (3H, t, 12-H3), 2.91 (111, dq, 11-11), 3.50 
(1H, dq, 11-H), 3.91 (2H, ©J3. X, 1-H2), 4.25 (111, m, 2-11), 4.85 (111, in, 3- 
H) (became d on exchange with D20), 7.25 (511, nt, aromatic 11); 8C (50 
MHz, CDC13) 12.4 (C-12), 36.7 (C-11), 59.8 (C-2), 62.6 (C-1), 69.8 (C-3), 
125.8 (C-5 and -9 or C-6 and -8), 127.9 (C-7), 128.6 (C-5 and -9 or C-6 
and -8), 139.3 (C-4), 158.0 (C-10); Vmax (KIM disc) / cn1-1 3300,2964, 
1760 (OCON); m/z 114 (100, M- C5 H8N02), 107 (53.7, M- C611501011), 
77 (59.3). (Found: C, 65.2; H, 6.7; N, 6.3. Cale. for C 121115N03: C, 65.15; 
H, 6.74; N, 6.27%). 
R. 2S) 2-Ethylamino-l-pheny]propane-1.3-ý 
(using the procedure of Roush et al. 94) 
A solution of (2S, 3R)-3-ethyl-4-(1-hydroxybcnzyl)-2-oxazolidinone 
(144) (1 g, 4.5 mmol) and lithium hydroxide (3.3 g, 0.14 mol) in 
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aqueous ethanol (30%, 20 ml) was heated under reflux for 15 h. After 
the reaction mixture was cooled to room temperature, it was diluted 
with brine (30 ml) and extracted with ethyl acetate (3 x 30 nil). The 
combined extracts were dried with magnesium sulfate, filtered and 
concentrated to give a white solid. Recrystallisation from ethyl acetate- 
hexane afforded white needles (0.82 g, 93%); nip 75-76 OC; [aID22 - 40.9 
(c 0.86 in CHC13); 8j (200MHz, CDC13) 0.97 (311, t, 11-113), 2.56 (311, nt, 
10-H2 and 2-H), 3.40 (2H, &3. X, 1-H2), 3.71 (111, br s, Nil), 4.80 (111, d, 
3-H, J 4.5 Hz), 7.19 (5H, m, aromatic H); 6c (50 Mllz, CDC13) 15.0 (C-11), 
41.4 (C-10), 59.9 (C-1), 63.0 (C-2), 73.6 (C-3), 125.8 (C-5 and -9 or C-6 
and -8), 127.3 (C-7), 128.3 (C-5 and -9 or C-6 and -8), 141.9 (C-4); viax 
(KBr disc) / cm-1 3448,3286,3083,2973; m/z 88 (100, M- C41I10NO), 
77 (13.6, M- C6H5CHOH). (Found: C, 67.7; 11,8.7; N, 7.1. Cale. for 
C 11 H 17N02: C, 67.66; H, 8.85; N, 7.09%). 
Methyl tetradecanoate (151)95 
14 
13 11 97 
ý 
53 101 15 
Hydrochloride gas was kept bubbling through a solution of 
tetradecanoic acid (10 g, 0.04 mmol) and methanol (300 till) until all 
the solid dissolved. After stirring the solution at room temperature for 
5 h, methanol was evaporated off under reduced pressure to afford a 
white solid. The white solid was redissolved in ethyl acetate (150 till) 
and water (100 ml). The organic layer was washed with saturated 
sodium bicarbonate solution (3 x 100 ml), dried with sodium sulfate, 
filtered and concentrated to give the title compound as a clear oil (10.5 
g, 95, %); 8H (200MHz, CDC13) 0.66 (3H, t, 14-113), 1.04 - 1.39 (2211, in, 3- 
H2 to 13-H2), 2.07 (2H, t, 2-H2), 3.43 (3H, s, 15-H3); 8c (50 Mliz, CDC13) 
13.8 (C-14), 22.5,24.8,29.0,29.1,29.2,29.3,29.4,31.8,33.8 (C-3 to C- 
13), 34.1 (C-2), 50.9 (C-15), 173.7 (C-1); Vmax (film) / cm-1 2924,2854, 
1744; m/z 242 (M+, 0.6%), 154 (10.8), 112 (43.2), 87 (31.3,74 (100); 
(found M+, 242.2237. Calc. for C15H30O2,242.2245). 
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Tetradecan- l -ol (152) 
(using the procedure of Weinreb et al. 38) 
14 OH 
A solution of methyl tetradecanoate (151) (5 g, 0.019 mmol) in dry TIIF 
(20 ml) was added dropise at 0 oC to a stirred suspension of lithium 
aluminum hydride (0.72 g, 0.019 mmol) in dry T111' (100 ml). After the 
reaction was stirred at this temperature for 2 h, it was quenched by 
addition of saturated ammonium chloride solution (20 nil). The mixture 
was extracted with ethyl acetate (3 x 50 nil) and the combined extracts 
were dried with magnesium sulfate, filtered and concentrated to afford 
the title compound as a white solid (3.8 g, 94%); Rf 0.2 (hexane-ethyl 
acetate; 9: 1); 811 (200MHz, CDC13) 0.78 (311, t, 14-113), 1.18 (2211, br s, 3- 
H2 to 13-H2), 1.47 (2H, m, 2-H2), 2.67 (1H, br s, O11), 3.52 (211, t, 1-112); 
8C (50 MHz, CDC13) 14.0 (C-14), 22.6,25.7,29.3,29.4,29.6,31.9 (C-3 to 
C-13), 32.6 (C-2), 62.6 (C-1); vmax (KBr) / cm-1 3421,2924,2853; nj /z 
196 (12.2, M- H2O), 168 (13.2), 111 (30.6), 97 (62.6), 55 (100); (found 
M- H2O, 196.2191. Cal c. for C14H28,196.2191). 
Tetradecanal (153) 
(using the procedure of Swern et al. 101) 
14ý ý842 ýi, 
vvvvvv 
13 11 9753 
Dimethylsulfoxide (2.6 ml, 0.028 mol) in dry dichloromethane (20 ml) 
was added dropwise via dropping funnel to a cooled -50 oC solution of 
oxalyl chloride (1.48 ml, 15.4 mmol) in anhydrous dichloromethane 
(150 ml). The reaction was stirred for 10 min before tetradccan-l-ol 
(152) (3 g, 0.014 mol) in dry dichloromethane (20 nll) was introduced. 
Stirring at this temperature was continued for Ih and triethylamine 
(10 ml, 0.14 mol) was then added. The resulting solution was allowed 
to warm to room temperature and stirred for a further 30 min. 
Saturated ammonium chloride solution was added and the whole 
mixture was extracted with dichloromethane (3 x 80ml). The combined 
160 
extracts were dried with magnesium sulfate, filtered and concentrated 
to give a yellow oil. The oil was purified by flash chromatography 
eluting with hexane-ethyl acetate (9: 1) to give tht title compound as a 
waxy solid (2.5 g, 84%); Sii (200MHz, CDC13) 0.82 (311, t, 14-113), 1.30 - 
1.52 (22H, m, 3-H2 to 13-H2), 2.30 (2H, dt, 2-H2, J 1.8 and 7.2 llz), 9.70 
(1H, t, 1-H, J 1.8 Hz); 3c (50 MHz, CDC13) 13.6 (C-14), 22.6,24.5,29.3, 
29.4,29.5,29.6,29.7,31.7,32.4 (C-3 to C-13), 43.8 (C-2), 202.6 (C-1); 
umax (KBr) / cm-1 2924,2864,1720; m hz 212 (M+, 0.5), 178 (10), 84 
(40), 74 (100); (found M+, 212.2314. Calc. for C14H2803,212.2349). 
Methyl (2E, 4E)-octadccadicnoatc (154)38 
19 
17 . 
A solution of methyl 4-dimethylphosphono-2-butenoate (1.7 g, 9.4 
mmol) in dry THE (20 ml) was slowly added to a stirred, cooled (0 oC ) 
solution of LDA prepared in dry THE (30 nil) from diisopropylaminc 
(1.14 g, 11.3 mmol) and butyllithium (1.6 M, 7.05 ml, 11.3 mmol) for 1 
h at 0oC. The red solution was allowed to reach -40 oC and 
tetradecanal (153) (2 g, 9.4 mmol) dissolved in dry Till' (20 nil) was 
added dropwise to the reaction mixture. After 2h the reaction was 
quenched by addition of water (100 ml) and extracted with ether (3 x 
80 ml). The combined extracts were dried with magnesium sulfate, 
filtered and concentrated to afford an oily solid. The residue was 
partially purified by column chromatography eluting with hexanc-ethyl 
acetate (20: 1) to give the title compound as a clear oil (1.7 g, 62%); 6jj 
(200MHz, CDC13) 0.88 (3H, t, 18-113), 1.30 (2211, m, 7-112 to 17-112), 1.7 - 
2.3' (2H, m, 6-H2), 3.70 (3H, s, 19-H3), 5.81 - 7.72 (4I1, m, 2-, 3-, 4- and 
5-H); Sc (50 MHz, CDC13) 14.1 (C-18), 29.2,29.3,29.4,29.5,29.6,29.7, 
31.7,31.8 (C-7 to C-17), 34.4 (C-6), 51.4 (C-19), 118.5,128.2,144.9 (C- 
2, -3 and -4), 120.0,126.3,137.8,141.7 (cis-isomer), 145.3 (C-5), 167.7 
(C-1); Vmax (KBr) / cm-1 1718,1650; in/z 294 (M+, 10%), 264 (21), 195 
(100); (found M+, 294.2534, Cale. for C 19113402,294.2558). 
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(2E. 4@: Octadecadien-l-ol (149)38 
OH 
A solution of methyl (2E, 4E)-octadecadienoate (154) (1 g, 3.4 mmol) in 
dry ether (20 ml) was slowly added to a cooled 0 oC stirred suspension 
of lithium aluminum hydride (0.12 g, 3.4 mmol) in dry ether (30 ml). 
After it was stirred for 0.5 h at -10 OC, the mixture was quenched by 
addition of saturated ammonium chloride solution (50 ml) and then 
extracted with ether (3 x 50 ml). The organic layer was washed with 
water, dried over magnesium sulfate, filtered and concentrated to give 
a, solid. The solid was partially purified by column chromatography 
eluting with hexane-ethyl acetate (9: 1) to give the title compound (0.72 
g, 80%) as a white solid; mp 45 oC (lit., ref 51 OC); 811 (200MHz, CDC13) 
0.80 (3H, t, 18-H3), 1.18 (22H, m, 7-H2 to 17-112), 1.8- 2.1 (211, in, 6- 
H2), 1.90 (1H, br s, OH), 4.05 (2H, d, 1-H2, J 6.0 lllz), 5.51 - 6.40 (411, in, 
2-, 3-, 4- and 5-H), -5C(50 MHz, CDC13) 14.1 (C-18), 22.6,29.1,29.3,29.4, 
29.5,29.6,29.7,31.7,31.9 (C-7 to C-17), 32.6 (C-6), 63.4 (C-1), 126.7, 
127.5,131.5,133.1 (cis-isomer), 129.3,131.9,135.7 (C-2, -3, -4 and -5); 
umax (KBr) / cm-1 3318,2921,1645. 





A flame-dried four-necked flask was fitted with a thermometer and 
two dropping funnels and charged with (-)-diethyl tartrate (0.46 g, 2 
mmol) and dichloromethane (100 ml). After the mixture was cooled to 
-20 O C, activated powdered molecular sieves (0.5 g), titanium 
tetraisopropoxide (0.38 g, 1.4 mmol) and tert-butylhydropcroxidc (11 
ml of 5-6 M solution in decane; ca. 55 mmol) were added sequentially. 
The mixture was stirred at -20 oC for 1h and then treated with a 
solution of (2E, 4E)-octadecadien-l-ol (149) (0.2 g, 0.75 mnlol) in 
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dichloromethane (10 ml). After 3h at -20 o C, the reaction was 
quenched with a 10% solution of sodium hydroxide saturated with 
sodium chloride. After ether (20 ml) was added, the cold bath was 
removed and the stirred mixture was allowed to warm up to 10 °C, 
whereupon magnesium sulfate (1 g) and Celite (0.1 g) were added. The 
mixture was then filtered through Celite, washed with diethyl ether and 
concentrated to give a yellow oil. The oil was purified by column 
chromatography eluting with hexane-ethyl acetate; (9: 1) to give the 
title compound (10 mg, 5%), starting material (0.1 g) and (2R, 3R)-4Z- 
2,3-epoxy-3-octadec-4-ene-l-ol (156) (20 mg, 10%) (57). 
The title compound was isolated as an oily solid; Rf0.23 (hexane-ethyl 
acetate; 9: 1); 8H (200MHz, CDC13) 0.78 (3H, t, 18-H3), 1.16 - 1.56 (22H, 
m, 7-H2 to 17H2), 2.01 (2H, m, 6-H2), 3.03 (1H, m, 2-H), 3.30 (1H, dd, 3- 
H, J 2.2 and 8.4 Hz), 3.70 (2H, m, 1-112), 5.11 (111, ddt, 4-H, J 8.4 and 
15.5 Hz), 5.89 (1H, dt, 5-H, J 6.8 and 15.4 Hz); 8C (50 MHz, CDC13) 14.1 
(C-18), 22.6,29.2,29.4,29.5,29.8,29.9,30.9,31.9 (C-7 to C-17), 32.4 
(C-6), 55.9 (C-2), 59.9 (C-3), 61.2 (C-1), 126.2 (C-4), 138.1 (C-5); vmax 
(KBr disc) / cm-1 3200,1645,1245,1340; m/z 282 (M+, 4.2%), 251 
(36.5), 149 (5.4), 83 (100); (found M+, 282.2548. Calc. for C18H34NO2, 
282.2559). 
(2R, 3R)-4Z-2,3-Epoxy-3-octadec-4-ene-l-ol (156) was isolated as a 
solid. 




Rf 0.25 hexane-ethyl acetate, (9: 1); 6H (200MHz, CDC13) 0.80 (3H, t, 18- 
H3), 1.16 - 1.59 922H, m, 7-H2 to 17-H2), 2.20 (2H, m, 6-H2), 3.09 (111, 
m, 2-H), 3.60 (2H, m, 1-H2), 3.90 (1H, br dd, 3-H), 5.00 (IH, ddt, 4-H, J 
9.0 and 11 Hz), 5.67 (IH, dt, 5-H, J 7.7 and 11 Hz); 6c (50 MHz, CDC13) 
14.1 (C-18), 22.6,22.8,29.2,29.4,29.7,29.8,29.9,31.6,31.9 (C-7 to C- 
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17), 31.9 (C-6), 51.3 (C-2), 59.7 (C-3), 61.0(C-1), 125,6 (C-4), 137.7 (C- 
5); vmax (KBr disc) / cm-1 3250,1640,1340,1236; m/z 282 (M+, 0.6%), 
269 (32.0), 239 (32.7), 137 (15.4), 109 (58), 95 (100); (found M+, 
282.2535. Calc. for C18H34N02,282.2559). 
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